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ABSTRACT 
  
 This dissertation features a small molecule, non-peptidic, ligand designed to bind a 
cell surface receptor called tropomyosin receptor kinase C (TrkC).  TrkC is 
overexpressed on various types of tumors including breast cancer and melanoma.  It 
would be advantageous in clinical applications to conjugate the novel ligand with 
imaging or therapeutic agents then treat TrkC-positive cancers.   
 For proof of concept, first, we used our ligand conjugated to a commercial 
cytotoxic drug, 6-mercaptopurine, then tested the agent in NIH-3T3 cells stably 
transfected with TrkC, and compared with wild type NIH-3T3 (TrkC-).  A targeting 
effect was observed but we could not obtain an IC50 value for the conjugate due to lack 
of solubility at the concentrations that would have been required.  Therefore, we chose a 
cytotoxic rosamine dye to conjugate with the targeting ligand.  Selective cytotoxicity of 
the conjugate was observed, but high levels of non-specific binding also occurred.    
 Conjugation of the TrkC-targeting ligand with a fluorescent dye may be useful for 
optical imaging in vivo, and they are also cytotoxic then these theranostics can be used to 
both image and treat the tumor.  We hypothesized that BODIPY dye derivatives could be 
suitable candidates for this approach since they have excellent fluorescent characteristics 
and can be modified for photodynamic therapy (PDT).  Results collected from cellular 
assays proved the selectivity of this probe and its fluorescence led us to where the 
conjugate functioned inside the living cells.  
 Some cancer cell lines that naturally overexpress TrkC include metastatic breast 
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cancer and metastatic melanoma.  Consequently, this study was expanded from stable 
TrkC transfectants to include metastatic-breast and –melanoma.  The results show the 
beneficial effects of TrkC targeting in histochemistry and cellular assays, including 
internalization and selective cell killing.  In a mouse model, collaborators discovered our 
PDT probe at 10 mg/kg (one injection, intravenous tail vein) caused complete ablation of 
a tumor after 6 days post injection with no sign of metastasis to other organs.     
 PDT can be effective if near-IR absorbing photosensitizers (λmax >700 nm) are 
used to excite organs located in the deeper tissue.  For this reason, the cargo was 
modified to aza-BODIPY dyes, which can absorb light at a longer wavelength than 
BODIPYs.  Simultaneously, the conjugate structure was changed because we 
hypothesized this might lead to decreased neurotoxicity.  Histological studies showed 
the new probe selectively stained breast tissues leaving normal tissues unstained.  In vivo 
optical imaging also proved that the new TrkC targeting probe was effective in a murine 
breast cancer model.   Incidentally, the spinal cord of the mouse was nicely imaged by 
this same reagent, presumably because TrkC+ cells are highly concentrated in the 
peripheral nervous system.   
 Finally, we hypothesized that the novel near-IR targeting probe could be applied to 
imaging and treatment of metastatic melanoma.  A rare Sinclair Swine model, available 
at TAMU, was part of the plan for these studies.  Histology results showed selective 
staining by the targeting probe on melanoma tissue, as compared with normal tissue 
obtained from the same pig.  Similarly, our probe stained tissue from human patients 
with metastatic melanoma tissue, but it did not stain healthy skin.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
Small Molecules for Active Targeting of Solid Tumors 
Active targeting1 involves use of an entity that selectively binds surface receptors 
of particular cell types, and can deliver cargos, preferably into the cells.  In cancer 
research, active targeting can be used for histological staining, selective imaging, and to 
increase therapeutic indices for cytotoxic drugs.  In other words, active targeting has 
enormous potential to improve diagnostics, imaging, and chemotherapy in cancer 
treatment. 
Currently, the most prevalent active targeting systems are antibody–drug 
conjugates (ADCs).2-6  Two ADCs are already on the market (trastuzumab emtansine7 
and brentuximab vedotin)8 and many more are in clinical trials.   Most active targeting 
strategies center on monoclonal antibodies (mAbs) because it is comparatively easy to 
produce ones that bind cell surface receptors.  However, active targeting with mAbs has 
some serious limitations.  First, mAbs are too big to penetrate and efficiently diffuse into 
tumors.  Moreover, the ones that do diffuse into tissue tend to be trapped at the antigen 
barrier,9-11 which is a concentration of antigen located on the perivascular tumor cells, 
preventing permeation into the tumor mass.12  In addition, high normal tissue exposure13-
15 results from slow clearance of mAbs from the body.  They tend to accumulate in the 
liver and some fragments in the kidneys and do not reach their targets.16-17  MAbs can 
also cause immunogenicity which might change their pharmacokinetic properties.17  
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Moreover, issues associated with cost, and stability/shelf life of mAbs need to be 
considered.   
Recently, many researchers have tried to develop lower molecular weight 
systems for active targeting (e.g. non-peptidic small molecule, aptamer and peptide 
targeted drugs).18  Small molecule systems for actively targeted cancer agents are 
attractive because this technique is not constrained by the factors outlined above for 
mAbs.  For instance, folate-rhodamine conjugates (EC 17) can saturate folate receptors 
on tumors within five minutes of intravenous injection and rapidly exit blood vessels.19  
Although, the antigen-barrier still affects folate-small molecule conjugates, there is 
almost no effect at saturating doses.19 Generally, small molecules travel faster to their 
target in vivo, have no immunogenicity, can provide sites for conjugation to cargoes, 
they have superior stability/shelve lives relative to mAbs, and can be produced at lower 
cost. 
There are a few small molecules for targeting agents, and we hypothesize this is 
because relatively few cell surface receptors are known to be useful for active targeting 
of cancer cells and cancer subtypes.20-22  Small molecule ligands that are commonly used 
for active targeting include some vitamins (e.g. folic acid,20-21,23-24 biotin,25 and 
cobalamin26-27), RGD28-32 and NGR33 peptidomimetics, a few carbonic anhydrase 
ligands,34-37 and mimics of the prostate specific membrane antigen (PSMA; Figure 1-
1).38-39 This is a limitation because not all tumor types overexpress high number of the 
corresponding receptors, and that some of these ligands have sub-optimal properties for 
targeting entities.40   
  3 
 
 
 
Figure 1-1.  Small molecules that are most common in active targeting. 
 
 
Design of agents for active targeting in cancer usually features selection of 
receptors that are overexpressed on certain tumors, identification of small molecule 
ligands for these, and design of suitable spacers to link these ligands to appropriate 
cargos.41  For receptor selection, Phillip Low, a leader in the field, recommends at least 
appropriate levels of overexpression of the receptor must occur on tumor surface relative 
to normal cells.42-43  Moreover, the ideal receptor should be expressed on the cell 
surface, and not only internally.  The rate of internalization and receptor recycling is also 
crucial. Receptors that recycle frequently and/or are resynthesized or degraded quickly 
tend to be preferred.   
Selection of suitable active targeting ligands in cancer is essential.  Ligands with 
high binding affinity (i.e. sub-nanomolar dissociation constants, Kd) tend be preferable.  
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Additionally, the selectivity of a potential ligand is an issue.  Targeting ligands should be 
easy to derivatize, and to conjugate with drugs of imaging agents without disrupting 
their binding abilities.  Size of the conjugates also influences drug delivery mechanisms.  
Large conjugates, such as polymers or liposomes, usually accumulate in tumor tissues 
due to the enhanced permeability and retention (EPR) effect; however, large particles are 
often retained within blood vessels of healthy tissues, and that can cause unnecessary 
toxicities.  Moreover, large particles usually have slow clearance from body.  
Successful small molecule ligand conjugates in clinical treatments mostly 
involve removable linkers or spacers that facilitate penetration into tissue but do not 
interfere with receptor’s binding and drug efficacy (Figure 1-2). 
 
 
 
Figure 1-2.  Examples of small molecule targeting ligands conjugated to imaging or therapeutic 
agents. 
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Figure 1-2  Continued. 
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Small molecule ligands that target neurotrophin receptors are the main focus in 
this research.  Two types of neurotrophin transmembrane receptors are known: (i) the 
p75 receptor, which binds all neurotrophins; and, (ii) a family of cell-surface 
neurotrophin receptor tyrosine kinases known as tropomyosin-receptor-kinase; TrkA, 
TrkB and TrkC which are more selective and tend to have higher binding affinities.  For 
example, Nerve Growth Factor (NGF) selectively binds to TrkA, Brain-derived 
Neurotrophic Factor (BDNF) and neurotrophin-4/5 (NT-4/5) bind to TrkB, and 
neurotrophin-3 (NT-3) binds to TrkC.  NT-3 can also bind to TrkA and TrkB receptors 
but with lower affinity.  The binding of neurotrophin to Trk receptors may lead to 
activation of signal cascades resulting in the promotion of cell death, survival and 
differentiation.44-49 
Up-regulation of Trk receptors is associated with several forms of cancer.  For 
instance, overexpression of TrkC is found in some forms of neuroblastoma,2,6-8,18,42-43,50-
55 glioblastoma,54,56-60 metastatic breast cancer61-67 and metastatic melanoma.68-76 Small 
molecule fragments that target TrkC are promising for use in several applications for 
treatment of these types of cancer.   
Previous work in our group featured, bivalent peptide mimics designed to imitate 
β-turns of (NT-3).77  These NT-3 mimics selectively bound TrkC, over TrkA and p75 
receptors (c.f. NT-3 binds strongly to TrkC but has low affinity to TrkA, TrkB and p75).  
Our group discovered eight bivalent ligands that selectively bind to TrkC with small 
partial agonistic effects.  Three of them regulated cell survival while the other five 
mimics induced neuron differentiation in the presence of NT-3.  The use of these novel 
  7 
ligands to conjugate with imaging or therapeutic agents would be useful in clinical 
applications.   
  
Photodynamic Therapy 
Photodynamic therapy (PDT: Figure 1-3) uses photochemical reactions for 
destruction of tissue.60,78 A typical PDT clinical procedure is to inject an appropriate 
dose of photosensitizer into a patient’s blood stream, where, ideally, the photosensitizer 
will accumulate in tumors.  Light of a suitable wavelength, usually a red laser beam, will 
be directed to the tumors, where it excites the sensitizers, generating reactive oxygen 
species (ROS, e.g., 1O2); ROSs cause cellular damage, resulting in vascular collapse, 
tissue destruction, and cell death.79-80  Two important features of PDT are, first, the 
sensitizer only kills cells in the region that is irradiated (1O2 has a half-life of about 1 ns), 
and, second, targeting deep tissue requires agents that absorb light at longer wavelengths 
(ideally, >700 nm).81-82    
PDT is a well-recognized modality for cancer treatment.78-79,83  It destroys blood 
vessels that support tumor cells and activates immunological responses against them.78  
However, only a small number of PDT drugs have been approved; these include: (i) 
porfimer sodium (Photofrin) for the treatment of lung and digestive tract cancers and 
Barrett’s esophagus; (ii) temoporfin (Foscan) for the treatment of head and neck cancers; 
and, (iii) aminolevulinic acid (ALA) for the treatment of actinic keratosis.80 
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Figure 1-3.  Illustrative photodynamic therapy (PDT).  A photosensitizer (BODIPY shown in 
green) absorbs light at a specific wavelength, electrons from the ground state (S0) will absorb 
energy and move to singlet-excited states (S1).  Some of the absorbed energy will be released via 
intersystem crossing (ISC) hence the promoted electron will move to a triplet-excited state (T1).  
This triplet state has a relatively long half-life allowing energy to be transferred to oxygen 
molecules nearby, generating single oxygen that can damage the cells at that location. 
 
 
 
Most clinically relevant PDT agents are cyclic tetrapyrroles (porphyrins, 
chlorins, and bacteriochlorins)84-85 with modifications to modulate their photophysical 
and biological properties.  However, there is growing interest in non-porphyrin 
photosensitizers that might be made more easily.86-88  A well-known category of this 
type of PDT agent includes phenothiazinium-based structures; these are relatively easy 
to fabricate but have low light-to-dark toxicity ratios.89	  
A new class of PDT agents has emerged over the last decade and they are based 
on the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) core.  BODIPYs have 
many ideal photosensitizer characteristics including high extinction coefficients, 
environmental insensitivity, resistance to photobleaching,90 and higher light-dark 
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toxicity ratios91 than phenothiazinium89 agents.   Several reviews indicated the role of 
BODIPYs as fluorescence imaging probes,92-96 but none of these focused on their PDT 
properties.  Fluorescence occurs via relaxation from singlet excited states, hence high 
fluorescence quantum yields are undesirable for PDT sensitizers since the energy 
absorbed on excitation does not cross to triplet states if fluorescence occurs.  
Consequently, BODIPYs for PDT have to be modified to depress fluorescence and 
enhance singlet-to-triplet inter-systems crossing.  Recent reviews in this area, one by 
us,97 summarize characteristics of selected members in this emerging class of BODIPY-
based PDT agents.98 
 
 
Figure 1-4.  Concepts of active targeting via PDT.  A PDT agent kill cells most effectively when 
it binds a cell surface receptor, induces receptor-mediated internalization, then light induces the 
generation of reactive oxygen species.   
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In this dissertation, novel BODIPY-based PDT agents have been synthesized.  
The use of active targeting to concentrate novel PDT sensitizer in tumors, and spatial 
targeting of light to ensure the PDT effect is confined to that region is one of the main 
focuses on my research (illustrate in Figure 1-4).  There are several examples of actively 
targeted PDT agents in literature,83,99-105 but this work gave the first agents for TrkC+ 
tissue as applied to metastatic breast cancer and melanoma. 
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CHAPTER II  
SMALL MOLECULE LIGANDS FOR ACTIVE TARGETING OF TRKC 
EXPRESSING TUMOR CELLS* 
 
Introduction 
Current US-approved small molecule pharmaceuticals for treatment of cancer 
tend to have low therapeutic indices, i.e. similarly toxic to cancerous and healthy tissue.  
Therapeutic indices of anti-cancer compounds can be increased by selective delivery; 
this is a form of “targeting”.  Unfortunately, the word “targeting” is ambiguous in 
biomedical research.  For instance, compounds that inhibit enzymes over-expressed in 
tumor cells are sometimes described as “targeted”, but they are not guided to the target 
via an extracellular chemical interaction.106  Conversely, some physical or 
physiochemical properties (e.g. enhanced permeability and retention, and pH effects) 
favor accumulation of nanoparticles or acid-sensitive compounds in tumors; for the 
purposes of this work, we refer to this as passive targeting.  Passive targeting can be 
useful, but the particles can still accumulate in healthy tissue surrounded by either 
relatively impermeable vasculature, or by abnormally acidic interstitial fluid.  Active 
targeting occurs when proteins or small molecule ligands form chemical interactions 
with macromolecules selectively expressed on the surface of the targeted cells.107   
                                                
* Reprinted with permission from “Small Molecule Ligands For Active Targeting Of TrkC-
expressing Tumor Cells” by Eunhwa Ko, Anyanee Kamkaew, and Kevin Burgess, ACS 
Med. Chem. Lett. 2012, 3, 10.  Copyright 2012 American Chemical Society. 
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At least two possible factors can favor active targeting: (i) affinity of the ligand 
for that cell surface receptor; and, (ii) internalization of the ligand into the cells by the 
receptor.  Actively targeted cytotoxicity occurs if one or both these effects are in play.  
One cells surface receptor that could be targeted is TrkC.  We hypothesized this receptor 
is a good target because several tumor types over-express TrkC, including 
neuroblastoma,50 medulloblastoma,108 and breast cancer.63   Moreover, this receptor 
internalizes the natural {neurotrophin} ligands that bind to it, fulfilling criterion (ii).109 
 
 
 
Figure 2-1.  Targeting ligands used in this study, and the non-targeting control compound 2mor-
6MP. 
 
 
Research that is described in this chapter was undertaken to demonstrate active 
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targeting ligands.  Specifically, a triazine-bridged compound IY-IY-TEG was used as a 
basis for this study (Figure 2-1).  That compound was previously shown to bind TrkC-
expressing cells and elicit agonistic effects, but only in synergy with the parent TrkC 
ligand, a protein growth factor called NT3.77  Side-chain pharmacophores {shown in 
red} in IY-IY-TEG and related molecules were shown to be pivotal to binding.   
 
Results and Discussion  
The central hypothesis here is that the partial agonist activity of the IY-IY motif 
could be overwhelmed by incorporating a highly cytotoxic fragment in the same 
molecule, leading to selective binding and internalization for TrkC-expressing cells.  6-
Mercaptopurine (6MP)110 and a rosamine (Ros, a highly cytotoxic fluorescent probe)111 
were used for their cell-killing effects.  We theorized permeation of IY-IY-6MP and IY-
IY-Ros into cells would be disfavored because of size and polarity effects, unless active 
targeting was involved.  To evaluate our hypothesis, cytotoxicities of IY-IY-6MP 
towards a cell line that does not express TrkC (wild type-NIH3T3 abbreviated to 
WT)112-113 were compared with the same cell line stably transfected with TrkC 
(NIH3T3+TrkC abbreviated to TrkC; expression levels 10-20 x 103 receptors cell-1). 
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Figure 2-2.  Anti-proliferative assays.  a IY-IY-6MP selectively targets TrkC expressing cells 
(red) and not the parent line (WT, purple; data are shown with controls that demonstrate both the 
IY-IY amino acid side-chains and the 6MP fragment were essential for cytotoxicity).  b IY-IY-
Ros shows more cytotoxicity for the TrkC expressing cells, TrkC (red) and 4T1 (purple), than 
non-TrkC expressing cells, WT (blue).  Error bars were based on 3 runs, but are barely visible 
for the TrkC expressing cells (red) because they are so tight. 
 
 
Figure 2-2a shows cytotoxicity data for IY-IY-6MP; the red line is for the TrkC-
expressing cells (TrkC) and the purple one is for wild type (WT) NIH3T3 cells.  The 
conjugate is more cytotoxic towards cells that express TrkC.  All the other data in Figure 
3-2a are for controls that, in the event, support this conclusion.  Thus the non-targeted 
analog 2mor-6MP (where the IY-IY motif is substituted by morpholine; Figure 3-2a) is 
not significantly cytotoxic to the TrkC or WT cells, and neither is the targeted but non-
cytotoxic compound IY-IY-TEG.    
It was impossible to determine an IC50 for IY-IY-6MP because the 
concentrations required exceeded the solubility of the compound.  A relatively high 
amount was needed in solution because the cytotoxicities of N9-alkylated derivatives of 
6MP are less than the parent system (ED50 = 50 µM for 6MP, 400 µM for N9-butyl and 
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600 µM for N9-ethyl in Chinese hamster ovary cells).114  For this reason the focus of the 
study shifted to IY-IY-Ros; the rosamine fragment of this molecule is significantly more 
cytotoxic (IC50 0.39 ± 0.22 µM111 for Ros vs 2.79 ± 0.69 µM110 for 6MP; both for MCF-
7, human breast cancer cell line).   
Figure 2-2b compares cytotoxicity data for IY-IY-Ros on the TrkC cells (TrkC; 
IC50 = 15.80 ± 0.18 µM), and on a murine breast cancer line that also expresses TrkC 
(4T1; IC50 = 19.88 ± 2.53 µM), with that for the non-TrkC expressing NIH3T3 cells 
(WT; IC50 = 27.58 ± 1.38 µM). More cell death occurred for the TrkC-expressing cells 
than for the non-TrkC expressing ones when ligand concentrations above about 18 µM 
were used.  Cytotoxicity data for an analog with the inverted amino acid sequence YI-
YI-Ros was used as a negative control (the YI-YI motif does not bind TrkC expressing 
cells).77  The cytotoxicity of YI-YI-Ros with respect to the TrkC and WT cells was 
almost the same.  Moreover, this data was also almost identical to that for IY-IY-Ros on 
the WT cells (IC50 = 25.80 ± 2.24 and 25.79 ± 1.79 µM); these data further support the 
targeting effect of the IY-IY motif. 
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Figure 2-3.  Dose-dependent reduction of IY-IY-Ros cytotoxicity (red) in competition with the 
TrkC ligands NT-3, 3.5 nM (blue) or IY-IY-TEG, 20 mM  (green) occurs for a TrkC cells, but 
not for b WT cells.  The concentration of NT-3 and IY-IY-TEG were kept constant throughout 
the experiments. 
 
 
Further evidence for the targeting effect of the IY-IY motif was obtained from 
competition studies (Figure 2-3).  The cytotoxicity of IY-IY-Ros was reduced in a dose 
dependent way by natural protein (NT3) and by synthetic (IY-IY-TEG) ligands, but 
only for the TrkC (Figure 2-3a), and not for the WT (Figure 2-3b), cells.  Moreover, no 
competition was observed for the control with the inverted sequence YI-YI-Ros (see 
Appendix D). 
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Figure 2-4.  a 2mor-Ros and MitoTracker colocalize in TrkC cells; whereas, b IY-IY-Ros 
colocalizes with LysoTracker in the same cells, and c in murine 4T1 breast cancer cells that also 
express TrkC. 
 
 
Complexes of NT3 with TrkC are internalized by cells and localize in the 
lysosome.109  Conversely, the rosamine dye corresponding to Ros permeates into cells 
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and accumulates in the mitochondria.111  Experiments were performed in the current 
study to probe if the rosamine fragment with the bridging triazine (2mor-Ros) was 
imported in the same way as the dye without that fragment (Ros).  Figure 2-4a shows the 
distribution of the MitoTracker label in TrkC cells, distribution of 2mor-Ros in the 
same cell, and the degree of overlay.  These data indicate 2mor-Ros localizes in the 
mitochondria, just as the parent dye does. 
When the Trk cells were exposed to IY-IY-Ros, this targeted {cytotoxic} dye 
was internalized within 30 min.  Fluorescence microscopy indicated the dye co-localized 
with LysoTracker (Figure 2-4b) and not with MitoTracker, i.e. it accumulated in the 
same intracellular compartment as the TrkC-NT3 complex, and not in the same place as 
the rosamine dye.  When another TrkC-expressing line, murine 4T1 cells, was treated 
with IY-IY-Ros then this targeted {cytotoxic} dye also localized in the lysosome 
(Figure 2-4c).  These data support the hypothesis that the IY-IY motif binds the TrkC 
receptor and is internalized. 
 
Conclusions 
A small molecule motif was used in “active targeting” to deliver cytotoxic 
substances into tumor cells that express the TrkC receptor.  Underlying this study was 
the hypothesis that internalization of targeted conjugates into cells would be facile if 
mediated by receptor binding and receptor-ligand internalization.  Initial experiments 
using 6-mercaptopurine gave encouraging data, but demonstrated the importance of 
maintaining solubility and high cytotoxicity.  Conjugates of the targeting agent with a 
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cytotoxic rosamine (similar to a rhodamine) were more successful.  Targeting of TrkC 
was observed, validated in a series of competition experiments featuring other TrkC 
ligands, and accumulation into lysosomes was observed, as expected for receptor-
mediated internalization. 
The featured targeted compounds IY-IY-6MP and IY-IY-Ros are not well suited 
for in vivo studies, for different reasons.  The water-solubility and cytotoxicity of IY-IY-
6MP is inadequate for in vivo work.  For IY-IY-Ros the reasons are different; while 
these studies were in progress our collaborator Dr Hong Boon Lee tested the parent 
rosamine and found it caused severe weight loss in animals with inadequate concurrent 
reduction in tumor mass (personal communication).  Consequently, studies to use the 
same targeting entities in conjunction with other cytotoxic compounds are underway. 
Only a few small molecules are known for their active targeting effects; the 
important ones are as follows.  Folic acid targets the folate receptor23 expressed on many 
human cancers.115  Mimics of the RGD peptide116 target integrins,117-118 and riboflavin-
based compounds has been used to target its receptor expressed on some tumor types.119-
120  Bile acids target the vitamin D receptor in colon cancer and this has been 
exploited.121 Lectin-based molecules122 have been employed to direct therapeutic agents 
to the asialoglycoprotein receptor in the liver,123 and cholestenoic acid, a ligand for the 
Liver X receptor,124 also has value.  γ-Amino-n-butyric acid (GABA) or the GABA-
derivative baclofen targeting the GABAB receptor have been used in a novel approach 
for pancreatic cancer.125  Overall, there is a great deal more interest in antibody-drug 
conjugates than in targeting-small-molecule-drug conjugates.   
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Given the exquisite affinities of antibodies (mAbs) for antigens, it is easy to 
understand why mAbs have attracted so much interest in targeting approaches.  
However, we postulated above that affinity and cell permeability are both important, and 
large proteins such as mAbs tend not to permeate into cells, where as small molecules 
can.  Selective cytotoxicity studies of the kind performed here show the net effect of 
affinity and cell permeability.   
Medicinal chemistry has been heavily biased towards the discovery and 
syntheses of cytotoxic compounds whereas development of small molecule ligands for 
active targeting has received much less attention.  We suggest design and testing of 
small molecule ligands for active targeting of cancer cells, indeed for specific cell types 
in general, is both important and, so far, somewhat neglected. 
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CHAPTER III  
DOUBLE-TARGETING USING A TRKC-LIGAND CONJUGATED TO BODIPY-
BASED PDT AGENT† 
 
Introduction 
In oncology, the main problem with most FDA approved drugs is that they have 
poor therapeutic indices, i.e. they kill healthy tissue almost as effectively as tumors.  In 
response there are many contemporary efforts to perturb biochemical pathways that are 
selectively upregulated in cancerous cells, ie molecular target-oriented approaches.126  
Kinase inhibitors are target-oriented in this way because they inhibit enzymes that are 
critical to the survival of cancer cells.127-129  Another form of targeting features agents 
that selectively bind to certain types of cells and deliver imaging or cytotoxic agents 
inside.   Most current research on cellular targeting involves antibodies; this strategy is 
useful but usually does not lead to intracellular delivery.4,130  Conversely, some small 
molecules can be used for cell-based targeting and intracellular delivery;20-22,118,131  the 
problem is how to design and validate substances that will do this.  Yet another form of 
targeting is in photodynamic therapy (PDT).  PDT is physically targeted insofar as only 
the tissue illuminated by the light source is vulnerable to production of reactive oxygen 
                                                
† Reprinted with permission from “Double-Targeting Using a TrkC Ligand Conjugated to 
Dipyrrometheneboron Difluoride (BODIPY) Based Photodynamic Therapy (PDT) Agent” by 
Anyanee Kamkaew and Kevin Burgess, J. Med. Chem. 2013, 56, 7608. Copyright 2013 
American Chemical Society. 
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species from a photosensitizer and triplet oxygen.  One problem with PDT is how to 
localize the required photosensitizer in tumor tissue.  
Any strategy that involves two of the approaches outlined above might be called 
“doubly-targeted”.  For instance, a PDT agent conjugated to a small molecule cell-
targeting unit might preferentially localize in tumor cells, giving a first level of targeting.  
A second level of targeting could then be achieved by limiting the light excitation source 
and consequently generation of reactive oxygen species to that area.  There is, in fact, 
very little in the literature about cell-targeted PDT agents,83,99,132 and, to the best of our 
knowledge,97 nothing on such agents featuring BODIPY-based photosensitizers.98  
Chapter 2, we reported on a novel small molecule system for targeting cells that 
overexpress the TrkC receptor.133  That study featured two conjugates with cytotoxic 
compounds (6-mercaptopurine and a rosamine derivative), neither of which are PDT 
active.  We found the potency of the conjugates to be somewhat restricted by inadequate 
solubility or cytotoxicity of the cargo.  This chapter reports conjugates of the same cell-
targeting agent, based on Tyr and Ile side-chains (IY-IY), to a diiodo-BODIPY PDT 
sensitizer reported by Nagano et al.90 and us.91  Thus the featured conjugate called IY-
IY-PDT (Figure 3-1) can target TrkC+ cells and be physically-targeted by the regions 
exposed to light.  We had believed this is the first example of double-targeting involving 
a BODIPY-based PDT agent, but we recently became aware of similar work by Ng et al 
in a paper that now accompanies this.134 
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Figure 3-1.  Structures of TrkC+ targeting compound (1 or IY-IY-PDT) and the scrambled 
control compound (2 or YI-YI-PDT). 
 
 
Results and Discussion 
Compound 1 and Cell Lines Used.  The targeting unit IY-IY has non-cytotoxic 
groups attached to the triazine entity; it weakly synergizes with the natural TrkC 
neurotrophin-ligand, NT3, enhancing cell survival but not differentiation.77  
Overexpression of TrkC receptors is associated with some forms of cancer (e.g. 
neuroblastoma,50 medulloblastoma,108 and breast cancer63), and with melanoma,68,73,135-
137 the latter being particularly interesting because lesions near the tissue surface can be 
most effectively radiated by UV light.  Conversely, compounds with the inverted side-
chain sequence, ie YI-YI, did not show this activity.  Thus IY-IY-PDT is the featured 
cell-targeting agent, and YI-YI-PDT can be used as a negative control.  Compound 2 or 
YI-YI-PDT is an excellent control being isomeric with 1 but unable to target the TrkC 
receptor (structures shown in Figure 3-1).   Scheme 3-1 shows the synthetic route that 
was used to prepare IY-IY-PDT and YI-YI-PDT.  Basically, this entails copper-
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mediated 2+3 cycloaddition138-139 of the azido-diiodoBODIPY B, which has apparently 
not been made before, with the alkyne A featured in our earlier studies.77 
 
 
Scheme 3-1.  Synthesis of IY-IY-PDT and YI-YI-PDT 
 
 
Photophysical properties for the conjugates 1 and 2 were measured in DMSO and 
in DMEM medium; the data are presented in Figure 3-2 (and Appendix E).  The 
absorption maximum of the BODIPY core for these molecules is in the region of 540 
nm.  We judged this to be perfectly fine for the planned ex vivo studies.  As the project 
progresses after this paper, a more conjugated agent with a longer λmax will be required 
for in vivo work since tissue is far more permeable to longer wavelength light.140  
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Figure 3-2.  a UV-Vis and b fluorescence spectra (excited at 450 nm) of 1 and 2 (both at 5.5 
µM) in DMEM medium. 
 
 
Another strategy used to test for TrkC targeting in this work featured similar cell 
lines that do and do not express TrkC.  Wild type NIH3T3 fibroblast cells (NIH3T3-WT) 
do not express TrkC,141 and these could be compared with genetically modified forms of 
the same cell line stably transfected with TrkC at approximately 20,000 copies per cell 
(NIH3T3-TrkC, kindly supplied by Dr David Kaplan, The Hospital for Sick Children, 
Toronto).  We also tested a human neuroblastoma cell line, SY5Y that is TrkC-
positive.52,108 
Light and Dark Cytotoxicities.   Figure 3-3a shows data that demonstrates IY-IY-
PDT is only cytotoxic to NIH3T3-TrkC cells when illuminated (>480 nm source with 
fluence rate 12.2 mW/cm2 for 10 min), whereas this agent is not cytotoxic in the dark.  
The cells survive under the same conditions when a photosensitizer was not added (data 
not shown).  A significant PDT effect was also observed for IY-IY-PDT on the 
NIH3T3-TrkC cells as compared with the non-targeted agent YI-YI-PDT, (IC50 0.35 
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µM and >2 µM, respectively).  These experiments were performed by treating the cells 
with 1 or 2, washing them to remove the unbound agent, then illuminating.  Observation 
of some PDT effect for the negative control YI-YI-PDT can be attributed to non-
specific endocytosis; consistent with this light induced cell-death was also observed 
when the same experiment was performed using NIH3T3-WT cells (see Figure 3-6 
below and Appendix E). 
 
 
Figure 3-3.  a Cytotoxicities induced by IY-IY-PDT under light (red) and dark (blue) and 
scrambled negative control YI-YI-PDT under light (green) conditions for a cell line stably 
transfected with TrkC receptors.  Throughout this paper, in the light experiments the cells were 
illuminated with a broad spectrum source, filtered to only deliver photons of >480 nm 
wavelength, at a flux of approximately 12.2 mW/cm2 for 10 mins.  b Dose-dependent reduction 
of IY-IY-PDT photoinduced cytotoxicity (red) in competition with the TrkC ligands NT-3, 3.5 
nM (green) or IY-IY, 20 µM  (blue) on cells expressing TrkC.  The concentration of NT-3 and 
IY-IY were kept constant throughout the experiments.  Error bars were based on 3 runs. 
 
 
The PDT effect of 1 on NIH3T3-TrkC cells was dose dependent (Figure 3-3b, 
red bars).  In experiments also shown in Figure 3-3b the cells were simultaneously 
treated with a constant concentration of either the native ligand NT3 (green bars), or 
control compound A (or IY-IY; blue bars) comprised of the same targeting agent but 
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lacking the diiodo-BODIDY entity.  Data for the two competition experiments shows a 
“breakpoint” at around 0.2 µM of 1; below this, the two TrkC ligands that do not bear a 
PDT agent (ie 3.5 nM of NT3, and 20 µM of A) overwhelmed the affinity of IY-IY-
PDT to the cells so the green and blue bars do not show much cell death, whereas there 
were significant cytotoxicities in the experiments without these competing agents (red 
bars).  Above that breakpoint the effects of binding the targeted PDT agent are evident 
for the blue and green bars because the concentration of the PDT agent overwhelmed 
that of the innocuous competing controls. 
Imaging of Internalization via Confocal Microscopy.   NIH3T3 cells were treated 
with a supernatant containing 0.5 µM IY-IY-PDT for 2 h; the cells were washed (3 x 
PBS buffer), then imaged.  Figure 3-4 shows that the weak I2-BODIPY fluorescence 
becomes localized in punctates, but only for the cells that are transfected with TrkC.  No 
intracellular fluorescence was observed under these conditions for the negative control 
YI-YI-PDT (second row), or for TrkC-cells treated with the featured agent IY-IY-PDT. 
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Figure 3-4.  a Confocal imaging of: first row, the featured targeting ligand on TrkC+ cells 
showing the compound is internalized; second row, the negative control YI-YI-PDT is not 
localized under the same conditions; third row, the featured agent is not observed in TrkC- cells 
under the same conditions.  b Quantitative indications of the fluorescence intensity in each of the 
three experiments described above (error bars from 100 cells). 
 
 
The images in Figure 3-4 do not show strong fluorescence because emission 
from IY-IY-PDT is intrinsically weak.  However, bright images could be obtained by 
increasing the concentration and the incubation time from 2 h to 12 h, and these data are 
shown in Figure 3-5.  The {higher magnification} images in Figure 3-5 include 
experiments with LysoTracker Red showing that IY-IY-PDT localizes in the lysosome, 
and not in the mitochondria and endoplasmic reticulum.  It is known that when NT3 
binds the TrkC receptor the complex is internalized and also localized in the 
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lysosome.109  The fact that IY-IY-PDT is processed in the same way is therefore 
circumstantial evidence that it enters the cells via the same receptor, TrkC. 
 
 
Figure 3-5.  IY-IY-PDT colocalizes with LysoTracker Red in TrkC+ cells.  Throughout, the 
concentration of the agent used was 1 µM. 
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Photocytotoxicities on the SY5Y Neuroblastoma Cell Line.  Figure 3-6 shows that 
IY-IY-PDT is photocytotoxic to the TrkC+ neuroblastoma line SY5Y.  We were unable 
to find a neuroblastoma line that does not express TrkC, so this plot also shows the 
photocytotoxicity of the same agent on NIH3T3-TrkC and NIH3T3-WT for comparison.  
The observed photocytotoxicity of IY-IY-PDT was significantly greater for the cells 
that express TrkC than that observed for the non-targeted YI-YI-PDT control on the 
SY5Y cells. 
 
 
Figure 3-6.  Photoinduced cytotoxicity assays.  IY-IY-PDT shows high cytotoxicity for the 
TrkC expressing cells, NIH3T3-TrkC (red) and SY5Y (blue) compared to non-TrkC cells, 
NIH3T3-WT (purple).   The non-targeting ligand, YI-YI-PDT (green) is significantly less 
photocytotoxic.  Error bars were based on 3 runs. 
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Conclusions 
The featured agent IY-IY-PDT showed significantly higher photocytotoxicities 
(IC50 = 0.35 ± 0.06 µM NIH3T3-TrkC; IC50 = 0.15 ± 0.02 µM SY5Y) than similar 
conjugates we prepared featuring 6-mercaptopurine and a rosamine in place of the PDT 
agent.133  On the other hand, the non-targeted ligand YI-YI-PDT is considerably less 
cytotoxic.  
 In general, IC values can be used to calculate ex vivo therapeutic indices.142  
However, for IY-IY-PDT on TrkC+ cells relative to TrkC- ones, this was impractical 
because the conjugate had such a low photocytotoxicity to the TrkC- cells, which made it 
difficult to determine even an IC10 value.  These observations point to the considerable 
potential for selective killing of TrkC+ tumor cells, and indicate further studies to 
monitor the effects of IY-IY-PDT on TrkC+ tumors in vivo, and pharmacokinetic 
analyses of this agent, are justifiable. 
 Consideration of The Human Protein Atlas143 reveals neuroblastoma tends to 
express high levels of TrkC, and several other tumor types (notably breast and 
melanoma) express lower, but significant TrkC levels.  These tumors may therefore be 
suitable to test the targeting effects of IY-IY ligands.   
Patients afflicted with the same type of cancer may have genetically different 
tumor cell types that express different levels of TrkC.  Consequently, a goal for this type 
of research could be a form of personalized medicine of the following kind.  More 
fluorescent cell-targeting conjugates similar to IY-IY-PDT would be used to identify 
and locate TrkC+ cancers, cytotoxic materials like IY-IY-PDT are employed to reduce 
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the tumor mass, and the afflicted area is then re-imaged to gauge success.  The next step 
towards reaching this goal will be to modify the PDT agents, for the reasons below. 
Tissue is significantly more permeable to near-IR light than it is to radiation of 
shorter wavelengths.140,144-146  Consequently, it will be important to use PDT agents that 
absorb at longer wavelengths when this work progresses to the in vivo stage because in 
that case tumors can be addressed in deeper tissue.  The BODIPY fragment in IY-IY-
PDT has a UV absorption maximum of around 540 nm in DMEM (one of the culture 
media used in this work).  That absorption wavelength is suitable for ex vivo studies such 
as the ones described here.  Alternatives to the diiodo-BODIPY fragments that could be 
used for in vivo studies include aza-BODIPYs,147-151 and styryl-BODIPYs152-154 as 
featured in the accompanying paper by Ng et al.134 
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CHAPTER IV 
TARGETED PDT AGENT ERADICATES TRKC EXPRESSING TUMORS VIA 
PHOTODYNAMIC THERAPY (PDT)‡ 
 
Introduction 
Agents that selectively associate with cell surface receptors over expressed on 
tumor cells can be used to deliver therapeutics.  This strategy is referred to here as active 
to distinguish it from other forms of targeting (e.g. where the agent is intended to 
directly cause a therapeutic effect by binding cell surface receptor, or is designed to 
target intracellular pathways upregulated in cancer cells).155-156   
The most widely investigated active targeting agents are humanized monoclonal 
antibodies (hmAbs), but mAbs in general have limitations.40  First, only a few mAbs 
enter cells,4 most do not,12 and even cell-permeable mAbs may not reach the intracellular 
target.5 Moreover, mAbs can have undesirable immunogenic effects, circulation times, 
and they are further restricted by cost and shelf-life issues.16,157 
Active targeting via small molecules that selectively bind to receptors on tumor 
cells can have advantages relative to hmAbs with respect to cell-internalization and 
affordability; however, relatively few small molecule targeting entities are known.  Folic 
acid20-22,131 and Arg-Gly-Asp peptidomimetics28-32 are probably the most widely 
                                                
‡ Reprinted with permission from “Targeted PDT Agent Eradicates TrkC Expressing Tumors 
Via Photodynamic Therapy (PDT)” by Chin-Siang Kue, Anyanee Kamkaew, Hong Boon Lee, 
Lik Voon Kiew, Lip Yong Chung, and Kevin Burgess, Mol. Pharmaceutics 2015, 12, 212.  
Copyright 2015 American Chemical Society. 
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appreciated examples, but there are not many more besides these.  There are no 
clinically approved small molecule active targeting agents for delivering therapeutics to 
breast cancer.158   
 
 
 
Figure 4-1.  Fundamentals of active targeting.  a mAb conjugates have limited cell 
permeabilities, but, b many small molecule conjugates can.  c Structures of the targeted 
compounds featured in this work, 1-F and 1-PDT, and the parent iodinated BODIPY, I2-
BODIPY. 
 
 
TrkC, is a cell surface receptor and its natural ligand neurotrophin-3 were 
reported to plays an essential role in breast cancer growth and metastasis;61-62 
suppression of TrkC expression in highly metastatic mammary carcinoma cells inhibited 
their growth in vitro and their ability to metastasize from the mammary gland to the lung 
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in vivo.63  This paper features a novel molecular fragment IY (Figure 4-1) for active 
targeting of breast cancer types that overexpress TrkC.77,159-160  TrkC-targeting 
molecules 1, containing fragments IY (blue in Figure 4-1), elicit only weak functional 
effects.77  One fragment IY is not enough to bind TrkC adequately, but two joined as 
shown give good affinity.77  The scaffold part in molecules 1 (shown in black) supports 
the two TrkC-binding entities, and the BODIPY cargoes (colored purple and red here).  
The BODIPY dyes are similar, except that those without iodines are highly fluorescent, 
while ones with are only weakly fluorescent and act as sensitizers for singlet oxygen 
production.  Thus, compound 1-F (F = fluorescent) is designed for cell imaging and 
histology, while 1-PDT is intended for use in PDT.78,80   
Singlet oxygen is very reactive, half-life 1 ns to 1 ms, hence the effect of PDT 
agents illuminated in an aerobic environment is to generate 1O2 that kill cells in a highly 
localized area.  Some boron dipyrromethene (BODIPY) based-systems can have 
excellent attributes for PDT with high extinction coefficients, favorable light-to-dark 
toxicity ratios, high antitumor efficacies in vivo, and good body clearance90-91,97-98,150 but 
they are not inherently inclined to localized in tumors; accumulation of the sensitizers in 
tumors is important for PDT.  Experiments described in this paper were undertaken to 
explore the effects of coupling molecular fragments IY that can bind TrkC receptors 
expressed on breast cancer cells and deliver a BODIPY-based PDT agent to them.  As 
far as we are aware, there are no other agents, in the clinic or in the literature on 
experimental modalities, that actively target TrkC+ with a small molecular fragment that 
binds this receptor, conjugated to a therapeutic.  
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Results 
Compound 1-F Selectively Stains TrkC-expressing Tissue, and Is Internalized by 
TrkC+ Cells.  We hypothesized that agent 1-F could be used to stain tissue that 
expresses TrkC+ (e.g. from biopsies), and, TrkC+ tumors and metastases during 
surgeries.  In histochemistry on a commercial array of human breast cancer sections 
using 1-F, all 36 malignant tissues showed evidence for expression of TrkC (23 % with 
unambiguous staining in the cytoplasm and cell membrane, 65 % same but not as clear, 
and in 12 % not all the tumor cells stained); conversely, none of the normal breast tissue 
showed significant staining in the cytoplasm and cell membrane just as fluorescent anti-
TrkC mAb did (Figure 4-2a).  We infer 1-F has potential for histochemistry, and as a 
surgical marker for TrkC-expressing cancers.63 
Intracellular imaging studies featuring 1-F on murine 4T1 cells (Figure 4-2b) 
showed compound 1-F is internalized and partially co-localizes with a lysosome tracker 
dye. Thus, 1-F localizes into the lysosome, just as the natural TrkC ligand 
“neurotrophin-3” (NT3) does when it is internalized via the TrkC receptor,109 implying 
1-F also enters the cell via TrkC.  Similar experiments were performed using {the less 
fluorescent agent} 1-PDT, and the outcome was much the same (Appendix F).  
Moreover, import of 1-PDT at 2 h was more than 2-PDT into 4T1 cells, and that uptake 
of 1-PDT was suppressed by pre-treatment with the natural TrkC ligand, NT3.  
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Figure 4-2.  Compound 1-F stains in TrkC+ tumor tissue and is internalized TrkC+ cells.  a 
Histochemical stains for a library of 96 breast tissue slices were performed using 1-F (top) and 
anti-TrkC antibody as control (bottom), and the three illustrative ones shown here illustrate 
staining of the malignant tumor, whereas normal tissue is not stained.  No staining was observed 
in the tissues without the small molecule probe or mAb.  b Cell imaging on 4T1 cells shows 1-F 
was internalized into lysosomes just as the natural TrkC ligand NT3 is. 
Compound 1-PDT Selectively Kills TrkC-expressing Cells in Tissue Culture.  
Binding NT3 to TrkC on the surface of living cells causes growth and survival.161-162 
Some common breast cell lines used for cancer research express TrkC (eg human Hs578t 
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and murine 4T1) 63,163 but not in others (eg SKBR3, 67NR and MCF-10A).63,164 TrkC is 
expressed in the majority of metastatic breast tumors.66 
Figure 4-3a shows photocytotoxicities of 1-PDT are greater for the TrkC+ breast 
cancer cell lines HS578t and 4T1 than the immortalized, TrkC-, breast cell lines 67NR 
and MCF-10A.  Comparison of photocytotoxicities for the targeted PDT agent 1-PDT 
with the non-targeted form 2-PDT, and I2-BODIPY on TrkC+ expressing cells (Figures 
4-3b and 4-3c) shows the targeted agent is more photocytotoxic (IC50 = 0.325 µM in 
4T1; IC50 = 0.285 µM in HS578t) than the control ones, 2-PDT and I2-BODIPY 
(undetermined IC50), which does not bind TrkC.  These results suggest that 1-PDT 
induces selective photocytotoxicity in TrkC-expressing cells via TrkC receptor targeting.  
Some photocytotoxicity was observed for 2-PDT on the human HS578t but not on the 
murine 4T1 cells, indicating the scrambled control 2-PDT might be binding to some 
other receptor on the human line. 
Figure 4-3d shows the photocytotoxicities of 1-PDT on TrkC+ cells can be 
suppressed by the natural TrkC ligand (NT3) or the targeting agent without any 
BODIPY dye attached, “IY-IY-TEG” (structure in Appendix F).  When interpreting this 
data it is important to note that the concentration of NT3 is constant throughout, so 1-
PDT only becomes noticeably competitive with the small molecule ligand at higher 
concentrations (eg > ca 0.1 µM for human cells, Figure 4-3d right side).   
All the photocytotoxicity experiments described above involved adding the test 
compounds for 2 h incubation, washed off before illuminating the cells.  Effects of 
prolonging the incubation on the cell viability in PDT revealed that more selective cell-
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growth inhibition was achieved for TrkC+ 4T1 compared to TrkC- 67NR at 2 h 
incubation (Appendix F), and the difference becomes less noticeable when 4 h and 6 h 
incubation was used; thus a shorter incubation time is optimal for selective photo-killing 
by the TrkC-seeking conjugate.  For a full comparison, the same time course 
experiments for the untargeted 2-PDT and the parent iodinated BODIPY, I2-BODIPY, 
were also performed (Appendix F).  As expected, both compounds caused increased 
photocytotoxicity with increasing incubation time.  However, the cell viability observed 
between 4T1 and 67NR cells were similar across the different time points for incubation 
implying no selective binding to cell surface receptors (Appendix F). 
Figure 4-3.  1-PDT is photocytotoxic in TrkC+ cell lines.  a Photocytotoxicities for 1-PDT are 
more for the following breast cells: murine metastatic 4T1 and human metastatic, Hs578t; 
compared with the following breast cell lines: murine non-metastatic, 67NR; human 
immortalized MCF-10A.  b Photocytotoxicities on the 4T1 and Hs578t cells were enhanced for 
1-PDT compared to the scramble control 2-PDT featuring an isomer of the targeting fragment 
that does not adhere to TrkC+ cells and control I2-BODIPY.  c Structure of 2-PDT.  d 
Photocytotoxicities for 1-PDT on 4T1 and HS578t cells are dose dependent (red bars), and 
suppressed by fixed concentrations of competing: (i) natural ligand NT3 (blue); and, (ii) 
targeting ligand without a PDT group “IY-IY-TEG”. Data shown are mean ± SEM of three 
independent experiments.  *, p < 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 vs control using One-way 
ANOVA (A. TrkC- cell line; Β. I2-BODIPY; D. red bars) 
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Maximal Tolerated Dose (MTD) of 1-PDT is 20 mg/kg in a Murine Model.  1-
PDT at 20, 30 and 100 mg/kg was administered to mice intravenously via the tail vein, 
and toxicity was evaluated based on typical symptoms (apathy, horrent fur, diarrhea, 
behavior changes, and loss of body weight).  All mice receiving doses of 30 mg/kg or 
more experienced motility and balancing difficulties, and died 1-3 h post drug 
administration.  However, 20 mg/kg 1-PDT was well tolerated, and gave no signs of 
toxicity and death up to 17 days of post-treatment (Figure 4-4), and no sign of gross 
organ toxicity was found in autopsies performed at the end of study.   
Figure 4-4.  1-PDT was not toxic to mice at 20 mg/kg.  Healthy 7-8 weeks old Balb/c female 
mice were administered intravenously via tail vein respectively with 1-PDT and 2-PDT at 20, 
30, and 100 mg/kg (I2-BODIPY content equivalent to 6.25, 10, and 30 mg/kg respectively, ie 
corrected for MW), and the parent I2-BODIPY (30 mg/kg). The mice were then kept in the dark 
and observed for 16 days.  Data represent the average body weight (grams) of 2 mice/treatment 
group. 
No death or signs of toxicity was observed in mice receiving equivalent doses of 
2-PDT and BODIPY.  These results suggest 20 mg/kg is the maximum tolerated dose 
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(MTD) for 1-PDT.  If after further studies, these compounds were to be used 
therapeutically, then the dose should be significantly less than this; however, 
modifications to the dye structures are required first (see below). 
Agent 1-PDT Accumulated Maximally in Tumor Tissues 1 h after Administration 
and Cleared from the Body 72 h Post-treatment.  The biodistribution of 1-PDT and the 
isomeric non-TrkC targeting control 2-PDT were monitored in 4T1 tumor bearing mice 
(n=3) up to 72 h.  Significant and prolonged accumulation of 1-PDT was observed in 
tumor (Figure 4-5).  At 1 h post administration, the fluorescence intensity of tumors in 
mice treated with 1-PDT was 2.1x higher (897,000 ± 135,800) than the corresponding 
intensities for tumors treated with the non-targeted control 2-PDT (416,000 ± 43,000) 
(p<0.05, Student’s t test).  The 1-PDT dye intensity in tumor tissue remained 
significantly higher compared with 2-PDT for up to 6 h, but there were no significant 
differences at 24 h onwards.  Trends in the 1-PDT tumor distribution were significantly 
different to that of 2-PDT, indicating selective accumulation of 1-PDT in the tumor.  
Maximum accumulation of 1-PDT at 1 h post administration led us to adopt a drug-to-
light interval of 1 h in determining 1-PDT’s in vivo antitumor efficacies in the 
subsequent studies. 
A large amount of 1-PDT accumulated in the liver (ca. 20 fold more than in the 
tumor), then in the kidney and lung within the first 3 h post administration (Figure 4-5), 
but these accumulations dissipated swiftly in the subsequent monitoring period.  A 
similar pattern of accumulation was found for 2-PDT.  Swift clearance of both 
compounds in this organs is typical of small molecular weight compounds,150 and 
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indicates that the accumulation in these organs was random and not due to TrkC receptor 
binding.  
Non-selective accumulation of 1-PDT and 2-PDT was also observed in 
lymphoid organs such as spleen and lymph node at a much lower level (Figure 4-5); 
others have observed no significant TrkC expression for these organs.165  Interestingly, 
2-PDT but not 1-PDT was found to accumulate significantly in the lymph node for a 
prolonged period of time.  The eye has relatively impermeable blood capillaries and low 
TrkC receptor expression,166 whereas murine eyes express relatively few TrkC receptors, 
concentrated mainly at nerve bundle portions.167 
1-PDT at 10 mg/kg Gave Effective Eradication of 4T1 Tumor with 96% Average 
Tumor Regression.  Compound targeting efficacies and effects on TrkC+ tumors were 
assessed in the following experiments.  Aggressive TrkC+ murine breast carcinoma 
(4T1) cancer cells were subcutaneously injected to the murine mammary fat pad and 
then treated with 1-PDT, 2-PDT, and I2-BODIPY when the tumor sizes reached 80 
mm3.  In a control, mice inoculated with TrkC- murine breast carcinoma 67NR cancer 
cells were also treated using these compounds. 
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Figure 4-5.  1-PDT demonstrated significant and prolonged accumulation in tumor tissue for up 
to 6 h and cleared from the body 72 h post-administration.  4T1-tumor bearing female Balb/c 
mice were treated at 10 mg/kg via the tail vein.  Mice (n=3) were sacrificed at 0, 0.25, 1, 3, 6, 24, 
48, 72 h.  a Organs and tissues (tumor, draining lymph nodes, spleen, kidney, liver, lung, skin 
and eye) were harvested; and, b fluorescence intensities in each organ were imaged using an in 
vivo imager (data represent mean ± SEM of three mice at each time point). * p< 0.05; ** p< 0.01 
Student’s t test; for 1-PDT vs 2-PDT. 
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Agent 1-PDT significantly reduced tumor growth after illumination when treated 
at 2 and 10 mg/kg (equivalent to 0.6 and 3.0 mg/kg of I2-BODIPY, respectively).  
Inflammation and erythema surrounded the irradiated tumor region was observed in the 
1-PDT treated groups at 4-6 days post PDT, but was less pronounced or not observed in 
the control groups (Figure 4-6a).  Subsequently, tumor sizes were drastically reduced in 
the 1-PDT treated groups 4-6 d post-illumination (61 % and 96 % maximum tumor 
reduction in mice treated with 2 and 10 mg/kg of compound compared to pre-treatment 
tumor size, Figure 4-6b).  In contrast, 2-PDT and I2-BODIPY treatment induced only 
moderate tumor size reduction within the first 6 d after illumination (20 % reduction for 
mice treated with 10 mg/kg of 2-PDT, and 11% reduction for mice treated with 10 
mg/kg of I2-BODIPY, Figure 4-6b).  At day 13, both 2-PDT and I2-BODIPY treated 
mice showed rapid tumor re-growth at the necrotic tumor tissue periphery while tumor 
regrowth in 1-PDT treated mice was minimal and delayed (Figure 4-6a & 4-6b).  More 
importantly, 1 out of 7 mice (14%) treated with 2 mg/kg, and 5 out of 7 mice (71%) 
treated with 10 mg/kg of 1-PDT healed from eschar by day 13-15 after illumination, and 
showed no palpable tumor for up to 90 d post-treatment.  Such total tumor remission was 
not found in both the 2-PDT and I2-BODIPY treated groups.   
To confirm the targeting ability of 1-PDT on TrkC+ cells in vivo, the compound 
efficacy in the non-TrkC expressing 67NR tumor cell line in mice was examined and 
compared to that in the 4T1 model; as expected, neither 1-PDT nor 2-PDT at 10 mg/kg 
fully eradicated the 67NR tumors in mice (Figure 4-6c); the tumor volumes were 
reduced at day 4 - 6 days post-illumination but re-grew at day 9. 
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Mice Surviving Treatment with 1-PDT Showed Complete Remission up to 90 
Days Post-illumination, with No Metastasis Development.  All 1-PDT treated mice that 
showed complete tumor regression remained disease free with no palpable tumor at the 
primary site up to 90 d.  Tumors from 4T1 cancer cells are known to be aggressive and 
typically metastasize to lymph nodes, liver and lung, even in the early stages of the 
disease168.  Thus, at 90 d post-illumination, the surviving mice that were physically 
active were sacrificed for major organ/tissue histopathology by a certified veterinary 
pathologist.  H&E staining showed no 4T1 tumor metastases in all the examined organs 
(liver, lung, draining lymph node, spleen, kidney and heart) of the 10 mg/kg 1-PDT 
treated survivor mice and tumor free control mouse (Figure 4-6d).  However, in 4T1 
tumor bearing control mice, tumor metastases were found in liver, lung, lymph nodes 
and spleen with extramedullary hematopoiesis observed in this animal (Figure 4-6d).  
These results show effective eradication of TrkC expressing 4T1 tumor by 1-PDT post 
PDT treatment in the survivor mice. 
Discussion 
The assertion that agent 1-PDT targets TrkC+ breast cancer cells is supported by 
the observation that it has a more profound effect on these tumors than the isomeric 
compound, 2-PDT, and the PDT agent without any appendage, ie I2-BODIPY.  This is 
consistent with the significant in vivo selective accumulation of 1-PDT in TrkC+ tumors 
1 h after administration, as calibrated relative to levels of 2-PDT at the same time.  
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Moreover, 1-PDT, 2-PDT, and I2-BODIPY have comparable effects on tumors from 
TrkC- cell lines.   
 
 
 
Figure 4-6.  1-PDT effectively suppressed the growth of TrkC+ (4T1) tumor, but not in TrkC- 
(67NR).  a Regrowth of TrkC+ 4T1 tumor (yellow arrow) in female Balb/C mice receiving 2-
PDT (10 mg/kg), I2-BODIPY (3.0 mg/kg) and saline controls, but not in mice receiving 1-PDT 
(10 mg/kg).  b Significant dose dependent mean tumor volume reduction and delayed tumor 
regrowth in TrkC+ 4T1 tumor bearing mice receiving 2 and 10 mg/kg 1-PDT, as compared to 
rapid tumor growth in mice receiving the control substances.  c 1-PDT gave impermanent and 
non-selective antitumor effect (resembled that with 2-PDT) in mice bearing TrkC- 67NR tumor. 
Photo-activation was conducted at 100 J/cm2 with a fluence rate of 0.16 W/cm2 1 h after 
intravenous injection of the compounds. All graph showed mean tumor volume ± SEM (n=7). * 
p< 0.05; ** p< 0.005; for I2-BODIPY vs 1-PDT and 2-PDT group using One-way ANOVA.  d 
There were no tumor metastases in 1-PDT treated survivor mice post 90 d.  Mice treated with 10 
mg/kg 1-PDT that survived up to 90 d with no palpable primary tumor found were metastases 
free in all the major organs assessed (liver, lung, draining lymph node, and spleen, representative 
histological images).  Control (tumor free healthy and 4T1 tumor burden mice) results were 
included for comparison (yellow arrow = 4T1 tumor metastases).  Scale bar: 100 mm.  The 
current results had been verified by certified veterinary pathologist.   
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Figure 4.6  Continued. 
 
 
The data outlined above are consistent with ex vivo studies on cells stably 
transfected with TrkC,169 but those experiments did not involve breast cancer cells.  In 
this manuscript we report selective photocytotoxicity of 1-PDT ex vivo correlates with 
natural levels of TrkC+ expression in breast cell lines.  The cell studies established that a 
4 – 6 h interval between treatment and illumination decreased the selectivity for TrkC-
expressing cells relative to a 2 h interval; perhaps due to relatively slower, and non-
selective, interaction with cells, something that could be anticipated from the 
literature.107,170  Consequently, we used a 1 h interval between injection and light 
treatment for the in vivo work.   
It is remarkable that 1-PDT at 10 mg/kg in vivo caused, on average, 96% tumor 
volume reduction in the mice bearing TrkC+ tumor at day 6 post-PDT.  Among these 
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mice, 71 % showed full remission and were tumor- free for 90 days after therapy, and 
histology indicated no metastasis development in these animals.  The fact that 1-PDT 
was ineffective for suppressing TrkC- (67NR) tumors in mice supports the overall 
assertion that this compound targets TrkC+ expressing tissue in vivo. 
Long- and short-term toxicities of agents like 1-PDT must be considered in the 
context of experimental therapeutics.  In the dark, the TrkC-targeting fragments featured 
are capable of transducing signals similar to NT3 upon binding to TrkC,77 so it is 
conceivable that in the long term 1-PDT might induce tumorigenesis just as NT3 does.62-
63,171  However, this was not the case in the extended time course of these experiments 
since, in the dark mice receiving saline control or 2-PDT (no TrkC binding) have 
comparable tumor volumes, with no significant differences, to the 1-PDT group 
(Appendix F). 
Another relevant long-term toxicity issue relates to photosensitivity.  Intravenous 
administration of photosensitizers can result in accumulation in different tissues and 
undesirable photosensitivities.172 Adverse photosensitivity is common in PDT,173-174 but 
targeting PDT agents to tumors that express TrkC should alleviate some of these effects. 
Short-term toxicities for agents that bind TrkC could be anticipated since NT3 promotes 
neuronal cell survival, differentiation and synapse transmission, antagonism at the TrkC 
receptor might have undesirable effects.   
Short-term toxicities of agent 1-PDT are a concern because, while doses of 20 
mg/kg were tolerated, 30 mg/kg was not.  A claim that high doses of neurotrophins 
(including NT3) promote relatively rapid excitotoxic necrosis of neurons 175 might be 
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pertinent.  In any event, 1-PDT requires further structural modifications because the 
light wavelength to excite this is optimally around 520 nm whereas PDT agents should 
absorb above 700 nm if they are to be addressed at more than 1 cm tissue 
penetration.140,144-146  Consequently, 1-PDT is a prototype for other compounds, 
currently under development in our laboratories, that involve the same targeting 
fragments differently disposed around other PDT active dyes.  It is anticipated that the 
short-term toxicities of the second-generation systems will be structure-dependent. 
 
Conclusions 
Overall, the data presented here demonstrate the potential of targeting TrkC+ 
tumors with PDT agents.  Excellent therapeutic indices can be achieved because PDT is 
spatially restricted to the illumination area, and active targeting accumulates the agents 
in the tumors.  This study features dosing with a targeted-PDT agent alone, but there is 
also the intriguing possibility of combination therapies featuring Trk inhibitors currently 
in trials as chemotherapeutic agents (eg Lestauritinib176 and PLX7486 
(http://clinicaltrials.gov/show/NCT01804530). 
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CHAPTER V 
AN AGENT FOR OPTICAL AND PET TARGETING OF THE TRKC RECEPTOR 
 
Introduction 
Tropomyosin receptor kinases (Trk’s) are a family of cell-surface receptors that 
bind the neurotrophin growth hormones.177  For instance, docking neurotrophin-3 (NT3) 
with TrkC triggers intracellular phosphorylation, then a network of cell signaling 
processes that lead to cell growth and differentiation.161,178  Mis-regulation of Trk 
receptors is associated with several forms of cancer.  Thus TrkC receptors are over-
expressed in some forms of neuroblastoma,2,6-8,18,42-43,50-55 glioblastoma,54,57-60,179 
metastatic breast cancer61-67 and metastatic melanoma.68-76   
Correlation of Trk receptor expression with cancer67,135,180-181 means that these 
receptors are possible targets for imaging agents.  Consequently, synthetic TrkB-182 and 
pan-Trk-binding agents55 functionalized with radionuclei have been explored for 
imaging with positron emission tomography (PET).  However, to the best of our 
knowledge, no synthetic imaging agents have been reported for selective PET- or 
optical-imaging of TrkC in vivo.   
Research described here was undertaken to establish a TrkC-selective optical 
imaging agent that could also be used for PET studies.  Prior studies from our 
laboratories featured the TrkC-homing ligand shown in 1 and a control, isomer 2, that 
does not bind TrkC (see Chapter 3 and 4 for details).  System 1 equipped with the 
BODIPY dye fragment shown was internalized by TrkC-expressing cells and it could 
  52 
also be used as a staining agent for breast cancer and melanoma tissue, both of which are 
associated with TrkC overexpression.  There are methods for 19F-to-18F substitution in 
BODIPY dyes,183-186 and in unpublished studies we tested these for 1 and obtained a 
derivative that selectively radiolabeled TrkC-expressing cells.  Based on these 
observations it seemed likely that a PET/optical imaging theranostic could be obtained 
from system 1, but the structure of the dye required optimization first, for the following 
reasons. 
 
 
 
Figure 5-1.  First generation TrkC targeting ligand-conjugate (1) and its control (2).  Second 
generation TrkC targeting proposed system C. 
 
 
Light of wavelength 520 nm, as used to excite the BODIPY in 1, is too short for 
efficient penetration of more a few mm in tissue.97-98  To overcome this challenge, the 
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most obvious solution is to prepare an almost identical structure with a near-IR-
absorbing probe directly replacing the BODIPY.  However, modifications to fluors to 
make them near-IR absorbing invariably increase their molecular size because more 
extended conjugation is necessary.  This requirement runs counter to a desire to keep the 
molecular mass of the targeted probe to a minimum thereby avoiding undesirable 
absorption, metabolism, and excretion effects.  We hypothesized one way to reconcile 
these opposing parameters was to replace the black part of structure 1, which serves no 
purpose other than as a scaffold-spacer, with a near-IR fluor giving the conceptual 
structures C (Figure 5-1).  Syntheses of these molecules would facilitate answering the 
key issue, ie what impact this structural modification has on the targeting efficiency.   
We speculated that type-C molecules might also help alleviate another issue with 
the design A: toxicity at elevated doses.  In a photodynamic therapy experiment,83,97-98 
10 mg/Kg of A (where the probe is an iodinated BODIPY dye) caused complete ablation 
of a tumor.  That amount of compound (10 mg/Kg) is well below the maximum tolerated 
dose (ca 20 mg/Kg) but above 30 mg/Kg that compound caused lethal neurotoxic effects 
in mice.187   Moreover, neurotoxicity was also observed when a much smaller dose (eg 
ca 1mg/kg) was used in anesthesia mouse model.  There was no way to test the 
hypothesis that adjusting the spacing of the targeting groups as in C might modulate the 
neurotoxicity, other than synthesis and testing.  Consequently, we set out to prepare 
type-C molecules and assay their targeting properties in vivo, while observing for 
evidence of neurotoxicity.   
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Design considerations noted above led to embodiments of systems C wherein the 
fluor is an aza-BODIPY (Figure 5-2).    Aza-BODIPY dyes tend to have significantly 
longer absorption and emission wavelength maxima than their BODIPY analogs.94,188-189  
Moreover, in our experience, aza-BODPY dyes tend to be more stable than alternatives 
like cyanines, and have the added advantage that the BF2 fragment can be tagged with 
18F.  Thus we decided to prepare the targeted aza-BODPY dyes 3a and b.  Probe 3a was 
appealing because the sulfonic acid groups would enhance the hydrophilicity of the 
molecule and their negative charge might reduce non-specific binding to cells.  
Conversely, 3b has the advantages of smaller size, and more facile synthetic access.  The 
objective of this study was to come to an early decision about the probe design, 3a or 3b, 
with the most suitable properties for targeting, by considering the physical properties of 
the dyes.  The lead candidate probe would then be tested for: (i) binding and 
internalization by TrkC-expressing cells; (ii) staining TrkC-expressing fixed tissue 
(histochemistry); and, (iii) comparative distribution in healthy mice and ones bearing 
TrkC-expressing breast cancer.  
 
 
Figure 5-2.  Second generation TrkC targeting ligands featured in this work. 
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Results and Discussion 
Coupling of the azido acid derived from L-tyrosine190 with the disulfonated aza-
BODIPY 5-2, prepared as described in Appendix C,191 gave the diazide 5-3.  A copper-
mediated cycloaddition138,192 of 5-3 with the alkyne derived from L-leucine190 gave the 
desired product 1a.  Probe 1b was prepared via an analogous route, but beginning with a 
diamine aza-BODIPY precursor to 5-2; a Scheme and full details of that synthesis are 
given in Appendix G. 
  
 
 
Scheme 5-1.  Preparation of TrkC-targeted near IR probe 3a. 
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Distribution of Probes 3a and b in TrkC+ Murine Breast Cancer Cells.  TrkC-
expressing, murine breast cancer cells (4T1 line) were treated with probes 3a and b.  
Observation of the cells using confocal microscopy (Figure 5-3a) showed the sulfonated 
system 3a was efficiently internalized whereas the more lipophilic system 3b gave 
significantly more cell-surface binding (Fig 5-3b).  For both probes, the material that 
was internalized overlaid with a lysosome tracker, indicating it accumulated in that 
organelle.  
 
 
Figure 5-3.  Imaging with 4T1 cells.  a Probe 3a was internalized; whereas, b much more of 3b 
accumulated in the cell walls.  c LysoTracker and probe 3a (d) colocalized; the fraction of 3b 
that internalized also accumulated in the lysosomes (not shown, see Appendix G). 
 
  57 
Data shown in Figure 5-3 support the assertion that the sulfonic acid groups of 3a 
reduce non-specific binding to TrkC+ cells relative to the neutral probe 3b.  This is 
somewhat expected because of repulsion between the negatively charged sulfonic acids 
and polar head groups at the cell surface.193  Consequently, all the subsequent work in 
this research was focused on 3a, and studies of 3b were discontinued. 
Probe 3a showed no signed of toxicity to 4T1 cells at concentrations up to and 
including 25 µM.  The intrinsic fluorescence of 3a was used to determine a dissociation 
constant for its binding to TrkC on the cell surface. 
Commercial samples of fixed human tissue from patients with stage 1, 2, and 3 
malignant breast cancer were purchased (US Biomax).  Probe 3a was used to treat these 
samples and the staining was compared to that observed for normal breast tissue 
proximal to the tumor, obtained from the same patient in each case; illustrative data are 
shown in Figure 5-4.  In all cases the tumor tissue stained strongly whereas the healthy 
samples showed much less fluorescence.  We were encouraged by the selectivity, but 
slightly surprised that the healthy tissue showed faint staining.  It appears that this is 
genuine binding to the TrkC receptor in the healthy tissue (rather than non-specific 
binding or fluorescence leakage into the red channel) because fluorescently labeled TrkC 
mAb also stained the normal tissue (see Appendix G).  This may mean the tumor 
environment is causing the surrounding normal tissue to upregulate TrkC expression. 
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Figure 5-4.  Histochemistry on human breast tissue array.  Probe 3a stained on breast cancer 
tissue (b) much brighter than matched adjacent breast tissue control (a), (example from 3 cases). 
 
 
In vivo studies of 3a were done by our collaborator in Houston Methodist 
Research Institute, Dr. Zheng Li.  Probes 3a and its control (isomer of 3a, structure in 
Appendix G) were injected into a murine breast cancer model via tail vein.  The optical 
imaging showed 3a rapidly accumulated in the tumor but was completely cleared after 
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24 h while most of the control compound accumulates in kidney, no tumor accumulation 
is observed (Figure 5-5).  Moreover, neurotoxicity was not observed at 100 nM and 
during the time course of the experiments. 
  
 
Figure 5-5.  In vivo imaging of 3a in mice bearing 4T1 breast tumor model.  Top panel, 
compound 3a accumulates in tumor and clearance from the body after 24 h.  In the control 
panel, most of the control compound (structure in Appendix G) accumulates in kidney, no tumor 
accumulation is observed. 
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Incidentally, the spinal cord of the mouse was nicely imaged by 3a, presumably 
because TrkC+ cells are highly concentrated in the peripheral nervous system.  This is 
interesting because a weak agonist of TrkC, that causes cells expressing that receptor to 
grow and divide have the potential to stimulate nerve cell regrowth; this can be useful 
for regeneration of spinal cord injury.  Thus, agonistic effect of 3a is under investigation.  
Our hypothesis is that the neat property of our agonist is that it is also a near-IR dye that 
would facilitate: (i) visualization of the spinal cord in animal model; and, (ii) may induce 
some spinal cord repair if administered repeatedly over time, and be self-indicating to 
observe that. 
 
Conclusions  
  Our second generation targeting probe is more suitable for in vivo studies 
because of its near-IR absorption.  Agent 3a is more practical than 3b because it has two 
sulfonic acid groups to enhance hydrophilicity and reduce non-specific binding. 
Histology and live cell imaging showed 3a selectively bound to TrkC+ tumor cells.  
Furthermore, in vivo imaging using a murine breast cancer model showed 3a 
accumulated rapidly in the tumor but was completely cleared after 24 h; moreover, 
neurotoxicity was not observed.  Probe 3a also has potential as a positron emission 
tomography (PET) agent via 19F to 18F exchange; use of this probe for PET is under 
investigation by collaborators.  
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CHAPTER VI 
ACTIVELY-TARGETED, NEAR-IR, PET-IMAGING AND PDT AGENTS FOR 
TREATMENT OF MELANOMA 
 
Introduction 
About a third of all cancers in the United States are associated with the skin, 
mostly basal- and squamous-cell carcinomas (ie surface and sub-surface).  Only 4% of 
these are malignant melanomas, but they are responsible for more than 75% of all skin 
cancer deaths.194  An estimated 114,900 new cases of melanoma were diagnosed in the 
United States in 2010 with nearly 8,700 resulting in death, and these were responsible 
for the third most common type of brain metastasis after lung and breast cancer.  
Melanoma is particularly resistant to conventional therapies.82 
Imaging Of Melanoma.  Each of the methods for imaging melanoma has 
attributes and limitations, so it is unclear which one is preferred.  Computed tomography 
(CT), magnetic resonance imaging (MRI), and ultrasound are anatomical imaging 
techniques.  CT and MRI detect structural changes, while tissue-density fluctuations at 
secondary tumor sites are exposed by ultrasound; however, tissue-density fluctuations 
are not characteristic of all forms of melanoma.  Ultrasound contrast agents have 
improved the accuracy of sentinel lymph node metastasis detection, but only if near the 
primary tumor.  Finally, fluorescence imaging is also valuable; surgical procedures can 
be improved by using fluorescent probes that bind to cancer cells, making them more 
conspicuous.195 
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2-18Fluor-deoxy-D-glucose (18FDG) labeling is the most common PET technique 
for detection of metastatic lesions and staging of melanoma.196-198  This method is 
sensitive and specific, but it tends to fail to detect lesions smaller than 3 – 4 mm, and 
tumors having insignificantly increased FDG metabolism.199  Moreover, FDG 18F can 
accumulate in inflammatory tissue and this may cause false positives which give the 
erroneous impression that certain patients are not responding to treatment.200  Thus 
imaging of cancer using PET would be advanced by development of targeting agents 
that overcome these problems, particularly for micrometastases.   
Syntheses of all new agents for 18F-PET imaging must overcome several 
challenges. The only practical source of 18F, 18-fluoride, is generated by proton 
irradiation of H218O in a cyclotron.201-204 The half-life of 18F is short (110 min) so its use 
requires fast, high-yielding, incorporation into the imaging agent immediately before 
administration.  However, fluoride ions are relatively unreactive to most electrophiles 
even at high concentrations in anhydrous media, and this inertness is accentuated for low 
concentrations of aqueous 18F- by dilution and H-bonding effects.  Consequently, 
syntheses must accommodate late-stage incorporation of 18F atoms into the imaging 
agents via reactions that can be performed in an hour or so, preferably with dilute 
aqueous 18F-, and which do not require extensive purification.  Many desirable potential 
18F PET agents simply cannot be made via procedures that fit this description.  
There have been some attempts featuring radiolabeled peptides to increase the 
sensitivity and specificity of PET for imaging small peripheral metastases.205   These 
studies include peptides targeting somatostatin receptors, metalloproteases,206-207 
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vasointestinal peptides, oligosaccharides targeting sentinel lymph nodes,208 gastrin-
releasing peptide,209 or the fibronectins210-211.212-213   None of these targeted PET-
imaging strategies are particularly suitable for melanoma.   
Photodynamic Therapy (PDT) Of Melanoma.  Photodynamic therapies feature 
photosensitizers that generate reactive oxygen species from triplet oxygen, thus 
inhibiting cell proliferation and survival, upregulating apoptosis, and inducing 
autophagy.  This strategy is minimally invasive, and inherently targeted (though not 
actively targeted) because tissue damage can be constrained to the illuminated area.194  
Preclinical studies of PDT for melanoma therapy194 have shown that methylene 
blue, verteporfin, and several other photosensitizers are effective.214  These data 
contradict a dogma, widely held until about 2005, that PDT is ineffective for treatment 
of melanoma because the dark-colored melanocytes interfere with absorption of light by 
the PDT agent.214  In fact, PDT can be effective if near-IR absorbing photosensitizers 
(λmax >700 nm) are used.81-82  Photosensitizers of this kind can be excited at relatively 
deep tissue penetrations, and at wavelengths above the absorption maxima of 
melanins.81-82,215  For instance, a human clinical trial using chlorin e6 as a PDT agent 
resulted in complete regression of skin melanoma metastases with no recurrence during 
the 2 year study.216 
The Sinclair Swine Melanoma Model.  The Sinclair swine cutaneous malignant 
melanoma model is highly heritable, highly penetrant, and histopathologically well-
characterized.217  This condition can develop in utero or after birth, and is lethal to about 
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one quarter of the animals.  All the congenital lesions in this model arise from epidermal 
melanocytes. 
 Sinclair pigs are excellent for preclinical studies because their melanoma occurs 
naturally without the need for suppression of the immune system or surgical procedures.  
This is important because tumor development and inflammation tend to be intimately 
related.  Pig models are more relevant to humans than many frequently used alternatives.  
The Sinclair model has similar pathology to human melanoma,218 and gives rise to a 
pattern of metastatic spread that is analogous to metastases in humans; in both cases the 
primary tumors can spontaneously metastasize to numerous organs including the brain.  
Consequently, Sinclair pigs are especially useful in studies to enhance PET and MRI 
imaging of small solid tumor metastases. The Sinclair pig model is not widely available, 
but it is established at TAMU (Prof. Duane Kraemer at TAMU). 
Experience gained applying this model at TAMU has shown that piglets as 
young as 6 wks old (3 – 5 Kg bw) can tolerate PET and MRI under anesthesia, and that 
the wash out times for labeling agents are comparable with those in humans.  
 
Figure 6-1.  Tumor on right leg of Sinclair piglet; subject died 4 weeks post-partum due to lung 
and liver metastases. 
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Photosensitizers coupled to targeting agents can be used to confine the PDT 
effect to tumor regions that are illuminated; this doubly targeted approach could greatly 
reduce collateral damage to healthy tissues.  Humanized mAbs have been used to 
achieve this,101 but these large proteins generally prevent PDT agents attached to them 
entering cells, lowering their effectiveness.  Moreover, application of mAbs in the clinic 
is restricted by the cost and difficulties of large-scale, GMP mAb preparations.  For 
these reasons, small molecule targeting may be preferable but, to the best of our 
knowledge, no small molecule ligands have been used to actively target PDT agents to 
melanoma.   
A small molecule that can be used to localize imaging agents in tumors must be a 
candidate to similarly direct conjugated PDT agents for therapy.  Consequently, 
simultaneous development of imaging and PDT agents based on the same small 
molecule targeting groups are highly synergistic. 
 
Results and Discussion 
Two fragments of the targeting, “IY” novel dipeptide mimics containing 
isoleucine and tyrosine side-chains are joined in molecule 1 (Figure 6-2).  This probe 
binds cells which overexpress TrkC,133,169 but it has only mild agonistic effects on the 
cells at high concentrations (20 µM).77   When that targeting motif is attached to an 
agent for fluorescence we refer to it as 1-F, or for photodynamic therapy (PDT) then the 
compound may be called 1-PDT.  Compound 2, an isomer of 1 with a scrambled of 
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dipeptide fragment; it is a useful control because it has the same molecular mass, and 
therefore very similar polarity, solubility etc, but it does not target TrkC. 
 
 
Figure 6-2.  a Structures of first-generation agent 1, and an important control, 2.  I2-BODIPY is 
another control; it is the PDT photosensitizer without any targeting group. 
 
 
In healthy Balb/c mice, 20 mg/kg 1-PDT was well tolerated, and gave no signs 
of toxicity or death up to 17 d of post-treatment or indication of gross organ toxicity in 
autopsies at the end of study (see Chapter 4 for details; collaborative study with workers 
at University of Malaysia).  Agent 1-F is used in histological stains and intracellular 
imaging via confocal microscopy.  Tumor and healthy skin tissues were obtained from 
the same melanoma-afflicted pig (Figure 6-3b and c).   
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Figure 6-3.  a Under ambient light, 1-PDT shows no evidence of toxicity in mice (data obtained 
by collaborators, Dr’s L. Y. Chung and L. Kiew, University of Malaysia).  b Melanoma tissue 
from a melanoma afflicted pig (c). 
 
 
Figure 6-4 shows immunohistology that confirms the pig melanoma tissue, but 
not healthy skin from the same pig, expresses TrkC (binds anti-TrkC mAb).  Similarly, 
histochemistry confirms 1-F binds to cell surface receptors in melanoma tissue, but not 
to the healthy keratinocytes, from the same pig, implying the anti-TrkC mAb and agent 
1-F have similar binding profiles.  However, agent 2-F, the control probe, does not show 
significant fluorescence in melanoma or healthy skin tissue, implying that 2-F does not 
bind a receptor overexpressed on the skin surface (i.e. TrkC).  
 
50 
60 
70 
80 
90 
100 
110 
120 
130 
140 
150 
0 3 6 9 12 15 18 %
 o
f i
ni
tia
l b
od
y 
w
ei
gh
t (
g)
 
Days post compounds administration 
Control Saline 
I2-BODIPY (30 mg/Kg) 
2-PDT (100 mg/Kg) 
1-PDT (20mg/Kg) 
a b c
  68 
 
Figure 6-4.  Staining with a fluorescently labeled TrkC mAb shows a healthy skin tissue does 
not, but b melanoma tissue does, express significant amounts of the TrkC receptor.  c When 
treated with 1-F, healthy skin do not stain, but melanoma tissue from the same pig does (d), 
similar to anti-TrkC-F* mAb.  No significant fluorescence was observed from agent 2-F in both 
normal tissue (e) and melanoma (f).  Throughout the blue stains in cell nuclei, and the green 
coloration is due to the fluorescent mAb or 1-F. 
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The experiments in Figure 6-4 support the assertion that melanoma in the 
Sinclair swine overexpresses TrkC relative to healthy keratinocytes.  Human tissue 
samples were also tested to see if this observation holds for melanoma patients.  Thus, 
48 human tissue samples (US Biomax) were obtained, 40 from melanoma patients, and 8 
from healthy tissue.  There was some variance in the staining data from different tissue 
samples, but Figure 6-5 is representative of the overall trend.  All tissue samples from 
the melanoma patients stained in the cytoplasm and/or on the membrane when treated 
with 1-F (or anti-TrkC mAb), whereas the healthy tissues gave no similar staining 
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Figure 6-5.  Human melanoma tissues stained with 1-F in the cytoplasm (a), or on the 
membrane (b), whereas normal tissue does not. 
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We have cultured melanoma and healthy skin from the same pig, overcoming the 
problems that prevent healthy cells being cultivated through several passes.  The tissue 
cultures shown in Figure 6-6a on the left are from melanoma cells; these were relatively 
easy to grow.  However, the cultured healthy skin cells shown on the right would 
ordinarily be difficult to culture, but we were able to do this via “The Georgetown 
Method” (ROCK inhibitor and irradiated fibroblast feeder cells).219-220 
 
 
Figure 6-6.  a Cultured melanoma and normal skin from the same pig.  Healthy skin cells were 
cultured using “The Georgetown Method” that features irradiated feeder cells and a ROCK 
kinase inhibitor to ensure that multiple passages could be obtained.219-220  b 1-F is internalized 
into the lysosome of melanoma cells, (fluorescence overlays well with LysoTracker dye). 
 
 
Figure 6-7 shows the differential light induced toxicity of 1-PDT on melanoma 
cells relative to healthy skin cells.  The targeted PDT agent shows more 
photocytotoxicity to the pig melanoma cells, which overexpress TrkC, than to healthy 
pig keratinocytes that have insignificant TrkC expression.  Moreover, the targeted probe 
is more phototoxic than the control one (Figure 6-7a).  Parallel experiments featuring 
B16 murine melanoma cells, have been performed, and the outcome was similar (data 
not shown).  Figure 6-7b shows how the dose dependent effects of the targeted PDT 
agent can be competed using the natural TrkC ligand NT3, or the targeting fragment 
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with no appendage for PDT.  The background phototoxicity might be due to non-specific 
binding of PDT probes or the effect of PDT from the I2-BODIPY fragment. 
 
 
Figure 6-7.   a 1-PDT is more toxic to melanoma than to healthy keratinocytes (“normal”) from 
the same pig.  The targeted PDT is more toxic than the control one.  b Targeted 
photocytotoxicity of 1-PDT for melanoma cells can be suppressed by the natural protein ligand 
for TrkC (NT3), or by the targeting fragment without a PDT label on it (IY-IY-TEG, TEG = 
triethylene glycol) in a dose dependent manner. 
 
 
For in vivo optical imaging, the fluor in 1b, which absorbs around 520 nm, is 
unsuitable because observation of non-superficial tissue requires agents that absorb at 
longer wavelengths (ideally, >700 nm).  Therefore the near-IR probe that is used to 
target TrkC in the breast cancer model (Chapter 5) must be able to target TrkC in 
melanoma.  To prove this, probe 3a was used to stain tissues obtained from the Sinclair 
Swine.  Figure 6-8 shows bright fluorescence of 3a can be observed from melanoma 
tissue but significantly less is seen for the normal tissue.      
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Figure 6-8.  Melanoma pig tissues staining with 3a shows a healthy skin tissue does not, but b 
melanoma tissue does, imply significant amounts of the TrkC receptor expressed on melanoma.   
 
 
Data from one particular Sinclair swine is not reliably indicative of a trend in 
human melanoma.  Thus a panel of commercially available human melanoma tissue 
samples was stained to estimate the fraction of cases that would bind agent 3a (Figure 6-
9).  Duplicate tissue samples from 22 metastatic-melanoma patients were tested, and 
every one of them stained with agent 3a.   Conversely, no significant staining was 
observed when the two duplicate samples of normal skin available were treated with the 
same probe. 
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Figure 6-9.  Example of human tissues stained with agent 3a.  a Normal skin tissue does not 
show significant staining while the other malignant tissues do (b and c).    
 
 
The “aza-BODIPY”221-222 system 3a is suitable for observation of non-superficial 
tissue because it can absorb light at a longer wavelength (around 700 nm) than probe 1-
F.97-98  Moreover, the probe is also amenable to 19F/18F metathesis (Gabbai, personal 
communication) which can be used for PET imaging.  
It is possible to modify compound 3a to be a PDT agent.  Substitution of halogen 
atoms (i.e. Br or I) at the 2,6-positions of the aza-BODIPY core results in an increased 
population of triplet states upon excitation, giving of PDT activity.97-98  Thus, the 
structure shown in Figure 6-10 was conceived, synthesized and tested for active 
targeting of TrkC in melanoma.     
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Figure 6-10.   Proposed structure of near-IR targeted PDT probe for TrkC cells. 
 
 
Conclusions 
 An active targeting probe for TrkC receptors on melanoma, possibly the first of 
its kind, has been successfully made and tested in histology and cell expreiments.  The 
first generation probe proved targeting efficacy in cells, and we hypothesize this can be 
used for diagnostic (fluorescence imaging or possibly PET imaging) and therapeutic 
(PDT) applications in melanoma-afflicted pigs.  Our second generation targeting probe 
is more suitable for in vivo studies because of its near-IR absorption; this probe showed 
its stained melanoma tissue from pigs and human patients.  PDT studies of this modified 
structure in mice and pigs is planned (samples have been submitted for the mouse 
studies, are in hand for the pig studies, and will be used if the murine model is 
successful).  From the preliminary results, we believe the new agent will be successful 
for treatment of melanoma. 
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CHAPTER VII 
CONCLUSIONS 
 
This dissertation featured design and development of novel active-targeting 
probes for treatment of TrkC overexpressing tumors, specifically metastatic forms of 
breast cancer and melanoma.  The first generation targeting probe (1-PDT) showed 
encouraging, positive results from in vivo studies testing its role as a therapeutic.  Thus 
at day 6 post-illumination, 1-PDT at 10 mg/kg (single injection) caused 96 % volume 
reduction in murine TrkC+  (4T1 murine breast cancer cells) tumors.  Among these mice, 
71 % showed full diminution and were tumor-free for 90 days after therapy.  Moreover, 
histopathology indicated no metastasis development in these animals.  However, 1-PDT 
required further structural modifications for several reasons.  The first of these was that 
it triggered neurotoxicity at high doses (> 30 mg/kg) in mice.  Secondly, the light 
wavelength to excite 1-PDT is optimally ~520 nm whereas PDT agents should absorb 
above 700 nm to be effective in deeper tissue.  Our second-generation targeting probes 
were designed to use the aza-BODIPY (λmax around 700 nm) for more effective imaging 
in tissue, and as a spacer between two targeting IY fragments to make the system more 
compact.  Agent 3a of this type was more difficult to produce than 3b but it has two 
sulfonic acid groups to enhance hydrophilicity and reduce non-specific binding.  
Histology and live cell imaging showed 3a selectively bound to TrkC+ tumor cells.  
Furthermore, in vivo imaging using an orthotopic breast cancer model showed 3a 
accumulated rapidly in the tumor but was completely cleared after 24 h; moreover, 
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neurotoxicity was not observed.  Probe 3a also has potential as a positron emission 
tomography (PET) agent via 19F to 18F exchange; use of this probe for PET is under 
investigation by collaborators using material made in this thesis work.  In the last 
chapter, a Sinclair Swine model was used in melanoma research.  Our first- and second-
generation probes were shown to successfully bind and treat melanoma tissue ex vivo.  
The near-IR absorbing probe 3-PDT was prepared and sent to collaborators to 
investigate as a therapeutic agent in the pig model.        
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APPENDIX A  
CATIONIC POLYFLUORENES FOR INTRACELLULAR DELIVERY OF 
PROTEINS§ 
 
A.1 Introduction 
Delivering native and active proteins into cells is essential to many therapeutic 
applications.223   Protein-based therapeutic methods are safer in comparison to gene 
therapy because only transient actions of proteins are required and no random, 
permanent genetic changes are involved.  In general, most native proteins are unable to 
cross the plasma membrane and usually suffer from loss of biological function due to 
proteolysis or aggregation in serum; consequently, a general intracellular protein 
delivery system is highly desirable.  One approach to achieve intracellular protein 
delivery is via non-covalent delivery agents. 
Our hypothesis for the mode of action for non-covalent carrier agents is that they 
tend to contain hydrophobic parts that can bind similarly lipophilic regions of protein 
cargos, then somehow facilitate passage through cell membranes.  Stoichiometries of 
carrier-to-protein in such delivery systems are often set to ensure that the complexes 
have a net positive charge, which creates an attractive electrostatic interaction with cell 
membranes.  Hydrophobic parts of carriers tend to embed into the membranes and 
                                                
§ “Cationic Polyfluorenes For Intracellular Delivery Of Proteins” by Anyanee Kamkaew, Roula 
Barhoumi, Robert C. Burghardt, and Kevin Burgess, Org. Biomol. Chem. 2011, 9, 6513.  
Reproduced by permission of The Royal Society of Chemistry. Copyright 2011 The Royal 
Society of Chemistry. 
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initiate the translocation event.  After passage through the membrane some of the 
cargoes imported into cells are encapsulated in endosomes while others escape from the 
endosomes to provide functional responses.  In summary, we surmised that ideal carrier 
systems might have: (i) hydrophobic regions to bind protein and to associate with the 
inner cell membrane; (ii) positive-charged complexes to facilitate attraction to cell 
membranes: and, (iii) properties conducive to endosomal release.  
Some non-covalent carriers including a few commercial products have been 
reported.  Pep-1, a commercial peptide from Active Motif (Figure A-1), complexes with 
proteins or peptides and facilitates their transport into cells.224-226  It has been shown that 
Pep-1 can transport large fluorescent proteins (>119 kDa, and mAb’s of ca. 250 kDa) at 
a high transport efficiency (65 - 95%).224,227  The fluorescent protein-Pep-1 complex 
rapidly dissociates upon cellular internalization.  Inventors of Pep-1 claimed that this 
deliverly system allows the fluorescently-tagged protein cargos to proceed to their 
intracellular targets while Pep-1 is degraded.  Subsequent studies, however, have shown 
that the cargo is often entrapped in endosomes after Pep-1-mediated import. 
An alternative to the Pep-1 delivery system is the K16SP peptide linked with the 
signal peptide sequence of Kaposi’s fibroblast growth factor 
(AAVALLPAVLLALLAP).228  This system was reported to be 3 – 4 times more 
effective than Pep-1 for non-covalent transport of proteins into cells (four different 
human cell lines were tested), but endosomal release was not addressed.  Later, the same 
research group synthesized K16 peptide linked with 20-amino acid segment 
corresponding to the low-density lipoprotein receptor (LDLR)-binding domain of 
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apolipoprotein E (LRVR LASH LRKL RKRL LRDA), called K16ApoE.229  This carrier 
peptide can successfully transport various proteins, immunoglobulins and some 
therapeutic agents across the blood brain barrier (BBB) in a non-covalent manner.229-230 
 
 
 
Figure A-1.  Structures of some non-covalent carriers. 
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non-covalent carrier for proteins.233 In one example, PEI transported avidin-Alexa Fluor 
488 and the antibody, anti-lamin, into human fibroblast cells without degrading protein’s 
structure. 
Arginine-rich peptides, R8 and azo-R8, have been reported to import four 
differently labeled (Alexa Fluor® 488) proteins {avidin, recombinant streptavidin, 
bovine serum albumin (BSA), and beta-galactosidase} via non-covalent delivery.234  R8 
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and azo-R8 (ie a conjugate of R8 with an azo-compound that binds proteins non-
specifically) showed similar temperature dependence of carrier-mediated protein 
delivery to Pep-1.  At 37 ºC, labeled-avidin was imported but the fluorescence primarily 
accumulated in vesicles that co-localized with the endosomal marker FM 4–64.  
Surprisingly, however, diffuse fluorescence was observed within the cytoplasm with 
little evidence of punctate vesicle formation at 4 ºC. 
Interactions of polymers with cells depend on a complex interplay of chemical 
and physical properties. For instance, the cationic poly(p-phenyleneethynylene) material 
A (Figure A-2) is imported into punctate endosomal structures within NIH 3T3 
fibroblast cells, whereas the corresponding anionic polymer binds to fibronectin fibrils 
on the surface of those cells.235 
 
 
Figure A-2.  Structures of cationic (A) and anionic (B) polymers. 
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There is much to be learned about polyfluorene derivatives interacting with cells, 
and there is considerable potential for exploiting this knowledge. Fluorene monomers 
can be easily derivatized to incorporate charges, impart water solubilities, and be 
conjugated to biomolecules.236 Moreover, polyfluorenes are brilliant and conspicuous 
under fluorescence microscopes due to their high extinction coefficients and 
fluorescence quantum yields. Consequently, polyfluorene (or dendric fluorene) 
derivatives have been tested for cell permeation and staining of organelles,237 
transfection of DNA plasmids,238-240 and import then release of cytotoxic materials.241   
We are particularly interested in non-covalent import of proteins into cells for 
imaging intracellular biochemical events. Covalently bound carriers based on HIV-1 Tat 
and Drosophila Antennapedia homeodomain proteins242-243 are common, but agents that 
can simply be added to protein cargoes to bring about import are much rarer. Some of 
the first non-covalent protein import systems include Chariot®,224 the cationic 
pyridinium amphiphile and a helper lipid, SAINT-PhD,244 BPQ24 BioPORTER® 
QuikEaseTM (a protein delivery kit of unspecified composition),245 the peptide K16SP,228 
a cationic polymer containing cholesterol,246 and the somewhat cytotoxic 
polyethyleneimine (PEI),233,247 None of these systems are perfect, and many import 
proteins into living cells but deposit them in endosomes or lysosomes where they are 
degraded. Consequently, there is considerable interest in finding simpler systems that 
release protein cargoes into the cytoplasm of living cells. For instance, the oligomers of 
arginine, R8 and R16 have been reported to facilitate significant cellular uptake, while 
R4 gave relatively little internalization.248-249  However, we showed that these systems 
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tend to result in endosome-trapped proteins, unless the import was carried out at reduced 
temperatures (4 oC).234,250  In any case, oligomers of arginine are not particularly easy to 
make.251  Meanwhile others have observed that delivery of proteins into cells can be 
influenced by lipophilic counter-ions like pyrenebutyrate.252-253 
In the research described here, we investigated how the simple, and readily 
accessible, cationic polyfluorenes might function with respect to import of proteins into 
living cells. Proteins of different sizes and pI values were used, and they were either 
labeled with small molecule fluors (FITC, Texas Red®, Alexa Fluor®488) or chosen 
because they are intrinsically fluorescent (green fluorescent protein, GFP). The 
objectives of this study were to establish where the protein and polymer are delivered to 
inside cells, if indeed they were imported at all. 
 
A.2 Materials and methods 
See the section A.6 for protocols and characterization information for polymers 1 
and 2. Avidin-FITC and streptavidin-Texas Red® conjugates were purchased from 
Invitrogen by Life Technologies. b-Galactosidase was purchased from Calbiochem and 
labeled with Alexa Fluor® 488. GFP was kindly provided by Dr Wenshe Liu at Texas 
A&M University. 
Cell culture 
Clone 9 cells were cultured on 75 cm2 culture flasks in Ham’s Nutrient Mixture 
F-12 with 10% fetal bovine serum (FBS) in a humidified incubator at 37 oC with 5% 
CO2. Cells grown to subconfluence were plated in Lab-Tek two-well chambered 
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coverglass slides (Nunc) 2–3 d prior to the experiments. CHO K1 cells were cultured on 
75 cm2 culture flasks in DMEM supplemented with 10% FBS in a humidified incubator 
at 37 oC with 5% CO2. Again, cells grown to subconfluence were plated in Lab-Tek two-
well chambered coverglass slides 2-3 d prior to the experiments. 
Fluorescence microscopy 
Subcellular protein localization was measured on living Clone 9 and CHO K1 
cells using a Zeiss 510 META NLO Multiphoton Microscope System consisting of an 
Axiovert 200 MOT microscope. Throughout, digital images were captured with a 40x 
/1.3 oil objective with the following filter sets: for polymer 1 and 2: excitation 740 nm; 
emission BP 435–485; for FITC, Alexa Fluor® 488 and LysoTracker ® Green DND- 26 
(abbreviated to “LysoTracker® Green” above): excitation 488 nm; emission BP 500–
530; for the Texas Red® protein conjugates: excitation 543 nm; emission BP 565–615 
Sequential optical sections (Z-stacks) from the basal-to-apical surfaces of the cell were 
acquired. Digital image acquisition was initiated approximately 1 mm below the basal 
surface of the cells and optical slices were collected at 0.5 mm steps through their apical 
surface using a high numerical objective lens (C-APO 63X/1.2W CORR D = 0.28M27). 
These wide-field images were subjected to deconvolution using Intelligent Imaging 
Innovations (3I) software. 
The protein : carrier complexes were pre-formed at room temperature for 1 h by 
mixing (mol : mol ratios throughout) the protein and the carrier in Ham’s Nutrient 
Mixture F-12 supplemented with 10% FBS for Clone 9 cells. The CHO K1 cells were 
supplemented with DMEM containing 10% FBS.  Protein : carrier at 1 : 1 was used for 
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avidin-FITC and streptavidin-Texas Red®, while 3 : 1 GFP, and 1.0 : 25 b-gal-Alexa 
Fluor® were used. To study the cellular uptake of the proteins, the culture medium was 
removed, the preformed protein : carrier complexes were added, and the cells were 
incubated for 12 h at 37 oC. After the incubation period, the cells were washed with 
phosphate-buffered saline (PBS, pH 7.4) and heparin solution several times before 
imaging. 
Lysosomal colocalization 
Clone 9 cells were incubated with streptavidin : polymer complex for 12 h at 37 
oC. After the cells were washed with PBS and heparin, LysoTracker® Green was added 
and the cells were incubated for 30 min at 37 oC. The cells were washed again with PBS 
before imaging. 
Cell viability assays 
Clone 9 cells (3.5 K cells/well, 50 mL, in Ham’s medium) were plated on 96-
well plates and allowed to adhere at 37 oC in 5% CO2 and 95% air for 3 h. The cells 
were then treated with 50 mL of each test compounds in PHFM-II (protein free medium) 
at 0 to 200 mM concentrations. The cells were then incubated for 72 h at 37 oC, then 
their viabilities were assessed through an MTT conversion assay.254  Briefly, 25 mL of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT (5 mg mL-1, in 
Hank’s balanced salt solution) were added and the cells were incubated for an additional 
2 h. They were then lysed and the dark blue crystals solubilized with 100 mL of an 
aqueous solution containing 35% (v/v) N,N-dimethylformamide, 15% (v/v) glacial acetic 
acid, 15% (w/v) SDS with an adjusted pH of 3.8. The optical density of each well (at 
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570 nm) was measured with a BioTek Synergy 4 Microplate Reader. The viability of 
each cell line in response to the treatment with tested compounds was calculated as: % 
dead cells = 100 - (OD treated/OD control) × 100. 
 
A.3 Results and discussion 
Design and synthesis of potential polyfluorene carriers 
Amino functionalized polyfluorenes have been made before255  but never 
exploited as protein delivery systems.  Our early studies showed that only the quaternary 
ammonium system 1 was water soluble; corresponding primary amine, secondary N-
methylamine, and tertiary N,N-dimethyl amines polymers were all surprisingly insoluble 
in aqueous media, even at reduced pHs.  However, the quaternary salt 1, very similar to 
a known material,256 gave a clear solution in water even at neutral pH.  Consequently we 
made a batch of this material via a modification of the literature procedure256 that 
involved similar steps but in a different order. 
 
 
Figure A-3.  Polymers 1 and 2 that feature in this study. 
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also prepared the guanidine-functionalized polyfluorene 2.  Synthesis of one monomer 
for the preparation of polymer 2 was achieved via modification of the protected diamine 
3 into the masked guanidine 4 (Scheme A-1).  The complementary diboronate 7 was 
prepared via the azide intermediates 5 and 6.  Finally, Suzuki coupling of monomers 4 
and 7, then deprotection afforded the target material 2.  
Polymers 1 and 2 had the weight average molecular weight (Mw) of 8200 (Poly 
Dispersity Index, PDI, 1.21) and 9400 (1.25), respectively, from gel permeation 
chromatography (GPC).  Dynamic light scattering experiments (DLS) indicated polymer 
1 in water aggregated to form particles that had average diameters of 140 nm.  Polymer 2 
was insoluble in water, but it appeared to dissolve in methanol while DLS indicated it 
had in fact aggregated to form particles with an average diameter of 45 nm.  Both 
polymers exhibited a strong UV absorbance centered on 380 nm, and they fluoresced 
around 415 nm in water with quantum yields of 0.58 (1) and 0.42 (2). 
We were particularly interested in the cytotoxicities of these nanoparticles, so 
they were tested using Clone 9 rat liver cells in an MTT assay.  No significant 
cytotoxicity was observed for either polymer (IC50 100 mM for both; polymer 2 was 
delivered as a suspension in buffer).  Based on these data it appeared that 1 and 2 were 
suitable for testing with regards to their abilities to act as carriers for protein import. 
 
 
  111 
 
 
 
 
 
Scheme A-1. Syntheses of polymer 1 and 2. 
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between 26.9 and 540 kDa, and labeled with anionic dye (FITC, Alexa Fluor®488), 
cationic dye (Texas Red®), or no dye at all (GFP).  Two cell lines, Clone 9 and Chinese 
hamster ovary (CHO), were used in the import studies. 
Polymeric carrier-to-protein cargo ratios were optimized so that the signals 
observed in the cells were visible yet not saturated. A 1 : 1 ratio (mol:mol throughout) 
was thus found to be optimal for the two proteins of intermediate size.  Conversely, less 
carrier was used for the smallest protein (GFP; 1 : 3 carrier : cargo), and more was 
necessary for the largest (b-galactosidase; 25 : 1.0 carrier : cargo).  In each case, images 
for the uptake were recorded after 12 h of incubation, then checked after another 24 h.  
However, the signal for GFP was almost completely lost after 24 h indicating 
degradation, but the polymer fluorescence was still observed. 
 
Table A-1   Proteins For Cellular Uptake Studies 
Protein Molecular Weight 
(kDa) 
Amino Acids pI 
(unlabelled protein) 
Avidin-FITC 66-68 512 10 – 10.5 
GFP 26.9 238 5.3 
Streptavidin-Texas Red 52.8 4 x 159 4.5 
β-Galactosidase-Alexa 
Fluor 488 
540 1171 4.8 
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Figure A-4. Delivery of GFP into Clone 9 cells at 37 oC mediated by polymers 1 and 2; a 
represents no carrier used, and e is a differential interference contrast (DIC) image. Data for 
polymer 1: b channel showing fluorescence by polymer 1; c channel showing GFP import 
mediated by 1; d combined fluorescence for GFP and 1 inside the cells. Data for polymer 2: f 
channel showing fluorescence by polymer 2; g channel showing GFP import mediated by 2; h 
combined fluorescence for GFP and 2 inside the cells. Throughout, the Clone 9 cells were 
incubated with the carrier (1.0 mM) and GFP (3.0 mM) at 37 oC for 12 h; the cells were then 
washed 3x with PBS buffer and 3x with heparin and analyzed by fluorescence microscopy. Scale 
bar is 20 mm. 
 
 
Figure A-4 gives illustrative data for the cellular uptake experiments.  This graphic 
features GFP, but similar images were obtained for all the proteins in both cell lines (see 
supplement materials below).  Without carrier, little or no visible GFP was imported into 
the cells (Figure A-1a).  
A polyfluorene-based polymer similar to 1 (different alkyl groups, and another 
monomer included) has been reported to be imported into cells.257  Consequently, we 
were not surprised that polymer 1 alone permeated into the cells (data not shown).  
Polymer 1 and GFP incubated with the cells for 12 h resulted in import of both 
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fluorescent molecules (b and c).  Figure A-4d shows the extent of fluorescence overlap 
from the polymer and protein; this may be expressed in terms of a “colocalization 
coefficient” deduced using laser scanning microscopy (LSM) software, with larger 
coefficients corresponding to greater overlap. In this particular case, i.e. for GFP and 
polymer 1, the coefficient was 0.48. After a further 24 h the signals were weaker, but no 
diffuse fluorescence was observed. 
Polymer 2 under the same conditions gave noticeably more uptake of GFP in 
experiments for which the polymer signal inside the cells was qualitatively similar to 
those with GFP/polymer 1.  However, more of the GFP colocalized with 2 
(colocalization coefficient 0.68) than with polymer 1.  Images for import of the other 
proteins are shown in the supplement materials below and Figure A-5 summarizes the 
colocalization coefficients. Overall, more protein was released from the quaternary 
amine polymer 1 than it was from the guanidine 2. 
 
 
Figure A-5. Colocalization coefficients for polymers 1 (blue) and 2 (red) for the four featured 
proteins in Clone 9 cells.  
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Attempts to establish the location of the protein and polymer were made for each 
of the proteins imported.  Figure A-6 shows the data obtained to track the quaternary 
amine coated polymer 1, streptavidin-TexasRed®, and LysoTracker® Green.  Three dyes 
are involved in these experiments and all of them show up distinctly (a shows channel to 
detect polyfluorene; b streptavidin-Texas Red®; c LysoTracker® Green).  Three 
colocalization coefficients are significant in these experiments: LysoTracker® 
Green/polymer 1, LysoTracker® Green/streptavidin-Texas Red®, and polymer 
1/streptavidin-Texas Red®. These coefficients were 0.35, 0.56, and 0.46, respectively.  
This data indicates most of the polymer has escaped from the lysosomes, and less than 
half of the fluorescent protein escaped.  Correlations between the polymer 1 and 
streptavidin-Texas Red® do not distinguish if they are together in the lysosomes, 
elsewhere, or both.  However, Figure A-6d and A-6h show areas where all three 
fluorescent entities are colocalized in white.  Quantitative analysis of this situation is 
difficult and somewhat unnecessary because it is evident that for the quaternary amine 
polymer 1 regions with distinct blue, red, and green signals predominate; conversely, 
white areas indicating colocalization of all three labels are prevalent for the guanidine-
sheathed polymer 2. 
Colocalization experiments that parallel those above were attempted with 
markers for other organelles.  Specifically, streptavidin-Texas Red® was tested with 
compounds that are thought to localize in endosomes, and in the endoplasmic reticulum 
(ER). However, no significant colocalization was observed. 
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Similar series of experiments were attempted for the three other proteins.  
However, the labels involved (GFP, FITC, and Alexa Fluor®) are all green, so 
LysoTracker® Green could not be used. LysoTracker® Red was tested, but crosstalk 
between the red and green channels precluded accurate analyses.  Other labels could 
have been tested, but the chances of success were only moderate, and we made the 
decision that the scientific gains made by determining the degree of colocalization for 
these three proteins were not worth the costs and effort involved. 
 
 
Figure A-6. Delivery of streptavidin-Texas Red® into Clone 9 cells at 37 oC mediated by 1 and 
2. Data for transport using polymer 1: (a) polymer 1 channel; (b) streptavidin-TexasRed® 
channel; (c) LysoTracker® Green; (d) colocalization shows mostly distinct blue, red, and green 
areas. Data for transport using polymer 2: (e) polymer 2 channel; (f) streptavidin-Texas Red® 
channel; (g) LysoTracker® Green; (h) colocalization shows mainly white areas where all three 
labels coexist. Throughout, the carrier (1.0 mM), streptavidin-Texas Red® (1.0 mM), and the 
Clone 9 cells were incubated at 37 oC for 15 h; the cells were then washed 3X with PBS buffer 
and 3X with heparin and analyzed via fluorescence microscopy. Scale bar is 20 mm. 
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In previous studies, we had found that (Arg)8 mediated import of some of the 
same protein cargoes into lysosomes at 37 oC, but into the cytosol at 4 oC.234   
Experiments to test import with polymers 1 and 2 at 4 oC showed both polymers 
impregnated into the cell wall membrane, and none of the four proteins were imported. 
Futaki and co-workers have studied the influence of the lipophilic, fluorescent counter 
ion, pyrenebutyrate, in import mediated by oligoarginine-based cell penetrating 
peptides.252-253,258  Here import of bovine serum albumin-Texas Red® (BSA, MW = 66 
kDa, 538 amino acids, pI = 4.7) mediated by polymer 1 was briefly tested in the 
presence of pyrenebutyrate.  This counter ion dramatically increased the rate of transport 
into the cells at 37 oC so that the protein was conspicuous after only 5 min incubation. 
However, most of the protein colocalized with LysoTracker® Green and it was not 
liberated into the cytosol even after extended incubation.  The same experiment but run 
at 4 oC showed only impregnation of the polymer into the membrane as in the absence of 
pyrenebutyrate (see supporting materials below). 
 
A.4 Conclusion 
These studies were undertaken to determine if the cationic polymers 1 and 2 would 
import large and small, negative and positively charged, proteins into cells.  If protein 
import was observed, then it was also important to determine if the polymer would “let 
go” of the protein once inside the cell.  The data described shows that both the 
quaternary amine- and the guanidine-containing polymers 1 and 2 mediated import into 
the cells at 37 oC (but not at 4 oC).  Once inside the cells, the quaternary amine polymer 
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1 releases more of the protein cargoes than its guanidine relative 2, irrespective of the 
charge and size of the proteins involved.  
It was conveniently possible to determine the degree of endosomal release for 
streptavidin Texas Red®.  In this regard, it was again the quaternary amine polymer 1 
that gave superior release (cf. less white regions indicating colocalization of all three 
labels in Figure A-6d as compared with Figure A-6h).  Preliminary experiments indicate 
that the rate of import of proteins by these polymers is increased by pyrenebutyrate, just 
as Futaki et al. have observed in other systems. 
Intracellular localization of the proteins featured in this study (GFP, b-
galactosidase, and avidin) is of little interest.  However, others focused on the delivery of 
more significant proteins might now consider import using these fluorescent polymers, 
and the quaternary amine 1 system in particular. 
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A.6 Supporting Materials 
General Procedures  
Dry DMF, (<50 ppm water) was purchased from Acros. THF was dried with 
molecular sieves and Et3N was distilled from CaH2.  Other solvents and reagents were 
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used as received.  All reactions were carried out under an atmosphere of dry nitrogen.  
Unless otherwise indicated, common reagents or materials were obtained from 
commercial source and used without further purification. 
NMR spectra were recorded on a VXP-300 MHz and Inova-500 MHz 
spectrometers (1H at 300 MHz or 500 MHz, and 13C at 75 or 125 MHz) at room 
temperature unless other mentioned.  Chemical shifts of 1H NMR spectra were recorded 
and chemical shifts are reported in ppm from the solvent resonance (CDCl3 7.26 ppm, 
CD3OD 3.30 ppm, CD3SOCD3 2.50 ppm).  Data are reported as follows: chemical shift, 
multiplicity (s = singlet, br = broad, d = doublet, t = triplet, q = quartet, m = multiplet), 
coupling constants, and number of protons.  Proton decoupled 13C NMR spectra were 
also recorded in ppm from tetramethylsilane resonance (CDCl3 77.0, CD3OD 49.1, 
DMSO-d6 39.5 ppm).  Analytical thin layer chromatography (TLC) was performed on 
EM Reagents 0.25 mm silica-gel 60-F plates, and visualized with UV light.  Flash 
chromatography was performed using silica gel 60 (230–400 mesh).  MS were measured 
under ESI or MALDI conditions.  
 
Experimental Procedures and Characterization Of Compounds 1 - 11  
9,9-bis(3-Azidopropyl)-2,7-diiodo-9H-fluorene (5).  9,9-bis(3-Bromopropyl)-2,7-
diiodo-9H-fluorene (1.5 g, 2.3 mmol), prepared by alkylation of 2,7-diiodo-9H-fluorene 
and 1,3-dibromopropane (Liu, H. et al. Chem. Eur. J. 2009, 15, 2289-2295), NaN3 (533 
mg, 8.20 mmol) and 40 mL DMSO were added into a 250 mL round bottom flask.  The 
mixture was stirred at 70 oC for 12 h. The reaction mixture was extracted with Et2O (100 
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mL) then water (50 mL).  Aqueous layer was re-extracted with Et2O (50 mL x 2).  The 
combined organics were washed with water (50 mL x 3), brine (50 mL x 2), then dried 
over MgSO4.  The product was obtained without further purification (1.3 g, 98%) as 
yellow solid. 1H NMR (300 MHz, CDCl3), d 7.71-7.67 (m, 4H), 7.42 (d, J = 8.1 Hz, 2H), 
3.03 (t, J = 6.6 Hz, 4H), 2.06-2.01 (m, 4H), 0.90-0.84 (m, 4H); 13C NMR (75 MHz, 
CDCl3), d 150.6, 139.7, 136.8, 131.9, 121.8, 93.6, 54.6, 51.3, 37.0, 23.3.  FT-IR (NaCl): 
N3 band at 2101.72 cm-1. 
 
 
1H-NMR of 5 
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13C-NMR of 5 
 
Di-tert-butyl ((2,7-diiodo-9H-fluorene-9,9-diyl)bis(propane-3,1-diyl))dicarbamate 
(3).  Compound 5 (1.3 g, 2.2 mmol) was dissolved in THF (40 mL) and H2O (5 mL) in a 
250 mL flask. Triphenyl phosphine (1.56 g, 5.94 mmol) was added to the solution and 
the mixture was stirred at 25 oC for 12 h.  The solvents were removed under reduced 
pressure. The residue and di-tert-butyl dicarbonate (1.07g, 4.90 mmol) were dissolved in 
THF (45 mL).  The mixture was stirred at 25 oC for 12 h.  The solvent was removed 
under reduced pressure.  The residue was purified by flash chromatography eluting with 
CH2Cl2 and MeOH (98:2) to give desired product (1.5 g, 92%) as white solid. 1H NMR 
(300 MHz, CDCl3), d 7.67-7.62 (m, 4H), 7.39 (d, J = 7.8 Hz, 2H), 4.30-4.18 (br, 2H), 
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2.89-2.85 (m, 4H), 2.02-1.85 (m, 4H), 1.39 (s, 18H), 0.78-0.67 (m, 4H); 13C NMR (75 
MHz, CDCl3), d 155.8, 151.2, 139.7, 136.5, 131.8, 121.7, 93.4, 54.7, 40.4, 37.1, 28.4, 
24.5 MS (MALDI) calcd for C29H38I2N2NaO4 (M+Na)+ 755.08, found 755.30. 
   
1H-NMR of 3 
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13C-NMR of 3 
 
Di-tert-butyl ((2,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-fluorene-9,9-
diyl)bis(propane-3,1-diyl))dicarbamate (9).  In a 100 mL flask, compound 3 (500 mg, 
0.680 mmol), KOAc (400 mg, 4.08 mmol), bis(pinacolato)diborane (433 mg, 1.70 
mmol)  in degassed DMF (30 mL) were stirred at 25 oC.  The catalyst, Pd(dppf)Cl2 was 
added in one portion.  The mixture was deoxygenated for 3 min.  The reaction mixture 
was stirred at 80 oC under N2 for 12 h.  Water (50 mL) was added to the reaction 
mixture, and the product was extracted from water with CH2Cl2 (50 mL x 3).  The 
combined organics were washed with water (50 mL x 3) and brine (50 mL x 2), then 
dried over MgSO4.  After removing the organic solvent under reduced pressure, the 
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crude product was purified by flash chromatography eluting with CH2Cl2 and MeOH 
(99:1) to give desired product (400 mg, 80 %) as brown solid.  1H NMR (300 MHz, 
CDCl3), d 7.84 (d, J = 7.5 Hz, 2H), 7.74 (d, J = 7.5 Hz, 4H), 4.21-4.18 (br, 2H), 2.90-
2.80 (m, 4H), 2.10-2.05 (m, 4H), 1.40 (s, 18H), 1.31 (s, 24H), 0.80-0.65 (m, 4H). 13C 
NMR (75 MHz, CDCl3), d 155.8,149.2, 143.9, 134.2, 128.8, 119.7, 83.9, 83.6, 54.4, 
40.6, 28.4, 25.1, 25.0, 24.5.  MS (MALDI) calcd for C41H62B2N2NaO8+ (M+Na)+, 
755.46, found, 755.66. 
 
 
1H-NMR of 9 
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13C-NMR of 9 
 
Polymer 10. In a 5 mL flask, compounds 3 (50 mg, 0.068 mmol), 9 (50 mg, 0.068 
mmol), K2CO3 (116 mg, 0.840 mmol), and tetra-N-butylammonium bromide (0.45 mg, 
0.0014 mmol) in degassed 4:1 toluene/H2O (3 mL) were stirred at 25 oC.  The catalyst 
Pd(PPh3)4 (2.0 mg, 0.0014 mmol) was added.  The mixture was deoxygenated for 5 min.  
The reaction was then heated to 82 ºC with stirring under N2.  After 48 h, 2 drops of 
iodobenzene were added and the reaction was stirred for an additional 12 h at 82 ºC.  
After cooling to 25 oC, water (10 mL) was added to the reaction mixture, and the product 
was extracted with CHCl3 (10 mL x 3).  The combined organics were washed with water 
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(10 mL x 3), brine (10 mL x 2), then dried over MgSO4.  After removal of the solvent 
under reduced pressure, the residue was added to petroleum ether to give a precipitate.  
The precipitate was transferred to a vial equipped with a stir bar and was stirred in 5mL 
of acetone at 25 ºC.  After 24 h, the acetone was decanted off and the solid was stirred 
into an additional 5 mL of acetone.  This was repeated for a total of 3 times (72 h).  
Polymer 10 was obtained as a yellow powder (37 mg). 1H NMR (300 MHz, CDCl3): d 
7.93-7.82 (br, 4H), 7.82–7.60 (br, 2H), 3.16-2.85 (br, 4H), 2.93-1.50 (br, 4H), 1.41(s, 
18H), 1.03-0.78 (br, 4H). GPC (THF): Mn = 6762, Mw = 8187, PDI = 1.21 based on 
GPC analysis. FT-IR (NaCl): NH band at 3345.77 and 1506.48 cm-1; C=O band at 
1700.23 cm-1. 
 
1H-NMR of 10 
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Polymer 11.  Polymer 10 (30 mg) was dissolved in 1,4-dioxane (10 mL) in a 25 mL 
flask, then HCl in dioxane (4 M, 2 mL) was added in one portion and the solution 
mixture was stirred at 25 ºC for 72 h.  After removal of the solvent under reduced 
pressure, 5 mL of acetone was added to give a precipitate; this was filtered and washed 
with chloroform to give polymer 11 as a yellow powder (18 mg).  1H NMR (300 MHz, 
CD3OD): d 8.20–7.70 (m, 6H), 2.91–2.69 (m, 4H), 2.59-2.40 (m, 4H), 1.23-0.97 (m, 
4H). FT-IR (NaCl): NH (NH3+Cl-) band at 3448.16 and 1656.36 cm-1; C=O band at 
1700.23 cm-1. 
 
 
1H-NMR of 11 
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Polymer 1.  In a sealed tube, polymer 11 (8 mg), MeI (0.20 mL, 3.2 mmol), and K2CO3 
(442 mg, 3.20 mmol) were added in MeOH (2 mL).  The mixture was heated to 80 oC in 
a CEM Discover microwave for 45 min.  Polymer 1 was obtained as a brown powder (10 
mg).  1H NMR (300 MHz, DMSO-d6): d 8.39-7.70 (br), 3.20-2.80 (br), 2.60-2.40 (br), 
1.10-0.78 (br). FT-IR (NaCl) shows the absence of a N-H stretch in the region 3300-
3000 cm-1. 
 
BOC-Protected Guanidine 4.  In a 250 mL flask, compound 3 (800 mg, 1.09 mmol) 
was dissolved in dioxane (50 mL), then HCl in dioxane (4M, 8 mL) was added and the 
solution mixture was stirred at 50 oC for 12 h.  After cooling to 25 oC, the solvent was 
removed and the residue was dissolved in MeOH (10 mL).  An aqueous solution of 
KOH (10 % wt, 10 mL) was added.  The mixture was stirred for 15 min and the solvents 
were removed.  The residue was extracted with CH2Cl2.  The organic layer was washed 
with H2O and brine, and then dried over MgSO4.  The solvent was removed and the 
yellow oil product was dissolved in DMF (12 mL).  N,N’-bis(tert-Butoxycarbonyl)1H-
pyrrazole-1-carboxamidine (744 mg, 2.40 mmol), diisopropylethylamine (12 mL) were 
added to the solution.  The reaction mixture was stirred at 25 oC for 12 h.  The solvent 
was removed under reduced pressure. The residue was purified by flash chromatography 
eluting with CH2Cl2 and MeOH (99:1) to give desired product (930 mg, 85%) as yellow 
solid.  1H NMR (300 MHz, CDCl3): d 11.43 (s, 1H), 8.32 (s, 1H), 7.62-7.69 (m, 4H), 
7.41 (d, J = 8.1 Hz, 2H), 6.42 (s, 1 H), 3.16 (q, J = 5.4 Hz, 4H), 1.98 (m, 4H), 1.45 (s, 
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36H), 0.83-0.75 (m, 4H).  13C NMR (75 MHz, CDCl3): d 163.4, 155.9, 153.2, 150.7, 
142.7, 139.7, 139.1, 136.7, 131.7, 128.9, 121.8, 109.8, 93.6, 83.1, 79.2, 54.6, 40.6, 37.2, 
29.7, 28.3, 28.1, 28.0, 23.2. MS (ESI) calcd for C41H59I2N6O8+ (M+H)+ 1017.25, found 
1017.27. 
 
1H-NMR of 4 
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13C-NMR of 4 
 
Diborate Ester 6.  In a 250 mL flask, compound 5 (500 mg, 0.860 mmol), KOAc (500 
mg, 5.16 mmol), bis(pinacolato)diborane (524 mg, 2.06 mmol)  in degassed DMF (50 
mL) were stirred at 25 oC.  The Pd(OAc)2 catalyst (2 mg, 0.01 mmol) was added in one 
portion, and the mixture was deoxygenated for 3 min.  The reaction mixture was stirred 
at 75 oC under N2 for 1 h.  The solution was filtered through celite and the solvent was 
removed under reduced pressure.  The product was obtained without further purification 
(500 mg, quantitative) as brown solid.  1H NMR (300 MHz, CDCl3), d 7.83-7.59 (m, 
6H), 3.05-2.83 (m, 4H), 2.22-2.07 (m, 4H), 1.21 (s, 24H) 1.01-0.78 (m, 4H).  13C NMR 
(125 MHz, CD3Cl3), d 148.6, 143.8, 134.6, 128.7, 119.8, 83.9, 83.5, 83.1, 83.0, 54.4, 
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54.3, 51.5, 51.4, 37.0, 29.7, 25.0, 24.9, 24.8, 24.5, 24.1, 23.4. MS (ESI) calcd for 
C31H43B2N6O43+ (M+H)+ 585.35, found 585.35. 
 
1H-NMR of 6 
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13C-NMR of 6 
 
Boc-Protected Diguanidine 7.  Compound 6 (300 mg, 0.51 mmol) was dissolved in 
THF (22 mL) and H2O (3 mL) in a 100 mL flask.  Then PMe3 (1M in THF; 1.28 mL, 
1.28 mmol) was added to the solution and the mixture was stirred at 25 oC for 12 h.  The 
solvents were removed under reduced pressure, then the residue was dissolved in DMF 
(6 mL) and N,N’-bis(tert-butoxycarbonyl)1H-pyrrazole-1-carboxamidine (348 mg, 1.12 
mmol), and diisopropylethylamine (6 mL) were added.  The reaction mixture was stirred 
at 25 oC for 12 h.  The solvent was removed under reduced pressure.  The residue was 
purified by flash chromatography eluting with CH2Cl2 and MeOH (99:1) to give desired 
product (360 mg, 69%) as yellow solid.  1H NMR (300 MHz, CDCl3): d 11.40-11.35 (br, 
2H), 7.92-7.35 (m, 6H), 3.18-2.98 (m, 4H), 2.18-1.87 (m, 4H), 1.41-1.35 (m, 36H), 1.19 
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(s, 24H), 0.85-0.58 (m, 4H).  13C NMR (75 MHz, CDCl3, ppm): d 155.7, 153.0, 150.9, 
132.2, 132.0, 131.9, 128.6, 128.6, 128.4, 83.8, 82.9, 79.1, 41.1, 37.3, 31.9, 29.7, 29.3, 
28.3, 28.0, 25.0, 22.7. MS (ESI) calcd for C41H59I2N6O8+ (M+H)+ 1017.25, found 
1017.27. 
 
 
1H-NMR of 7 
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13C-NMR of 7 
 
Boc-Protected Oligoguanidine 8.  In a 5 mL flask, compound 7 (50 mg, 0.05 mmol), 
compound 4 (50 mg, 0.05 mmol), K2CO3 (83 mg, 0.6 mmol), and tetrabutylammonium 
bromide (0.3 mg, 0.001 mmol) in degassed 4:1 toluene/H2O (3 mL) were stirred at 25 
oC. Catalytic Pd(PPh3)4 (1.2 mg, 0.001 mmol) was added, and the mixture was 
deoxygenated for 5 min.  The reaction was heated to 80 ºC with stirring under N2.  After 
48 h, 2 drops of iodobenzene were added and the reaction was stirred for an additional 1 
h at 80 ºC.  The mixture was then precipitated by addition of MeOH, filtered, and 
thoroughly washed with MeOH.  The precipitate was transferred to a vial equipped with 
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a stir bar and was stirred in 5 mL of acetone at 25 ºC under N2.  After 24 h, the acetone 
was decanted off and the solid was stirred into an additional 5 mL of acetone.  This was 
repeated for a total of 3 times (72 h).  Polymer 8 was obtained as a yellow powder (15 
mg).  1H NMR (300 MHz, CD3OD): d 7.98–7.56 (m, 6H), 3.11-2.65 (br, 4H), 2.23-1.78 
(br, 4H), 1.37(br, 36H), 0.93-0.54 (br, 4H).  GPC (THF): Mn = 7558, Mw = 9446, PDI = 
1.25 based on GPC analysis. FT-IR (NaCl): NH band at 3393.31 cm-1; C=N band at 
1623.46 cm-1; C=O band at 1700.23 cm-1. 
 
 
1H-NMR of 8 
 
  136 
Oligoguanidine 2.  In a 25 mL flask, polymer 8 (10 mg) was dissolved in dioxane (10 
mL).  HCl in dioxane (4 M, 2 mL) was added and the solution mixture was stirred at 25 
ºC for 72 h.  Polymer 2 was obtained as a yellow powder (5 mg).  1H NMR (500 MHz, 
CD3OD): d 9.35-9.25 (br), 8.10–7.30 (br), 3.25-2.85 (br), 2.23-1.98 (br), 1.03-0.58 (br). 
FT-IR (NaCl): NH (amine) band at 3329.74 cm-1; NH (imine) band at 3161.91 cm-1; 
C=N band at 1651.51 cm-1. 
 
Delivery Of Avidin-FITC and b-Galactosidase-Alexa Fluor® 488 (at 37 oC mediated by 
polymer 1 and 2 into Clone 9 cells) 
A. 
 
(1-avidin-FITC) 
 
(2-avidin-FITC) 
B.  
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(1-b-galactosidase-Alexa Fluor® 488) 
 
(2-b-galactosidase-Alexa Fluor® 488) 
Figure A-S1.  Delivery of avidin-FITC (A) and b-galactosidase-Alexa Fluor® 488 (B) into Clone 
9 cells at 37 ºC mediated by polymers 1 and 2; a channels represent differential interference 
contrast (DIC) images, b channels showing fluorescence by polymer; c channel showing avidin-
FITC import (A) and  b-galactosidase-Alexa Fluor® 488 (B) mediated by 1 or 2; d combined 
fluorescence for protein and polymer inside the cells.  The Clone 9 cells were incubated at 37 ºC 
for 12 h; the cells were then washed 3x with PBS buffer and 3x heparin and analyzed by 
fluorescence microscopy. Note; the polymer 2 was added in 1 % MeOH, and a blank (no 
nanoparticles) was performed in parallel to check for the effects of MeOH. 
 
Delivery Of Streptavidin-Texas Red, Avidin-FITC, b-Galactosidase-Alexa Fluor® 488, 
and GFP (at 37 oC mediated by 1 and by 2 in CHO-K1 cells) 
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Figure A-S2.  Delivery of streptavidin-Texas Red® (A), avidin-FITC (B),  b-galactosidase-Alexa 
Fluor® 488 (C), and GFP (D) into CHO K1. Data for streptavidin-Texas Red® transport: (a) 
polymer channel; (b) streptavidin-Texas Red® channel; (c) LysoTracker® Green; (d) 
colocalization shows mostly distinct blue, red, and green areas for polymer 1 system while 
colocalization shows mainly white areas where all three labels coexist for polymer 2 system.  
Data for other proteins transport: a channels represent differential interference contrast (DIC) 
images, b channels showing fluorescence by polymer; c channel showing avidin-FITC import 
(B),  b-galactosidase-Alexa Fluor® 488 (C) and GFP (D) mediated by 1 or 2; d combined 
fluorescence for protein and polymer inside the cells.  The CHO K1 cells were incubated at 37 
ºC for 12 h; the cells were then washed 3x with PBS buffer and 3x heparin and analyzed by 
fluorescence spectroscopy. Note; the polymer 2 was added in 1 % MeOH, and a blank (no 
nanoparticles) was performed in parallel to check for the effects of MeOH. 
 
A. (1- streptavidin-Texas Red®) 
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A. (2-streptavidin-Texas Red®) 
 
B. (1-avidin-FITC) 
 
B. (2-avidin-FITC) 
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C. (1-b-galactosidase-Alexa Fluor® 488) 
 
C. (2-b-galactosidase-Alexa Fluor® 488) 
 
D. (1-GFP) 
 
D. (2-GFP) 
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Delivery Of BSA-Texas Red® at 4 oC Mediated By Polymer 1 in Clone 9 and CHO-K1 
Cells  
Fluorescence Microscopy 
Subcellular protein localization was measured on living Clone 9 and CHO K1 
cells using a Zeiss Stallion Dual Detector Imaging System consisting of an Axiovert 
200M inverted fluorescence microscope, CoolSnap HQ digital cameras and Intelligent 
Imaging Innovations (3I) software.  Digital images of Texas Red-tagged BSA and 1 
(blue polymer) were captured with a C-APO 63X/1.2 W CORR D=0.28M27 objective 
with the following filter sets: Exciter BP560/40, Dichroic FT 585, Emission BP 630/75 
for Texas Red; and Exciter G 365, Dichroic FT 395, Emission BP 445/50 for 1.  
Sequential optical sections (Z-stacks) from the basal-to-apical surfaces of the cell were 
acquired.  Digital image acquisition was initiated approximately 1 µm below the basal 
surface of the cells and optical slices were collected at 0.5 µm steps through the apical 
surface of the cells with a high numerical objective lens (C-APO 63X/1.2 W CORR 
D=0.28M27).  These wide-field images were subjected to deconvolution using 3I 
software. 
The protein:carrier complexes were pre-formed at room temperature for 1 h by 
mixing (in a mol:mol ratio) the protein and the carrier in Ham’s Nutrient Mixture F-12 
with 10% fetal bovine serum (FBS) and DMEM supplemented with 10% fetal bovine 
serum (FBS) for Clone 9 cells and CHO K1 cells respectively.  A 1:2 mol:mol ratio of 
protein:carrier was used.  To study the cellular uptake of the proteins, the culture 
medium was removed, the preformed protein:carrier complex was added, and the cells 
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were incubated for another hour at 4 or 37 ºC.  After the incubation period, the cells 
were washed with phosphate-buffered saline (PBS, pH 7.4) and heparin solution several 
times before imaging.  For experiments at 4 ºC, cells were pre-incubated at 4 ºC for 30 
min before being incubated with the protein solution for 1.5 h.  
 
A 
 
B 
 
Figure A-S3.  Delivery of BSA-Texas Red® into Clone 9 (A) and CHO-K1 (B) cells at 4 ºC 
mediated by polymers 1; a channels represent differential interference contrast (DIC) images, b 
channels showing no BSA-Texas Red® is imported mediated by 1; c channel showing polymer 1 
fluorescence; d combined fluorescence for protein and polymer. 
 
 
Effect Of Pyrenebutyrate  
Clone 9 and CHO K1 cells were first incubated with pyrenebutyrate (1-pyrenebutyric 
acid) (50 µM) in serum-free Ham’s medium for 2 min, and then the protein:polymer 
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complex in culture media was added to yield the final concentration of fetal bovine 
serum (FBS) 5%.  
 
Kinetic Study 
Clone 9 cells (1K cells, 1 mL, in Ham’s medium) were suspended in a centrifuge tube.  
After centrifugation and removal of the medium, the protein:polymer complex in Ham’s 
medium was added.  The cells were incubated at 37 °C in 5% CO2 and 95% air. After 5 
min, 100 µL of the cell suspension was transferred to a new centrifuge tube, and the 
remained for the suspension was incubated for an additional minute (15, 30, and 60).  
The cells were washed thoroughly by centrifugation with PBS (2x) then heparin (3x).  
Thereafter, the cells were resuspended in 500 µL of serum-free Ham’s media, and placed 
on a Lab-Tek chambered coverglass slides.  
 
 
Figure A-S4.  Delivery of BSA-Texas Red® in Clone 9 cells at 37 ºC mediated by 1 in the 
presence of pyrenebutyrate; a channel showing polymer 1 fluorescence; b channels showing 
BSA-Texas Red® import mediated by 1; c represents differential interference contrast (DIC) 
images; d combined fluorescence for protein and polymer. 
 
 
Kinetic Studies 
A 
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B 
 
C 
 
D 
 
Figure A-S5.  Delivery of BSA-Texas Red® in Clone 9 cells at 37 ºC mediated by 1 in the 
presence of pyrenebutyrate.  The cells were incubated for different times, A 5 min, B 15 min, C 
30 min and D 60 min; a channel showing polymer 1 fluorescence; b channels showing BSA-
Texas Red® import mediated by 1; c represent differential interference contrast (DIC) images; d 
combined fluorescence for protein and polymer. Throughout the carrier (1.0 µM), BSA-Texas 
Red® (0.5 µM) and the CHO K1 cell suspensions were incubated at 37 ºC with PBS; the cells 
were then washed 3x with PBS buffer and 3x heparin and analyzed by fluorescence microscopy. 
Images shown are after deconvolution using 3I software. 
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APPENDIX B 
A NOVEL SMALL MOLECULE FOR ACTIVE TARGETING OF METASTATIC 
MELANOMA 
 
B.1 Introduction 
Molecular fragments that bind receptors selectively overexpressed on tumor cell-
surfaces can be useful for active targeting.1  Active targeting is distinct from strategies 
designed to perturb biochemical pathways upregulated in cancer, eg involving kinases or 
proteases.  Small molecules that are commonly used for active targeting include some 
vitamins (eg folic acid,20-21,23-24 biotin,25 and cobalamin26-27), RGD peptidomimetics,28-32 
a few carbonic anhydrase ligands,34-37 and mimics of the prostate specific antigen,38-39 
but little else.  This is limiting because not all tumor types overexpress the corresponding 
receptors at usable cell surface copy-numbers, and some of these ligands have sub-
optimal properties for targeting entities.40  To facilitate discovery of novel ligands for 
targeting, we reported259 the method shown in Figure 1 to identify small molecules that 
bind unknown receptors selectively expressed on the surface of cancer cells.  
In the method described in Figure B-1, a set of monovalent dipeptide mimics 
were designed and prepared,77,190,260-261 with a bias towards two side-chain 
pharmacophores that correspond to the most common amino acids found at protein-
protein interfaces (Trp, Arg, Tyr, Lys, Glu, then Ser, Asn, Leu).262   
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Figure B-1.  A liposome assay to facilitate identification of small molecule ligands that promote 
preferential recognition of cancer cells over healthy tissue. 
 
 
Our hypothesis is that these small molecules mimic side-chains orientations on 
various dipeptides that have a relatively high tendency to bind other proteins.  Amino 
acid side-chains are important because they tend to dominate the thermodynamics of 
protein-protein interactions.262  These monovalent molecules were assembled into 
bivalent one, each bearing a long hydrophobic chain substituent.  Only n monovalent 
compounds are needed to make 2(n – 1) bivalent ones, so large libraries can be made 
from a small number of building blocks.263  In a one-compound-per-well format, each 
bivalent molecule was allowed to associate with a liposome via capture of the 
hydrophobic side-chain into the surface bilayer.  All the liposomes used in these 
experiments carried the plasmid encoding luciferase.  Cells will fuse with liposomes at a 
certain rate, but this happens faster if the liposome-supported bivalent compounds bind a 
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cell-surface receptor, and mediate internalization.  The degree of import after a set time 
can be determined by lysing the cells and adding agents to induce bioluminescence.259   
 
We now reveal one of the compounds found in this assay, 1a, selectively bound 
to melanoma SK-MEL-28 cells and was internalized more than it was when interacting 
with HUVEC cells.  The study reported here was designed to establish if: (i) the 
targeting fragments in 1 bind other live melanoma cells; (ii) they bind fixed tissue slices; 
(iii) modifications that replace the triazine core with a near-IR dye influence their 
binding. 
A weakness of the liposome assay in Figure B-1 is that the HUVAC cells used as 
the “healthy control” are not closely related to skin.  Fortunately, we have access to the 
Sinclair swine model217,264 that allowed us to take biopsy material from pigs with 
naturally occurring metastatic melanoma.   This was done to obtain samples of 
melanoma tumor and healthy skin tissue adjacent to the melanoma region.  That the 
tissue was obtained from the same animal is significant because it relates directly to how 
a particular individual would respond to the featured active targeting method.   The first 
step in treatment of an individual would be diagnosis.  Figure B-2 shows healthy skin 
tissue from the pig was not stained by the fluorescent analog 1b, whereas the melanoma 
N N
N NN
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tissue stained strongly.  This assay could be used for diagnosis of melanoma types that 
respond to ligands 1. 
  
 
Figure B-2.   Histochemistry with 1 does not stain healthy skin, but does stain melanoma tissue 
from the same Sinclair swine. 
 
 
The Georgetown method220,265 was used to obtain live cells from the melanoma.  
Thus, the pig tumor tissue was co-cultured with 3T3 Swiss fibroblast cells in the 
presence of the ROCK kinase inhibitor Y27632 and stem-like-melanoma cells were 
obtained after several passages.  Figure B-3 shows that 1b was internalized into the 
melanoma cells where it colocalized with a lysosome tracker.  This observation implies 
conjugates of 1 may have a tendency to accumulate in melanoma cells in vivo. 
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Figure B-3.  a Melanoma cells from Sinclair swine; b compound 1 is internalized by these cells.  
c Internalization of a lysosome tracker into the melanoma cells, d overlays with the fluorescence 
from 1b. 
 
 
Experiments described above validate the melanoma targeting effects of the 
“warhead” fragments in 1.  This successful confirmation leads to a range possibility for 
subsequent research, and the one featured in this paper is formation of a theranostic that 
could be used for optical and PET imaging of melanoma. 
It is possible to substitute 19F in BODIPY dyes with 18F hence reagents 1 might 
be suitable precursors for PET studies.183-184  However, for in vivo optical imaging, the 
fluor in 1b, which absorbs around 520 nm, is unsuitable because observation of non-
superficial tissue requires agents that absorb at longer wavelengths (ideally, >700 nm).97-
98  One possibility would be to replace the BODIPY dye in 1 with a similar, but near-IR-
absorbing, fluor.  This is particularly important when intrinsically dark melanoma tissue 
is involved, though this too is permeable to light of λmax >700 nm.81-82  However, near-
IR dyes tend to be large, and, in general, it is good practice to keep molecular size as 
small as possible to avoid adverse absorption, metabolism and excretion effects.  For this 
reason we chose to investigate replacement of the triazine splitter in 1 with a near-IR dye 
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that could also act as a scaffold to present the melanoma-targeting groups.  Thus Scheme 
B-1 describes a synthesis of our new target, the “aza-BODIPY”221-222 system 2.  UV 
absorption maxima of aza-BODIPY fluors tend to be around 700 nm, and they are also 
amenable to 19F/18F metathesis (Gabbai, personal communication).  
 
 
 
 
Scheme B-1.  Functionalization of diamino aza-BODIPY A with the targeting groups in 
compounds 1. 
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Scheme 1 begins with coupling one equivalent of an amino acid-derived 
azide190,266 with the diamine A.    Stereochemistry in the isoleucine side-chain is an 
intrinsic probe for epimerization in this coupling, and none was detectable by 1H NMR.  
Copper-mediated Huisgen coupling gave 6 which has one dipeptide mimic supported on 
the aza-BODIPY scaffold.   Construction of the other dipeptide in 8 was achieved in the 
same way, ie via 7.  Finally, acid-mediated deprotection afforded the target system 2; 
this compound is not water-soluble, but can be dissolved in DMSO then diluted to 1 % 
DMSO in PBS buffer.   
Predictably, since the first coupling involving A is only controlled by 
stoichiometry, by-products in the synthesis of 2 made it cost effective to prepare the 
symmetrical probes 3 and 4 as interesting controls.  In the event, they were far more 
interesting than we had anticipated. 
 
 
 
Disappointingly, treatment of pig melanoma tissue with dye 2 showed only very 
weak staining (Figure B-4a).  However, to our surprise, the symmetrical control 3 gave a 
much stronger signal, whereas almost no staining was observed for the other 
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symmetrical control 4 (Figure B-4b and B-4c, respectively).  Figures 4d and 4e compare 
normal skin and melanoma stained with agents 2 and 3, respectively; these data confirm 
that 3 gives a far better contrast between tumor and healthy tissue than our original target 
2.   From this point on, 3 became our lead probe, and no further studies were performed 
2.  Overall, this is fortunate because 2, which needs to be prepared via stepwise 
couplings, is significantly more time-consuming to make than the symmetrical analog 3 
(see supporting for synthesis). 
 
 
 
Figure B-4.   Metastatic melanoma tissue stained with agents: the original lead probe 2 (a); and 
the symmetric probes 3 (b), and, 4 (c).  d Probe 2 gives weak staining and almost no contrast 
between normal and melanoma tissue from the Sinclair swine, but e agent 3 gives a distinct 
contrast. 
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Data from one particular Sinclair swine is not reliably indicative of a trend in 
human melanoma.  Thus a panel of commercially available human melanoma tissue 
samples was stained to estimate the fraction of cases that would bind agent 3 (Figure B-
5).  Duplicate tissue samples from 22 metastatic melanoma patients were tested, and 
every one of them stained with agent 3.   Conversely, no significant staining was 
observed when the two duplicate samples of normal skin available were treated with the 
same probe. 
 
 
Figure B-5.  a Human normal skin tissue did not stain with agent 3; but, b - d human metastatic 
melanoma tissue did (illustrative data from tissue derived from three patients are shown). 
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B.4 Materials and Methods 
General Procedures  
All reactions were carried out under an atmosphere of argon. Unless otherwise 
indicted, common reagents or materials were obtained from commercial source and used 
without further purification. All α-amino acids used were of the L-configuration. Dry 
DMF, (<50 ppm water) was purchased from Acros. Tetrahydrofuran (THF), Acetonitrile 
(MeCN), dichloromethane (CH2Cl2), and methanol (MeOH) were dried by Mbraun 
solvent drying system. Other solvents and reagents were used as received. 
NMR spectra were recorded on a Bruker-400 MHz spectrometers (1H at 400 
MHz and 13C at 100 MHz) at room temperature unless other mentioned. Chemical shifts 
of 1H NMR spectra were recorded and chemical shifts are reported in ppm from the 
solvent resonance (CDCl3 7.26 ppm, CD3OD 3.30 ppm, DMSO-d6 2.50 ppm).  Data are 
reported as follows: chemical shift, multiplicity (s = singlet, br = broad, d = doublet, t = 
triplet, q = quartet, m = multiplet), coupling constants, and number of protons. Proton 
decoupled 13C NMR spectra were also recorded in ppm from tetramethylsilane (TMS) 
resonance (CDCl3 77.0, CD3OD 49.1, DMSO-d6 39.5 ppm).  Analytical thin layer 
chromatography (TLC) was performed on EM Reagents 0.25 mm silica-gel 60-F plates, 
and visualized with UV light. Flash chromatography was performed using silica gel 60 
(230–400 mesh). MS were measured under ESI or MALDI conditions.  
Analytical HPLC analyses were carried out on 150 x 4.6 mm C-18 column using 
gradient conditions (10 – 90% B, flow rate = 0.75 mL/min). Preparative HPLC was 
carried out on 100 x 21.2 mm C-18 column using gradient conditions (10 – 70% B, flow 
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rate = 10.0 mL/min). The eluents used were: solvent A (H2O with 0.1% AcOH) and 
solvent B (CH3CN with 0.1% AcOH).   
The purity of all biologically evaluated compounds is > 95% confirmed by 
analytical HPLC. 
 
Syntheses Of aza-BODIPY Derivatives 2-4 
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Synthesis of compound 5 
EDCI (52.7 mg, 0.275 mmol) and HOAt (40.9 mg, 0.300 mmol) were added to a 
suspension of isoleucine azide190 (39.3 mg, 0.250 mmol) in 1 mL DMF at 0 oC.  After 
stirring at 0 oC for 30 min, A (146.9 mg, 0.250 mmol) was added to the above 
suspension followed by DIPEA (139 µL, 103.4 mg, 0.800 mmol) and catalytic amount 
of DMAP.  The resulting solution was stirred at 0 °C for 1 h and then warmed to 25 oC 
and continue stirring for 12 h.  Ethyl acetate (ca. 20 ml) was added to the reaction 
mixture, and the organic layer was washed with sat. NaHCO3 and brine then dried with 
anhydrous Na2SO4.  Solvents were removed to afford green solid.  The crude product 
was purified by column chromatography on silica gel, and eluted with a mixture of 
hexanes and ethyl acetate (2:1 to 1:2, v/v) afforded the desired 5 (93.9 mg, 34%) as a 
greenish solid.  1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 812 (s, 1H), 8.11 (dd, J = 
9.0, 4.1 Hz, 4H), 7.86 (t, J = 8.9 Hz, 2H), 7.62 – 7.55 (m, 1H), 7.48 (t, J = 7.9 Hz, 1H), 
7.39 (d, J = 7.8 Hz, 1H), 7.10 (s, 2H), 7.04 (dd, J = 9.1 Hz, 1.2 Hz, 4H), 6.80 (dd, J = 7.9 
Hz, 1.6 Hz, 1H), 3.97 (d, J = 4.9 Hz, 1H), 3.92 (s, 6H), 3.78 (s, 2H), 2.30 – 2.12 (m, 1H), 
1.67 – 1.56 (m, 1H), 1.42 – 1.32 (m, 1H), 1.11 (d, J = 6.9 Hz, 3H), 0.97 (t, J = 7.4 Hz, 
3H).  13C NMR (100 MHz, CDCl3) δ 167.7, 162.1, 161.9, 158.5, 157.6, 146.3, 145.5, 
145.0, 143.3, 141.3, 137.2, 133.4, 131.7, 131.7, 131.6, 129.4, 129.1, 125.7, 124.1, 124.0, 
121.9, 121.3, 119.6, 118.7, 116.7, 116.2, 114.3, 114.2, 69.8, 55.4 (2C), 29.7, 24.6, 16.1, 
11.4.  11B NMR (128 MHz, CDCl3) δ 0.96 (t, J = 31.9 Hz). 
 
Synthesis of compound 6 
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Copper powder (9.7 mg, 0.152 mmol) and CuSO4 (0.1 equiv, from 0.05 M 
aqueous solution) were added to a solution of 5 (110.3 mg, 0.152 mmol) and alkyne 
(29.9 mg, 0.152 mmol) in 7 mL dry THF at 25 °C.  The mixture was stirred at 25 °C for 
2 days (monitored by TLC).  Then, solvents were removed under reduced pressure and 
the residue was acidified with 0.2 N HCl.   After extracting with ethyl acetate three 
times, the combined organic phase was washed with 0.05M EDTA and brine.  The 
organic layer was separated and dried over Na2SO4.  Finally, the solvents were removed 
to afford green solid, which was purified by column chromatography on silica gel, and 
eluted with a mixture of CH2Cl2, and methanol (99:1 to 97:3, v/v) to afford the desired 6 
(117.2 mg, 84 %) as a green solid.  1H NMR (400 MHz, CDCl3) δ 9.29 (s, 1H), 8.32 (s, 
1H), 8.10 (dd, J = 12.2, 9.0 Hz, 4H), 8.03 – 7.95 (m, 1H), 7.76 (s, 1H), 7.70 (d, J = 8.3 
Hz, 2H), 7.42 (t, J = 8.0 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.12 (s, 1H), 7.09 – 6.99 (m, 
6H), 5.09 (d, J = 10.7 Hz, 1H), 4.57 (s, 1H), 4.23 (s, 2H), 3.91 (s, 6H), 3.18 (d, J = 6.1 
Hz, 2H), 2.79 (t, J = 7.6 Hz, 2H), 2.38 (dd, J = 9.3, 5.7 Hz, 1H), 1.77 (dt, J = 15.4, 7.7 
Hz, 2H), 1.61 (s, 2H), 1.46 (s, 9H), 1.28 (s, 2H), 1.24 – 1.09 (m, 1H), 0.99 (d, J = 6.7 
Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 166.8, 162.1, 161.9, 
158.5, 157.6, 156.0, 148.3, 145.5, 145.3, 145.1, 143.3, 140.5, 137.3, 133.5, 133.1, 131.7, 
131.6, 129.6, 129.1, 125.2, 124.0, 123.9, 122.5, 121.7, 120.1, 119.8, 118.6, 118.4, 118.1, 
116.7, 114.3, 114.2, 79.1, 69.3, 55.4, 55.4, 40.3, 38.2, 29.7, 28.4, 26.5, 25.5, 24.8, 15.4, 
10.3.  11B NMR (128 MHz, CDCl3) δ 0.91 (t, J = 32.0 Hz).  MS-ESI: m/z 924.4684 
[M+H]+  
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Synthesis of compound 7 
EDCI (133.9 mg, 0.70 mmol) and HOAt (96.8 mg, 0.71 mmol) were added to a 
suspension of Boc protected lysine azide190 (172.7 mg, 0.63 mmol) in 2 mL DMF at 0 
oC.  After stirring at 0 oC for 30 min, 6 (117.2 mg, 0.13 mmol) was added to the above 
suspension followed by DIPEA (354 µL, 262.6 mg, 2.03 mmol) and catalytic amount of 
DMAP.  The resulting solution was stirred at 0 °C for 1 h and warmed to 25 oC and 
stirred for 12 h.  Ethyl acetate (ca. 50 ml) was added to the reaction mixture, and the 
resulting suspension was washed with 5 % HCl, water, sat. NaHCO3 and brine.  The 
organic layer was separated, dried with Na2SO4, and solvent was removed to afford 
green solid.  The crude product was purified by column chromatography on silica gel, 
and eluted with a mixture of CH2Cl2 and methanol (99:1 to 97:3, v/v) to obtained 7 
(123.5 mg, 83%) as a green solid.  1H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H), 8.37 (s, 
1H), 8.14 (d, J = 9.4 Hz, 2H), 8.05 (ddd, J = 7.3, 4.7, 2.0 Hz, 4H), 7.81 (d, J = 7.7 Hz, 
1H), 7.75 (s, 2H), 7.64 (s, 2H), 7.36 (t, J = 7.9 Hz, 1H), 7.31 – 7.21 (m, 1H), 7.00 (s, 
2H), 6.98 (d, J = 2.6 Hz, 4H), 5.11 (d, J = 9.6 Hz, 1H), 4.83 (s, 1H), 4.68 (t, J = 5.6 Hz, 
1H), 4.08 – 3.92 (m, 1H), 3.88 (s, 6H), 3.14 (d, J = 5.2 Hz, 4H), 2.76 (t, J = 7.6 Hz, 2H), 
2.40 (dd, J = 13.8, 7.4 Hz, 1H), 2.12 – 1.82 (m, 4H), 1.73 (dt, J = 15.3, 7.7 Hz, 2H), 1.63 
– 1.49 (m, 6H), 1.45 (d, J = 7.1 Hz, 18H), 1.27 (d, J = 7.6 Hz, 1H), 1.24 – 1.14 (m, 1H), 
1.09 (d, J = 6.7 Hz, 3H), 0.86 (t, J = 7.3 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 168.0, 
167.9, 166.6, 162.1, 158.2, 158.1, 156.3, 156.1, 148.2, 145.3, 145.2, 142.3, 137.7, 137.3, 
133.4, 133.2, 133.1, 131.8, 131.7, 131.7, 129.1, 129.0, 126.1, 125.8, 123.9, 123.9, 121.1, 
121.0, 120.8, 120.6, 119.1, 114.3, 79.3, 79.1, 69.8, 64.0, 55.4 (2C), 40.2, 38.4, 31.7, 
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29.7, 29.6, 28.5, 28.4, 26.5, 25.4, 24.9, 22.7, 15.5, 10.4.  11B NMR (128 MHz, CDCl3) δ 
0.92 (t, J = 31.9 Hz)  ESI-MS: m/z 1178.7063 [M+H]+ 
 
Synthesis of compound 8 
Copper powder (6.7 mg, 0.11 mmol) and CuSO4 (0.1 equiv, from 0.05 M 
aqueous solution) were added to a solution of 7 (123.5 mg, 0.11 mmol) and alkyne (10.3 
mg, 0.11 mmol) in 7 mL dry THF at 25 °C.  The mixture was stirred at 25 °C for 2 days. 
Then, solvents were removed under reduced pressure and the residue was acidified with 
0.2 N HCl.   After extracting with ethyl acetate three times, the combined organic phase 
was washed with 0.05 M EDTA and brine.  The organic layer was separated and dried 
over Na2SO4.  Finally, the solvents were removed to afford green solid, which was 
purified by column chromatography on silica gel, and eluted with a mixture of CH2Cl2, 
and methanol (99:1 to 97:3, v/v) to afford the desired 8 (86.0 mg, 64 %) as a green solid.  
No good 1H NMR was recorded in CDCl3 or CD3OD. 13C NMR (100 MHz, MeOD) δ 
167.0, 162.0, 157.7, 157.1, 144.8, 141.6, 137.6, 137.5, 132.9, 131.6, 128.7, 126.2, 123.5, 
120.7, 120.2, 118.7, 113.7, 78.6, 78.5, 68.9, 64.3, 54.6, 47.0, 46.5, 39.6, 37.8, 33.5, 32.3, 
29.1, 28.9, 27.5, 26.3, 24.5, 22.7, 20.9, 14.6, 9.1, 7.8.  11B NMR (128 MHz, CDCl3) δ 
0.86 (t, J = 32.3 Hz)  ESI-MS: m/z 1276.7981 [M+H]+.   
 
tBu protected acid 
1H NMR (400 MHz, CDCl3) δ 9.55 (s, 1H), 9.15 (s, 1H), 8.20 (d, J = 21.8 Hz, 2H), 8.13 
– 7.97 (m, 4H), 7.89 – 7.65 (m, 4H), 7.52 (s, 2H), 7.30 (s, 1H), 7.25 – 7.11 (m, 1H), 6.98 
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(d, J = 8.1 Hz, 6H), 5.54 – 5.35 (m, 1H), 5.24 (d, J = 9.4 Hz, 1H), 4.94 (s, 1H), 4.72 (s, 
1H), 3.88 (s, 6H), 3.12 (d, J = 4.5 Hz, 4H), 3.04 (t, J = 7.3 Hz, 2H), 2.75 (t, J = 7.4 Hz, 
2H), 2.65 (t, J = 7.4 Hz, 2H), 2.40 (s, 1H), 2.34 – 2.07 (m, 4H), 1.84 – 1.64 (m, 2H), 
1.54 (s, 6H), 1.49 – 1.37 (m, 27H), 1.27 (d, J = 8.0 Hz, 2H), 1.09 (d, J = 6.6 Hz, 3H), 
0.84 (t, J = 7.3 Hz, 3H).  13C NMR (100 MHz, CDCl3) δ 172.0, 171.9, 166.9, 166.7, 
162.0, 158.1, 156.4, 156.1, 148.2, 147.1, 145.3, 145.2, 142.6, 142.3, 137.7, 137.5, 133.4, 
133.3, 133.2, 131.7, 129.0, 128.9, 126.3, 126.1, 125.9, 123.9, 121.2, 120.9, 120.8, 119.2, 
119.1, 114.3, 80.6, 79.4, 79.0, 69.5, 64.4, 55.4, 40.3, 40.0, 38.4, 34.8, 32.7, 29.7, 29.1, 
28.5, 28.4, 28.1, 26.5, 25.4, 24.8, 22.8, 21.3, 15.5, 15.4, 10.3, 10.3.  11B NMR (128 
MHz, CDCl3) δ 0.90 (t, J = 31.8 Hz). 
 
Synthesis of compound 2 
8 (12.7 mg, 0.01 mmol) was dissolved in 100 µL HCl in 1,4-dioxane (4 M), and 
the reaction mixture was stirred at 25 °C for 30 min.  After the reaction was done, the 
solvent was removed under reduced pressure to give desired product 2 as a green solid 
quantitatively.  The purity was confirmed by analytical HPLC (C18 column, CH3CN-
H2O 10-90 % with 0.1 % acetic acid).    
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Synthesis of compound 10 
To a solution of 9 (284.9 mg, 0.329 mmol) and alkyne (129.8 mg, 0.658 mmol) 
in 24 mL dry THF were added Cupper powder (41.8 mg, 0.658 mmol) and CuSO4 (0.1 
equiv, from 0.05 M aqueous solution) at 25 °C.  The mixture was stirred at 25 °C for 2 
days.  The reactions were monitored by TLC.  After the reaction was done, the solvent 
was removed under reduced pressure and 0.2 N HCl was added to the residue.  After 
extracted with ethyl acetate three times, the combined organic phase was washed with 
0.05M EDTA and brine.  The organic layer was separated and dried over Na2SO4, and 
concentrated to afford green solid.  The crude product was purified by column 
chromatography on silica gel, and eluted with a mixture of CH2Cl2 and methanol (100:2 
to 100:4, v/v) afforded the desired 10 (197.1 mg, 48%) as green solid.  1H NMR (400 
MHz, CDCl3) δ 9.45 (s, br, 2H), 8.14 (s, 2H), 8.06 (d, J = 8.4 Hz, 4H), 7.80 (s, 2H), 7.59 
(dd, J = 29.3, 8.5 Hz, 4H), 7.26 (m, 2H), 7.00 (q, J = 9.3 Hz, 6H), 5.25 (d, J = 8.3 Hz, 
2H), 4.65 (s, 2H), 3.88 (s, 6H), 3.13 (s, 4H), 2.76 (t, J = 6.9 Hz, 4H), 2.42 (s, 2H), 1.93 
(s, 2H), 1.71 (s, 4H), 1.63-1.47 (m, 4H), 1.44 (s, 18H), 1.33-1.25 (m, 4H), 1.21 (d, J = 
6.8 Hz, 6H), 0.88 (t, J = 7.3 Hz, 6H).  13C NMR (100 MHz, CDCl3) δ 166.70, 162.06, 
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158.13, 156.04, 148.27, 145.27, 142.85, 137.20, 133.37, 131.70, 129.01, 126.02, 123.94, 
121.69, 121.16, 119.40, 114.26, 79.07, 69.82, 55.40, 40.26, 38.26, 29.65, 28.42, 26.48, 
25.38, 24.88, 15.43, 10.34.  11B NMR (128 MHz, CDCl3) δ 0.84 (t, J = 31.8 Hz).  19F 
NMR (376 MHz, CDCl3) quartet at δ -132.16 HRMS-ESI+: cald 1282.6527, found 
1282.6589 [M+Na]+. 
   
Synthesis of compound 3 
6 (12.6 mg, 0.01 mmol) was dissolved in 100 µL HCl in 1,4-dioxane (4 M), and 
the reaction mixture was stirred at 25 °C for 30 min.  After the reaction was done, the 
solvent was removed under reduced pressure to give desired product 1 as green solid 
quantitatively.  The purity was confirmed by analytical HPLC (C18 column, CH3CN-
H2O 10-90% with 0.1% acetic acid).  1H NMR (400 MHz, MeOD) δ 8.32 (s, 2H), 8.16 
(s, 2H), 8.08 (d, J = 8.9 Hz, 4H), 7.89 (d, J = 7.8 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 7.23 
(t, J = 8.0 Hz, 2H), 7.16 (s, 2H), 6.99 (d, J = 9.0 Hz, 4H), 5.37 (d, J = 10.5 Hz, 2H), 3.87 
(s, 6H), 2.98 (t, J = 7.1 Hz, 4H), 2.86 (t, J = 7.2 Hz, 4H), 2.49 (dd, J = 9.5, 5.8 Hz, 2H), 
1.92 – 1.67 (m, 8H), 1.22 (dd, J = 7.3, 3.2 Hz, 2H), 1.14 (d, J = 6.7 Hz, 3H), 0.92 (t, J = 
7.4 Hz, 3H).  13C NMR (100 MHz, MeOD) δ 166.43, 162.36, 157.90, 146.37, 144.90, 
142.09, 137.68, 133.04, 131.64, 128.76, 126.09, 123.51, 122.57, 120.78, 120.28, 118.98, 
113.83, 69.49, 54.67, 38.98, 37.70, 26.54, 25.47, 24.51, 23.86, 14.33, 9.04.  11B NMR 
(128 MHz, MeOD) δ 0.87 (t, J = 31.8 Hz) 
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Synthesis of compound 11 
EDCI (210.9 mg, 1.10 mmol) and HOAt (152.4 mg, 1.12 mmol) were added to a 
suspension of Boc protected lysine azide (272.3 mg, 1.00 mmol) in 4 mL DMF at 0 oC. 
After stirring at 0 oC for 30 min, A (117.2 mg, 0.127 mmol) was added to the above 
suspension followed by DIPEA (557 µL, 413.6 mg, 3.20 mmol) and trace amount of 
DMAP.  The resulting solution was stirred at 0 °C for 1 h and warmed to 25 oC and 
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stirred for overnight.  Ethyl acetate (ca. 100 ml) was added to the reaction mixture, and 
the resulting suspension was washed with 5%HCl, H2O, sat. NaHCO3 and brine. The 
organic layer was separated, dried with Na2SO4, and concentrated to afford green solid.  
The crude product was purified by column chromatography on silica gel, and eluted with 
a mixture of CH2Cl2 and methanol (100:4, v/v) afforded the desired 11 (299.1 mg, 91%) 
as green solid.  1H NMR (400 MHz, CDCl3) δ 8.27 (s, 2H), 8.06 (d, J = 6.8 Hz, 6H), 
7.80 (d, J = 7.4 Hz, 4H), 7.39 (td, J = 7.8, 3.7 Hz, 2H), 7.03 (d, J = 3.0 Hz, 2H), 7.01 – 
6.93 (m, 4H), 4.70 (s, 2H), 4.05 (s, 2H), 3.89 (s, 6H), 3.14 (s, 4H), 2.06 – 1.90 (m, 4H), 
1.64 – 1.48 (m, 8H), 1.45 (s, 18H).  13C NMR (101 MHz, CDCl3) δ 167.68, 162.07, 
158.13, 156.09, 145.20, 142.03, 137.53, 133.25, 131.73, 129.12, 125.69, 123.89, 120.61, 
120.55, 118.96, 114.26, 79.22, 64.13, 55.42, 40.18, 31.84, 29.70, 28.41, 22.62.  11B 
NMR (128 MHz, CDCl3) δ 0.98 (t, J = 31.7 Hz).  
 
Synthesis of compound 12 
To a solution of 11 (110.2 mg, 0.100 mmol) and alkyne (19.6 mg, 0.200 mmol) 
in 24 mL dry THF were added Cupper powder (12.7 mg, 0.200 mmol) and CuSO4 (0.1 
equiv, from 0.05 M aqueous solution) at 25 °C.  The mixture was stirred at 25 °C for 2 
days.  The reactions were monitored by TLC.  After the reaction was done, the solvent 
was removed under reduced pressure and 0.2 N HCl was added to the residue.  After 
extracted with ethyl acetate three times, the combined organic phase was washed with 
0.05M EDTA and brine.  The organic layer was separated and dried over Na2SO4, and 
concentrated to afford desired 12 (108.7 mg, 84%) as green solid. 
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Synthesis of compound 4 
12 (12.9 mg, 0.01 mmol) was dissolved in 100 µL HCl in 1,4-dioxane (4 M), and 
the reaction mixture was stirred at 25 °C for 30 min.  After the reaction was done, the 
solvent was removed under reduced pressure to give desired product 4 as green solid 
quantitatively.  The purity was confirmed by analytical HPLC (C18 column, CH3CN-
H2O 10-90% with 0.1% acetic acid).  1H NMR (400 MHz, CDCl3) δ 9.38 (s, 2H), 8.13 
(s, 2H), 8.02 (d, J = 8.0 Hz, 4H), 7.77 (d, J = 29.8 Hz, 4H), 7.52 (s, 2H), 7.37 – 7.12 (m, 
2H), 6.96 (d, J = 8.5 Hz, 6H), 5.49 (s, 2H), 4.92 (s, 2H), 3.86 (s, 6H), 3.29 – 2.86 (m, 
4H), 2.62 (d, J = 5.0 Hz, 4H), 2.22 (d, J = 27.6 Hz, 4H), 1.98 (dt, J = 12.7, 6.3 Hz, 2H), 
1.53 (dd, J = 21.1, 15.0 Hz, 2H), 1.43 (s, 18H), 1.36 – 1.09 (m, 6H), 0.93 (d, J = 6.0 Hz, 
12H).  13C NMR (101 MHz, CDCl3) δ 166.89, 162.01, 158.02, 156.27, 147.60, 145.19, 
142.20, 137.65, 133.21, 131.71, 128.94, 126.07, 123.87, 121.07, 120.79, 119.04, 114.22, 
79.24, 64.37, 55.39, 40.03, 34.79, 32.84, 29.24, 28.60, 28.43, 22.84, 22.32, 22.29.  11B 
NMR (128 MHz, CDCl3) δ 0.87 (t, J = 31.9 Hz).  19F NMR (376 MHz, CDCl3) quartet at 
δ -131.76. MALDI-HRMS: theor 1258.6553 found  1258.6613 [M-H]- 
 
 
 
 
  166 
APPENDIX C 
AZA-BODIPY DYES WITH ENHANCED HYDROPHILICITY 
 
B.1 Introduction 
 Attempts to make a diamino disulfonic acid derivative of an aza-BODIPY 
showed it was difficult to add BF2 to a disulfonated aza-dipyrromethene, and sulfonation 
of an aza-BODIPY resulted in loss of the BF2 fragment.  We conclude the electron-
deficient character of aza-BODIPY dyes destabilizes them relative to BODIPY dyes.  
Consequently, sulfonation of the aza-BODIPY core is not a viable strategy to increase 
water solubility.  This assertion was indirectly supported via stability studies of a 
BODIPY and an aza-BODIPY in aqueous media.  To afford the desired compound type, 
an aza-BODIPY with two amino and two sulfonic acid groups was prepared via 
modification of the aryl substituents with cysteic acid. 
Relative to most BODIPY dyes, fluors in the aza-BODIPY series221-222,267 tend to 
have longer wavelength absorption and fluorescence emission maxima (Figure C-
1).94,188-189  This characteristic is advantageous for many potential applications of these 
materials as probes in biological systems, but it comes at a cost.  Red-shifted absorption 
and emission in aza-BODIPY dyes seems to depend on the presence of aryl substituents 
in the 1,3,5,7-positions making the heterocycles highly hydrophobic and inclined to 
aggregation in aqueous media.   
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Figure C-1.  Structures of BODIPYs and aza-BODIPYs. 
 
 
The literature describes some efforts to increase the hydrophilicity of aza-
BODIPY dyes based on functionalization of the aryl substituents.268  Modified aza-
BODIPYs resulting from those efforts feature ammonium salts,269 oligoethylene glycol 
fragments,270 sulfonic and carboxylic acids,269 and carbohydrate derivatives.271  We 
required a hydrophilic aza-BODIPYs with amino functionality on the aryl group that 
could be coupled with activated carboxylic acids to produce derivatized optical imaging 
agents.  Negatively charged dyes were also attractive to us because they are intrinsically 
repelled by negative polar head-groups on cell surfaces.     
Sometime ago we refined272 a procedure273-274 for adding sulfonic acid groups 
into the BODIPY 2- and 6-positions, that gave the water-soluble BODIPY dye C.  
Consequently, it seemed logical to apply the same approach to obtain the aza-BODIPY 
disulfonic acid D.  This Appendix describes why that approach does not work, and an 
alternative that enables sulfonic acid and amino functionalities to be introduced into the 
aza-BODIPY system, via functionalization of the aryl groups. 
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C.2 Results and discussions 
Treatment of the dinitro-aza-dipyrromethene (aza-DIPY; see SI) 1 under the 
sulfonation conditions for BODIPY dyes,272 gave predominantly the mono- or di-
sulfonated DIPY systems 2a and 2b, according to the equivalents of chlorosulfonic acid 
used (Scheme C-1).  Sulfonate 2a was isolated by chromatography on silica gel, whereas 
2b was obtained more straightforwardly by precipitation from dichloromethane.  
Unfortunately, treatment of the DIPY systems 2 under a variety of conditions (Table C-
S1) gave no trace of the corresponding aza-BODIPY dyes as monitored via fluorescence 
spectroscopy in water (with and without Triton X-100 to increase water solubility) or via 
11B NMR of the crude material.  
 
 
Scheme C-1.  Synthesis of disulfonated aza-DIPY. 
 
 
Scheme C-2 describes an alternative approach to compound D that was also 
unsuccessful.  Treatment of the aza-BODIPY 3 with excess chlorosulfonic acid led to 
the aza-DIPY 2b corresponding to loss of the BF2 fragment.   11B NMR, fluorescence 
and absorption spectroscopy (and ESI-MS), of the crude product from this reaction 
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showed no evidence that an aza-BODIPY was present, indicating loss of the BF2 
fragment was not caused by the work-up procedure (Fig. C-S1).   Several variations of 
the conditions for sulfonation of 3 also gave the same results, ie formation of the aza-
DIPY 2 and not the anticipated aza-BODIPY D. 
 
 
Scheme C-2.  Attempt to sulfonate aza-BODIPY. 
 
 
Based on the observations above, we decided to re-focus on obtaining the cysteic 
acid derivative 4 via the procedure outlined in Scheme 3.  Thus hydrogenation of 1 then 
reaction with BF3 gave the diamine 5 which was conveniently coupled with BOC-
protected cysteic acid to give the disulfonic acid 6 (isolated by MPLC on a reverse phase 
column) then the diamino-disulfonic acid 4 after a deprotection step (in which no further 
purification procedure was necessary). 
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Scheme C-3.  Synthesis of aza-BODIPY containing cysteic acid. 
 
 
Disulfonic acid 4 appears to give a homogeneous bright green solution in water 
or 1 mM PBS buffer.  The UV absorbance of the dye is broad and there is no significant 
fluorescence (Fig. C-2a).  However, the UV absorbance of this dye sharpens 
considerably, and it becomes significantly more fluorescent, when 0.1 % Cremophor 
(CrEL) is added (F 0.34 ± 0.010, Fig C-2b); CrEL is a non-ionic surfactant that is 
commonly used as an excipient in pharmaceutical formulations.  Near-IR concentration 
dependence of 4 in PBS buffer (without additives) was used to probe for further 
evidence of aggregation, but no significant dependence on the fluor concentration was 
observed (Fig. C-S3).  
A UV-based method from the literature275 was used to compare the aqueous 
thermodynamic equilibrium solubilities of dyes 3 - 5.  Thus 0.1 M stock solutions of the 
test compounds in DMSO were diluted with PBS to 0 – 100 mM in a 96-well plate, so 
that the highest concentration contained only 1 % DMSO.  The plate was shaken 
horizontally for 6 h at 25 oC and kept overnight for equilibration.  Thereafter, the plate 
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was centrifuged at 1000 rpm for 20 min, the supernatant was pipetted into a 96-well UV-
transparent plate and analyzed using a microplate reader, l = 680 nm, vs a blank (Fig C-
2c). 
 
 
 
Figure C-2.  a UV and b fluorescence (excitation l 650 nm) spectra of compound 4 in pH 7.4 
PBS + 0.1 % CrEL.  c Solubility profile of 3, 4 and 5 in PBS at pH 7.4 (analyses performed in 
triplicate for each compound). 
 
 
Data from the experiments described above show the featured sulfonic acid 4 is 
significantly more hydrophilic than the dinitro- and diamino-compound 3 and 5 (Fig. C-
2c).  In fact, the disulfonic acid 4 is soluble in PBS pH 7.4 up to 200 µM and even more 
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soluble (more than 1 mM) in carbonate buffer pH 9 (Fig. C-S4a).  At pH 4, the solubility 
of 4 decreases (<20 µM) whereas 5 is more soluble (<50 µM, Fig. C-S4b). 
Compound 5 is only very weakly fluorescent, and no staining was observed via 
confocal microscopy when this solution was incubated with 4T1 murine breast cancer 
cells.  After acylation to obtain disulfonic acid BODIPY 4, bright fluorescent was 
observed in 0.1 % CrEL/PBS, and the fluor was clearly internalized into lysosomes of 
the same cells (Figure C-3).   
 
 
Figure C-3.  a Compound 4 is readily internalized by murine 4T1 breast cancer cells.  A 
LysoTracker dye (b) colocalized with the intracellular fluorescence (c).  d Bright field image for 
reference. 
 
 
Failure to obtain the sulfonic acid system D led us to hypothesize the aza-
BODIPY framework with 2- and 6-sulfonic acids is too electron deficient to hold the 
BF2 fragment.  This would explain why the BODIPY disulfonic acid C is isolable 
whereas we were not able to obtain D.  Extrapolating this logic, we also hypothesized 
that aza-BODIPY dyes generally would be less stable than BODIPY systems even if 
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there were no 2-, 6-substituents.  Consequently, the stabilities of representative 
compounds were compared (Fig. C-4). 
 
 
Figure C-4.   Fluorescence studies to monitor stabilities of the fluors.  The t1/2 of aza-BODIPY 4 
is 50 min at 90 oC and 2 min at 100 oC, whereas BODIPY A gave less than 10 % decomposition 
under the same conditions.  
 
 
Heating the tetramethyl BODIPY A and our hydrophilic aza-BODIPY 4 in non-
deoxygenated 1:1 dioxane:water (Fig. C-4) proved BODIPY A persisted at 90 and 
100 °C, but the aza-BODIPY system showed significant decomposition after 30 min at 
90 °C, and was mostly decomposed under the same conditions but at 100 °C.  
 
C.3 Conclusions 
Our failure to obtain the disulfonic acid D illustrates a difference between the 
chemistry of BODIPY and aza-BODIPY dyes; BODIPY systems are more electron-rich 
and can support strong electron withdrawing groups attached directly to the core, 
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whereas similar electron withdrawing groups may destabilize aza-BODIPY systems with 
respect to bonding to the BF2 fragment.  Consistent with this, the diformyl BODIPY E 
and the formyl aza-BODIPY F are known, but same authors have reported being unable 
to form the diformyl aza-BODIPY G.276  Our interpretation of these observation is that 
the diformyl aza-BODIPY G may be unstable, even though the corresponding BODIPY 
is known.  The fact that the monoformylated aza-BODIPY F was isolated was possible 
even though monosulfonation was not, because formyl groups are less electron 
withdrawing.277 
 
 
Figure C-5  The diformyl BODIPY E and the mono-formyl aza-BODIPY F are known, but the 
diformyl aza-BODIPY has been proven difficult to prepare. 
 
 
Parenthetically, we note that, consistent with the observations above, attempts to 
derivatives of 3 with para- rather than meta-nitro groups failed because the BF2 
fragment could not be inserted.    
The negatively charged cysteic acid derivative 4 is significantly more hydrophilic 
than its parent diamine 5, and it has amino groups for functionalization with carboxylic 
acid derivatives.  Use of neutral carboxylic acid derivatives for such functionalization 
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will give products with two negative charges overall.  This is desirable because such 
negatively charged fluorescent derivatives tend to have an intrinsic repulsion for 
negative head groups on the cell membrane.  Intrinsic repulsion reduces non-specific 
binding of conjugates and facilitates studies of aza-BODIPYs designed to selectively 
bind certain cell surface receptors.   
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C.5 Supporting materials 
General Procedures  
All reactions were carried out under an atmosphere of dry argon.  Glassware was 
oven-dried prior to use.  Unless otherwise indicated, common reagents or materials were 
obtained from commercial source and used without further purification.  Dry DMF, (<50 
ppm water) was purchased from EMD.  Tetrahydrofuran (THF), acetonitrile (MeCN), 
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dichloromethane (CH2Cl2), and methanol (MeOH) were dried by MBRAUN solvent 
drying system. Other solvents and reagents were used as received. 
NMR spectra were recorded on a Bruker-400 MHz spectrometer (1H at 400 MHz and 
13C at 100 MHz) at room temperature unless otherwise mentioned.  Chemical shifts of 
1H NMR spectra were recorded and reported in ppm from the solvent resonance (CDCl3 
7.26 ppm, CD3OD 3.30 ppm, DMSO-d6 2.50 ppm).  Data are reported as follows: 
chemical shift, multiplicity (s = singlet, br = broad, d = doublet, t = triplet, q = quartet, m 
= multiplet), coupling constants, and number of protons.  Proton decoupled 13C NMR 
spectra were also recorded in ppm from tetramethylsilane (TMS) resonance (CDCl3 
77.0, CD3OD 49.1, DMSO-d6 39.5 ppm).  Analytical thin layer chromatography (TLC) 
was performed on EM Reagents 0.25 mm silica-gel 60-F plates, and visualized with UV 
light.  Flash chromatography was performed using silica gel 60 (230–400 mesh).  MS 
were measured under ESI or MALDI conditions. 
 
Syntheses Of Sulfonated aza-BODIPY Derivatives 
 
 
 
Table C-S1.  Conditions to form BF2 complex. 
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Solvent Base Temperature (oC) Time (h) 
Toluene iPr2EtN 80 12 
CH2Cl2 iPr2EtN 25 12 
CH2Cl2 Et3N 25 12 
CH2Cl2 NaH 25 12 
CH2CH2Cl2 iPr2EtN 60 12 
 
 
 
 
Figure C-S1. 11B NMR of the crude product showed the loss of the BF2 fragment.  
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Scheme C-S1.   
 
 
Scheme C-S2. 
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1-(4-methoxyphenyl)-4-nitro-3-(3-nitrophenyl)butan-1-one (7). 
Potassium hydroxide (33.6 g, 60 mmol) was added to a solution of chalcone H (17 g, 60 
mmol) in MeOH (250 mL) at 25 oC.  Nitromethane (64 mL, 1.2 mol) was added to the 
reaction mixture, and then the reaction was heated to reflux at 78 oC for 24 h.  After the 
reaction was cooled to 25 oC, HCl (0.2 N) was added to neutralize.  Precipitate was 
filtered out and washed with cold MeOH.  The product was obtained as slightly brown 
solid (14.5 g, 70 % yield) and used without further purification.  1H NMR (400 MHz, 
CDCl3) δ 8.21 (s, 1H), 8.19 (d, J = 7.7 Hz, 1H), 7.92 (d, J = 8.9 Hz, 2H), 7.69 (d, J = 7.7 
Hz 1H), 7.54 (dd, J = 7.9, 7.9 Hz, 1H), 6.95 (d, J = 8.9 Hz, 2H), 4.89 (m, 1H), 4.75 (m, 
1H), 4.38 (m, 1 H), 3.90 (S, 3 H), 3.47 (d, J = 6.9 Hz, 2H).  13C (100 MHz, CDCl3) δ 
194.3, 164.1, 141.5, 134.3, 130.3, 130.2, 130.0, 129.1, 122.9, 122.2, 114.0, 79.0, 55.5, 
40.7, 39.0.  MS (ESI+) calcd for C17H17N2O6 {M+H}+ 345.1087, found 345.1096. 
 
1H-NMR of compound 7 
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13C-NMR of compound 7 
 
(Z)-5-(4-methoxyphenyl)-N-(5-(4-methoxyphenyl)-3-(3-nitrophenyl)-1H-pyrrol-2-
yl)-3-(3-nitrophenyl)-2H-pyrrol-2-imine (1).  
7 (10 g, 29 mmol) was dissolved in nBuOH  (300 mL).  Ammonium acetate (78 g, 1 mol) 
was added to the solution. The reaction was heated up to reflux at 120 ºC and stirred for 
24 h.  The mixture was cooled to 40 ºC, then the solvent was removed.  The residue was 
precipitated in cold EtOH, the solid was filtered to give dark solid 1 (9 g, 52 % yield).  
The product was used without further purification.  NMR spectra cannot be obtained 
from compound 1 due to solubility.  However, after complexation with BF2 to yield 
compound 3, the NMR was obtained nicely.  1H NMR (400 MHz, CDCl3) δ 8.92 (s, 2H), 
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8.37 (d, J = 7.2 Hz, 2H), 8.28 (d, J = 8.0 Hz, 2H), 8.14 (d, J = 8.6 Hz, 4H), 7.70 (t, J = 
7.8 Hz, 2H), 7.20 (s, 2H), 7.06 (d, J = 8.6 Hz, 4H), 3.91 (s, 6H).  13C (100 MHz, CD2Cl2) 
δ 161.6, 158.3, 155.5, 149.4, 148.7, 141.3, 140.8, 135.0, 133.7, 133.3, 132.4, 131.5, 
130.7, 130.3, 130.2, 128.9, 124.2, 124.1, 124.0, 122.5, 122.3, 117.6, 116.7, 114.8, 114.6, 
55.8.  HRMS(ESI-) calcd for C34H24BClF2N5O6 {M+Cl}- 682.1476, found 682.1464. 
 
1H-NMR of compound 3 
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13C-NMR of compound 3 
 
Synthesis of disulfonic acid (2a, 2b) 
1 (30 mg, 0.05 mmol) was dissolved in CH2Cl2 (5.5 mL) and the solution was cooled to -
40 oC.  Solution of chlorosulfonic acid (1 eq. for 2a and 4 eq. for 2b) in CH2Cl2 (0.5 mL) 
was slowly added to the solution over 5 min at -40 oC.   The mixture was slowly warmed 
to 25 oC and stirred for 5-12 h.  The reaction was quenched with sat. NaHCO3 at -40 oC.   
Organic layer was separated and the crude product was purified by flash silica 
chromatography eluting with CH2Cl2:MeOH (85:15) to yield 20 mg (60 %) of 2a as a 
purple powder.  1H NMR (400 MHz, CDCl3) δ 8.54 (s, 2H), 8.18 (d, J = 7.2 Hz, 1H), 
8.18 (d, J = 7.6 Hz, 1H), 8.13 (d, J = 7.6 Hz, 1H), 8.06 (d, J = 7.2 Hz, 1H), 7.95 (d, J = 
7.8 Hz, 2H), 7.91 (d, J = 8.1 Hz, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.37 (s, 1H), 7.34-7.8 (m, 
1H, overlap with CDCl3) 7.01-6.97 (m, 4H), 3.86 (s, 6H).  HRMS (ESI-) calcd for 
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C34H24N5O9S- {M-Na}- 678.1300, found 678.1321.  For 2b, the product was precipitated 
from the reaction.  The precipitate was filtered to give a purple powder 60 mg, 79 % 
yield.  NMR cannot be obtained due to solubility.  HRMS (ESI-) calcd for 
C34H23N5NaO12S2- {M-Na}- 780.0676, found 780.0640. 
 
 
1H-NMR of compound 2a 
 
3,3'-(5,5-difluoro-3,7-bis(4-methoxyphenyl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinine-1,9-diyl)dianiline (5).  
1 (1 g, 1.67 mmol) was dissolved in CH2Cl2 : MeOH (1:1, 30 mL).  Pd/C (180 mg, 0.17 
mmol) was added to the solution.  The mixture was stirred under H2 (1 atm) at 25 oC for 
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20 h, the reaction was followed by TLC.  The product was filtered through Celite® to 
give dark blue solid after the solvent was removed.  The solid was then dissolved in 
CH2Cl2 (200 mL), N,N-diisopropylethylamine (2.9 mL, 16.7 mmol) was added to the 
solution.  The mixture was stirred at 25 oC for 20 min, BF3•OEt2 (3.1 mL, 25 mmol) was 
then added in portions and the mixture was stirred at 25 ºC for 12 h.  The reaction was 
quenched with careful addition of H2O (20 mL) and the system was stirred vigorously 
for 15 min. The organic layer was separated and washed with HCl (0.2 N, 1 × 10 mL), 
NaOH (2 N, 2 × 10 mL) and brine (10 mL).  The organic layer was dried over MgSO4, 
filtered, and the solvent was removed under reduced pressure.  The residue was purified 
by flash silica chromatography eluting with EtOAc:Hexanes (3:1 to 2:1) to yield 883 mg 
(90 %) of 4 as a dark green solid.   1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 8.9 Hz, 
4H), 7.71 (s, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.24 (d, J = 7.8 Hz, 2H), 7.03 (d, J = 9.8 Hz, 
4H). 6.77-6.74 (m, 2H), 3.91 (s, 6H).  13C (100 MHz, CDCl3) δ 161.9, 158.0, 146.6, 
145.3, 143.0, 133.5, 131.6, 129.4, 124.3, 119.3, 118.6, 116.4, 116.2, 114.2, 55.4.  11B 
NMR (128 MHz, CDCl3) δ 0.94 (t, J = 31.9 Hz, BF2) ppm.  19F NMR (376 MHz, 
CDCl3) δ -131.89 (q, J = 31.9 Hz, BF2).  HRMS (ESI+) calcd for C34H29BF2N5O2 
{M+H}+ 588.2382, found 588.2359. 
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1H-NMR of compound 5 
 
11B, 19F-NMR of compound 5 
  186 
 
13C-NMR of compound 5 
 
(2R,2'R)-3,3'-(((5,5-difluoro-3,7-bis(4-methoxyphenyl)-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,5,2]triazaborinine-1,9-diyl)bis(3,1-phenylene))bis(azanediyl))bis(2-
((tert-butoxycarbonyl)amino)-3-oxopropane-1-sulfonic acid) (6). 
Boc-protected Cysteic acid (367 mg, 1.28 mmol) was dissolved in DMF and cooled to 0 
oC.  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, EDC (274 mg, 1.43 mmol) and 1-
hydroxy-7-azabenzotriazole, HOAt (198 mg, 1.46 mmol) were added to the solution. 
After stirring for 30 min, compound 5 (150 mg, 0.26 mmol) was added to the reaction 
mixture.  N,N-Diisopropylethylamine (0.45 mL, 2.6 mmol) was then added in one 
portion.  The reaction was stirred at 25 oC for 14 h.  The solvent was removed and the 
product was purified by reverse phase MPLC eluting with water and acetonitrile to yield 
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212 mg (75 %) as a greenish powder.   1H NMR (400 MHz, CDCl3) δ 8.14 (s, 2H), 8.08 
(d, J = 8.6 Hz, 4H), 7.90 (d, J = 6.0 Hz, 2H), 7.53 (m, 2H), 7.33 (m, 2H), 7.15 (s, 2H), 
6.98 (d, J = 8.6 Hz, 4H), 3.86 (s, 6H), 3.62-3.59 (m, 2H), 3.17-3.11 (m, 4H), 1.47 (s, 
18H).  13C (100 MHz, CDCl3) δ 170.3, 162.2, 160.1, 157.7, 156.2, 144.9, 142.2, 138.4, 
132.7, 131.7, 128.7, 125.7, 123.6, 120.4, 118.9, 79.7, 55.2, 54.8, 42.1, 27.4.  HRMS 
(MALDI-) calcd for C50H53BF2N7O14S2 {M-H}- 1088.3156, found 1088.3108. 
 
1H-NMR of compound 6 
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13C-NMR of compound 6 
   
(R)-2-amino-3-((3-(9-(3-((R)-2-amino-3-sulfopropanamido)phenyl)-5,5-difluoro-3,7-
bis(4-methoxyphenyl)-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-1-
yl)phenyl)amino)-3-oxopropane-1-sulfonic acid (4).  
Compound 5 (40 mg, 0.37 mmol) was dissolved in dioxane (5 mL). Solution of HCl in 
dioxane (2 M, 5 mL) was added into the solution.  The reaction was stirred at 25 oC for 1 
h.  The solvent was removed to yield 4  33 mg, quantitative yield as a green solid.  1H 
NMR (400 MHz, CDCl3) δ 10.81 (s, 2H), 8.25 (s, 2H), 8.17 (d, J = 8.9 Hz, 4H), 7.95 (d, 
J = 7.7 Hz, 2H), 7.74 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 8.0 Hz, 2H), 7.44 (s, 2H), 7.16 (d, J 
= 8.9 Hz, 4H), 4.19 (br, 2H), 3.90 (s, 6H), 3.21-3.18 (m, 2H), 2.94 (dd, J = 9.8 Hz, 4H).  
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13C (100 MHz, CDCl3) δ 166.5, 162.6, 158.0, 145.0, 142.7, 139.0, 132.8, 132.3, 129.8 
125.9, 123.6, 121.6, 120.5, 120.3, 115.0, 56.1, 51.5, 50.7.  11B NMR (128 MHz, DMSO-
d6) δ: 0.88 (t, J = 32.0 Hz, BF2) ppm.  19F NMR (376 MHz, DMSO-d6) δ: -130.52 (q, J 
= 32.0 Hz, BF2).  HRMS (MALDI-) calcd for C40H36BF2N7NaO10S2 {M-Na}- 910.1925, 
found 910.1968. 
 
 
1H-NMR of compound 4 
  190 
 
11B, 19F-NMR of compound 4 
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13C-NMR of compound 4 
 
Spectroscopic Data Of Compound 4. 
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Fig. C-S2  UV and fluorescent spectra of 4 in DMSO.  
 
 
Table C-S2. Spectroscopic Data of Compound 4. 
 
Solvent λabs max (nm) ε (M-1 cm-1) × 104 λemis max (nm)a ΦFb 
DMSO 703 6.12 730 0.17 ± 0.003 
PBSc 701 4.72 729 0.34 ± 0.010 
aExcited at 650 nm. bRelative to Zn-pthalocyanine in 1% pyridine/toluene (ΦF = 0.30). 
cContained 0.1% CrEL 
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Fig. C-S3  UV absorptions of 4 at different concentrations. No evidence of aggregation was 
observed when concentration dependence of 4 in PBS buffer (without additives) was used. 
 
 
Thermodynamic Equilibrium Solubility Measurement 
Stock solutions (0.1 M) of test compounds were prepared in DMSO then diluted 
with aqueous media (PBS pH 7.4 or carbonate buffer pH 9 or acetate buffer pH 4) to 
desired concentrations (0 – 1000 µM, the highest concentration contained 1 % DMSO).  
Then, the plate covered with aluminium foil was shaken horizontally for 6 h at 25 oC and 
kept overnight for equilibration.  Thereafter, the plate was centrifuged at 100 rpm for 20 
min.  Supernatant was pipetted into 96-well UV transparent plate (Corning® 96 Well 
Clear Flat Bottom UV-Transparent Microplate) and analyzed at λ = 680 nm of 
compounds against blank using microplate reader (Biotek Synergy H4).  
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Fig. C-S4  Solubility Profile.  a Compound 4 is soluble in PBS pH 7.4 up to 100 µM and more 
than 1 mM can be dissolved in carbonate buffer pH 9.  b  In acetate buffer, compound 4 is only 
soluble up to 20 µM, where as 5 can be soluble up to 50 µM.  The analysis was performed in 
triplicate for each compound.    
 
 
Cell Culture And Imaging Studies   
4T1 cells were cultured on 75 cm2 culture flasks in Dulbecco’s Modified Eagle 
Medium/nutrient mixture F-12 (DMEM/F12, Sigma Chemical, St. Louis, MO) 
supplemented with 10 % FBS.  Cells were cultures in a humidified incubator at 37 °C 
with 5 % CO2 and 95 % air.   
Subcellular localization was measured on living 4T1 cells using an Olympus FV1000 
Confocal Microscope.  Throughout, digital images were captured with a 100x / 1.4 oil 
objective with the following filter sets: for LysoTracker Green: excitation 488 nm; for 
aza-BODIPY 4: excitation 633 nm.  Sequential optical sections (Z-stacks) from the 
basal-to-apical surfaces of the cell were also acquired.   
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Cells were incubated with fluors for 3 h at 37 oC.  After the cells were washed with PBS 
(2X), LysoTracker Green (0.5 µM) was added and the cells were incubated for 30 min at 
37 oC.  The cells were washed again with PBS before imaging. 
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APPENDIX D 
SUPPORTING INFORMATION FOR CHAPTER II 
 
General Methods  
All reactions were carried out under an atmosphere of dry nitrogen.  Glassware was 
oven-dried prior to use.  Unless otherwise indicted, common reagents or materials were 
obtained from commercial source and used without further purification.  All a-amino 
acids used were of the L-configuration.  Triethylamine (TEA) was obtained anhydrous 
by distillation over calcium hydride.  Acetonitrile (MeCN), dichloromethane (CH2Cl2), 
and methanol (MeOH) were dried by a Mbraun solvent drying system.  
Flash column chromatography was performed using silica gel 60 (230-400 mesh).  
Analytical thin layer chromatography (TLC) was carried out on Merck silica gel plates 
with QF-254 indicator and visualized by UV. 1H and 13C NMR spectra were recorded on 
a Varian 300 (300 MHz 1H; 75 MHz 13C) or Varian 500 (500 MHz 1H; 125 MHz 13C) 
spectrometer at room temperature.  Chemical shifts were reported in ppm relative to the 
residual CDCl3 (δ 7.27 ppm 1H; δ 77.0 ppm 13C), or d6-DMSO (δ 2.49 ppm 1H; δ 39.5 
ppm 13C).  NMR chemical shifts were expressed in ppm relative to internal solvent 
peaks, and coupling constants were measured in Hz. (br = broad). 
Analytical HPLC analyses were carried out on 150 x 4.6 mm C-18 column using 
gradient conditions (10 – 90% B, flow rate = 0.75 mL/min).  Preparative HPLC was 
carried out on 100 x 21.2 mm C-18 column using gradient conditions (10 – 70% B, flow 
  197 
rate = 10.0 mL/min).  The eluents used were: solvent A (H2O with 0.1% TFA) and 
solvent B (CH3CN with 0.1% TFA) 
 
Syntheses For 6-Mercaptopurine Derivatives 
 
 
General Procedure For Compound 1  
Preparation of compound 1 followed the procedure reported by F. I. Carroll and A. 
Philip.278 To a solution of mercaptopurine (9.9 mmol, 1.0 equiv) in DMF (1.0 M) was 
added K2CO3 (9.9 mmol, 1.0 equiv) under N2.  The solution was stirred at 25 °C for 15 
min.  To the mixture was added bromodiphenylmethane (9.9 mmol, 1.0 equiv), and the 
mixture was stirred at 25 °C for 4 h.  The mixture was diluted with water (90 mL), and 
then acidified with acetic acid.  The mixture was stirred vigorously for 30 min, filtered, 
and then dried to give an amorphous solid.  Recrystallization from MeOH gave 2.1 g (67 
%) of compound 1 as white powder. 
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1H NMR (500 MHz, DMSO) δ 8.63 (s, 1H), 8.45 (s, 1H), 7.51 (d, 4H, J = 7.5 Hz), 7.33 
(t, 4H, J = 7.5 Hz), 7.24 (7, 2H, J = 7.5 Hz), 6.72 (s, 1H) 
 
1H NMR of 1 
 
General Procedure for Compound 2 
To a solution of compound 1 (3.1 mmol, 1.0 equiv) in DMF (0.5 M) was added K2CO3 
(3.1 mmol, 1.0 equiv) and 2-[2-9chloroethoxyl)-ethoxy]ethanol (3.1 mmol, 1.0 equiv) 
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under N2 at 25 °C.  The solution was warmed to 80 °C and then stirred at the 
temperature for 2 h.  DMF was removed by lyophilizer, and then the mixture was 
purified by flash chromatography (1:19 MeOH/CH2Cl2).  1.2 g (82 %) of compound 2 
was obtained as colorless oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 8.38 (s, 1H), 7.51 (d, 4H, J = 7.5 Hz), 7.30 
(dd, 4H, J = 7.0, 13.5 Hz), 7.22 (t, 2H, 7.5 Hz), 6.82 (s, 1H), 4.42 (t, 2H, J = 4.5 Hz), 
3.80 (t, 2H, J = 5.0 Hz), 3.73 (t, 2H, J = 4.5 Hz), 3.57 (m, 4H), 3.54 (t, 2H, J = 4.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 159.2, 151.5, 148.2, 144.3, 140.9, 130.1, 128.4, 128.2, 
127.0, 72.5, 70.3, 69.9, 68.6, 61.3, 50.5, 43.4 
MS (ESI, m/z) calcd for C24H27N4O3S (M+H)+ 451.1, found 451.2 
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1H NMR of 2 
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13C NMR of 2 
 
General Procedure For Compound 3 
To a solution of compound 2 (2.6 mmol, 1.0 equiv) in CH2Cl2 (0.15 M) was added 
DMAP (0.026 mmol, 0.01 equiv) and TEA (6.4 mmol, 2.5 equiv) under N2 at 0 °C.  4-
Toluenesulfonyl chloride (5.13 mmol, 2.0 equiv) was portioned over 10 min at 0 °C.  
The solution was stirred at 0 °C for 10 min, and then the solution was warmed to 25 °C.  
After 2 h, DMAP (0.26 mmol, 0.1 equiv) was added more to the mixture, and then 
stirred at 25 °C for 14 h.  The mixture was diluted with water and then extracted with 
CH2Cl2.  The combined organic phases were dried over MgSO4.  After completely 
removing the solvent, tosyl-protected compound 2’ was purified by flash 
chromatography (1:49 MeOH/CH2Cl2).  1.3 g (84%) of compound tosyl-protected 
compound was obtained as colorless oil.   
 
 
1H NMR (500 MHz, CDCl3) δ 8.65 (s, 1H), 8.10 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.52 
(d, 4H, J = 8.0 Hz), 7.27 (m, 6H), 7.18 (t, 2H, J = 7.0 Hz), 6.85 (s, 1H), 4.32 (t, 2H, J = 
5.0 Hz), 4.08 (t, 2H, J = 3.0 Hz), 3.72 (t, 2H, J = 4.5 Hz), 3.55 (t, 2H, J = 4.5 Hz), 3.46 
(m, 4H), 2.34 (s, 3H) 
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13C NMR (125 MHz, CDCl3) δ 158.8, 151.2, 148.3, 144.5, 143.7, 140.9, 132.4, 130.3, 
129.5, 128.2, 128.1, 127.5, 126.8, 70.2, 69.9, 68.9, 68,6, 68.2, 50.3, 43.2, 21.2 
MS (ESI, m/z) calcd for C31H33N4O5S2 (M+H)+ 605.2, found 605.8 
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13C NMR of 2’ 
 
To a solution of compound 2’ (2.1 mmol, 1.0 equiv) in MeCN (0.1 M) was added NaN3 
(3.1 mmol, 1.5 equiv) under N2.  The mixture was refluxed for 25 h.  After 25 h, the 
mixture was cooled down to room temperature, and diluted with water, and then 
extracted with CH2Cl2.  The combined organic phases were dried over MgSO4.  After 
completely removing the solvent, compound 3 was purified by flash chromatography 
(3:97 MeOH/CH2Cl2).  1.0 g (97%) of compound 3 was obtained as yellowish oil. 
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1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H), 8.28 (s, 1H), 7.53 (d, 4H, J = 8.0 Hz), 7.31 
(t, 4H, J = 7.0 Hz), 7.23 (t, 2H, J = 80 Hz), 6.92 (s, 1H), 4.44 (t, 2H, J = 5.0 Hz), 3.82 (t, 
2H, J = 5.0 Hz), 3.59 (m, 6H), 3.33 (t, 2H, J = 5.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 159.3, 151.5, 148.4, 143.9, 141.0, 130.5, 128.5, 128.3, 
127.1, 70.4, 69.9, 68.9, 50.6, 50.4, 43.6 
MS (ESI, m/z) calcd for C24H26N7O2S (M+H)+ 476.2, found 476.7 
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13C NMR of 3 
 
Syntheses For IY-IY-6MP and 2mor-6MP  
Compounds IY-IY-TEG, and 2mor-TEG were prepared via the previously published 
methodology in our group.77,190  To a solution of compound 3 (1.0 equiv) and IY-IY-
TEG or 2mor-TEG (1.0 equiv) in DMSO:H2O (5:1, 0.01 M) were added TBTA (0.01 
equiv) at 25 °C.  CuSO4 (0.1 equiv, from 0.05 M aqueous solution) and fresh Na 
ascorbate (0.4 equiv, from 0.05 M aqueous solution) were added to the mixture at 25 °C.  
The mixture was stirred at 25 °C for 24 h.  The reactions were monitored by analytical 
HPLC.  The crude compounds were lyophilized to remove DMSO, and then purified 
with RP-reparative HPLC to obtain the bivalent mimics IY-IY-6MP’ or 2mor-6MP’.  
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Table D-S1. Characterization of Compounds IY-IY-6MP’ and 2mor-6MP’. 
compounds 
retention time 
(min) 
chemical 
formula 
[M+H]+ 
calculated 
[M+H]+ 
founda 
     
IY-IY-6MP’ 14.4 C76H100N23O9S 1510.8 1510.6 
2mor-6MP’ 17.2 C44H59N13O7S 913.4 913.9 
                           aMALDI-MS 
(i)  3
CuSO4, Na ascorbate
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Deprotection of diphenylmethyl group from thione IY-IY-6MP’ or 2mor-6MP’ 
was performed with 50 % TFA/CH2Cl2 and phenol (3.0 equiv) at 25 °C.  The mixture 
was stirred at 25 °C for 16 h.  The reactions were monitored by analytical HPLC.  The 
crude compounds were purified with RP-reparative HPLC to obtain the bivalent mimics 
IY-IY-6MP or 2mor-6M.  The final products were lyophilized three times in 1.0 % 
acetic acid to remove TFA. 
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Table D-S2. Characterization of Compounds IY-IY-6MP and 2mor-6MP. 
 
compounds 
retention time 
(min) 
chemical 
formula 
[M+H]+ 
calculated 
[M+H]+ 
founda 
     
IY-IY-6MP 10.6 C63H90N23O9S 1344.7 1345.1 
2mor-6MP 10.5 C31H49N13O7S 747.4 746.7 
                                          aMALDI-MS 
 
Syntheses For Rosamine Derivatives 
 
 
 
 
 
O
N
N
I
NHBoc
PdCl2(PPh3)2
CuI, TEA, CH2Cl2
25 oC, 24 h
O
N
N
BocHN
H
4, quant
(i) HCl/dioxane
25 oC, 4 h
(ii) TfN3, MeOH
25 oC, 20 h
O
N
N
N3
5, 82 %
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General Procedure For Compound 4 
Iodo-rosamine279 (0.36 mmol, 200 mg), PdCl2(PPh3)2 (0.036 mmol, 25.2 mg) and 
CuI (0.036 mmol, 6.86 mg) were added to a dried round bottom flask.  The flask was 
placed under vacuum for 15 min, and then dried CH2Cl2 (24 mL) was added under N2; 
red solution was observed.  To the mixture were added tert-butyl prop-2-yn-1-
ylcarbamate (3.6 mmol, 562 mg) and TEA (0.36 mmol, 0.50 mL).  The reaction mixture 
was stirred at 25 oC for 24 h.280  The solvents were removed under reduced pressure and 
the residue was purified by flash chromatography (5 % MeOH/CH2Cl2) to afford the 
pure product 4 (240 mg, quantitative) as a purple solid. 
 
1H NMR (300 MHz, CDCl3) δ 7.64 (d, 2H, J = 8.4 Hz), 7.33 (d, 2H, J = 9.5 Hz), 7.29 (d, 
2H, J = 8.4 Hz), 7.07 (dd, 2H, J = 9.5, 2.7 Hz), 7.00 (d, 2H, J = 2.7 Hz), 4.87 (br, 1H), 
4.20 (d, 2H, J = 5.4 Hz), 3.75 (br, 8H), 1.78 (br, 12H), 1.47 (s, 9H)  
13C NMR (75 MHz, CDCl3) δ 165.0, 158.3, 156.4, 155.8, 132.2, 131.8, 131.5, 129.6, 
125.3, 115.0, 113.4, 97.7, 88.4, 81.9, 49.3, 28.4, 26.0, 24.1 
MS (ESI) m/z calcd for C37H42N3O3+ 576.3221; found 576.2374. 
 
O
N
N
I
NHBoc
PdCl2(PPh3)2
CuI, TEA, CH2Cl2
25 oC, 24 h
O
N
N
BocHN
H
4, quant
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1H NMR of 4 
 
 
13C NMR of 4 
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General Procedure For Compound 5 
Boc-protected amino rosamine 4 (0.42 mmol, 240 mg) was dissolved in dioxane 
(5 mL).  Hydrogenchloride (4 M in dioxane, 2 mL) was added at once and the solution 
was stirred at 25 oC for 4 h.  The solvent was removed under reduced pressure and the 
product was used without further purification.  
A solution of sodium azide (10 mmol, 650 mg) in a 2:1 mixture of H2O (4 mL) 
and CH2Cl2 (2 mL) was cooled using an ice bath.  Triflic anhydride (2.0 mmol, 0.34 mL) 
was added over 5 min and the solution was then stirred at 0 °C for further 2 h.  The 
CH2Cl2 phase was separated, and the aqueous portion was extracted with CH2Cl2 (3 x 5 
mL).  The organic fractions were combined, washed once with saturated Na2CO3, and 
the solution was used without further purification.190   
Amino rosamine (after Boc deprotection) (0.20 mmol, 100 mg) was combined 
with K2CO3 (0.30 mmol, 40 mg), CuSO4 (0.002 mmol, 0.32 mg), H2O (1 mL) and 
CH3OH (4 mL).  The CH2Cl2 solution of triflyl azide prepared above was added in one 
portion, and the mixture was stirred at 25 oC for 20 h.  The organic phase was separated, 
then washed with a 1:3 mixture of NH4OH (3 mL) and H2O (9 mL), brine, and dried 
over Na2SO4. The solvents were removed under reduced pressure and the residue was 
purified by flash chromatography (5 % MeOH/CH2Cl2) to afford rosamine azide 5 (82 
mg, 82 %) as a purple solid. 
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1H NMR (500 MHz, DMSO-d6) δ 7.78 (d, 2H, J = 8.5 Hz), 7.55 (d, 2H, J = 8.5 Hz), 
7.30 (dd, 2H, J = 2.5, 9.5 Hz), 7.21 (d, 2H, J = 9.5 Hz), 7.15 (d, 2H, J = 2.5 Hz) 4.48 (s, 
2H), 3.77 (m, 8H), 1.71 (m, 4H), 1.63 (m, 8H) 
13C NMR (125 MHz, DMSO-d6) δ 158.2, 156.4, 155.3, 132.9, 132.4, 131.9, 130.5, 
123.6, 115.5, 113.3, 97.4, 86.1, 85.4, 49.0, 26.2, 24.2 
MS (ESI) m/z calcd for C32H32N5O+ 502.2601; found 502.2859 
FT-IR (NaCl): N3 band at 2109.24 cm-1 and sp-C band at 2363.25 cm-1.  
 
1H NMR of 5 
O
N
N
BocHN
4, quant
(i) HCl/dioxane
25 oC, 4 h
(ii) TfN3, MeOH
25 oC, 20 h
O
N
N
N3
5, 82 %
  213 
 
 
13C NMR of 5 
 
Syntheses For IY-IY-Ros, YI-YI-Ros and 2mor-Ros 
Compounds IY-IY-TEG, YI-YI-TEG, and 2mor-TEG were prepared via the 
previously published methodology in our group.  To a solution of compound 5 (1.0 
equiv) and IY-IY-TEG, YI-YI-TEG or 2mor-TEG (1.0 equiv) in DMSO:H2O (5:1, 
0.01 M) were added TBTA (0.01 equiv) at 25 °C.  CuSO4 (0.1 equiv, from 0.05 M 
aqueous solution) and fresh Na ascorbate (0.4 equiv, from 0.05 M aqueous solution) 
were added to the mixture at 25 °C.  The mixture was stirred at 25 °C for 24 h.  The 
reactions were monitored by analytical HPLC.  The crude compounds were lyophilized 
to remove DMSO, and then purified with RP-reparative HPLC to obtain the bivalent 
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mimics IY-IY-Ros, YI-YI-Ros or 2mor-Ros.  The final products were lyophilized three 
times in 1.0 % acetic acid to remove TFA. 
 
 
 
IY-IY-Ros 
1H NMR (500 MHz, DMSO-d6) δ 9.27 (br, 1H), 8.33 (br-s, 1H), 8.23 (br, 7H), 7.71 (d, 
2H, J = 8.5 Hz), 7.48 (d, 2H, J = 8.5 Hz), 7.24 (m, 2H), 7.11 (m, 4H), 6.92 (d, 2H, J = 
8.5 Hz), 6.74 (br, 1H), 6.53 (d, 2H, J = 8.5 Hz), 5.61 (s, 2H), 4.50 (s, 2H), 4.32 (m, 2H), 
3.68 (m, 8H), 3.44 (m, 28H), 3.18 (s, 2H), 1.84 (m, 2H), 1.63 (m, 4H), 1.56 (m, 8H), 
1.26 (m, 2H), 0.92 (m, 2H), 0.80 (t, 6H, J = 7.0 Hz), 0.67 (d, 6H, J = 6.5 Hz) 
13C NMR (125 MHz, DMSO-d6) δ 166.3, 165.0, 164.9, 158.4, 158.2, 156.8, 156.4, 
156.1, 155.3, 144.8, 142.0, 133.0, 132.7, 132.5, 131.8, 130.8, 130.4, 125.9, 124.6, 124.0, 
123.5, 115.5, 113.4, 97.4, 85.4, 84.9, 70.2, 70.1, 70.0, 69.5, 69.5, 63.8, 52.7, 51.1, 49.0, 
45.0, 45.4, 37.6, 26.2, 25.6, 24.3, 14.1, 11.6 
Hi-Res MALDI-MS: m/z calcd for C84H107N21O8+ 1536.8528; found 1536.8582 
5
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1H NMR of IY-IY-Ros 
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COSY NMR of IY-IY-Ros 
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13C NMR of IY-IY-Ros 
 
Table S3. Characterization of Compounds IY-IY-Ros, YI-YI-Ros and 2mor-Ros. 
compounds 
retention time 
(min) 
chemical 
formula 
M 
calculated 
M 
   found 
     
IY-IY-Ros 15.6 C84H107N21O8+ 1536.8528 1536.8582a 
YI-YI-Ros 15.8 C84H107N21O8+ 1536.8528 1536.8571a 
2mor-Ros 18.0 C52H65N11O6+ 938.5036 938.5072b 
                                          a Hi-resolution MALDI-M;  b Hi-resolution ESI-MS 
 
 
Cytotoxicity Comparison 
MTT Cell Viability Assays with IY-IY-6MP and 2mor-6MP 
TrkC NIH3T3 cells (TrkC) (10,000-12,000 cells/well, 50 mL in Dulbecco’s 
Modified Eagle Medium/nutrient mixture F-12 (DMEM/F12, Sigma Chemical, St. 
Louis, MO) including G418 (200 mg/mL, GIBCO) were plated on 96-well plates and 
allowed to adhere at 37 °C in 5 % CO2 and 95 % air for 3 h.  Thereafter, the cells were 
treated with 50 mL aliquot of each test compounds in PFHM-II and 10 % NBCS 
(newborn calf serum, GIBCO) at different concentrations, ranging from 0.1 mM to 200 
mM.  The final concentration of NBCS was 5 %.  The cells were then incubated for 56 ~ 
60 h.  For wild-type NIH3T3 cells, 50 mL in Dulbecco’s Modified Eagle 
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Medium/nutrient mixture F-12 (DMEM/F12) that does not include G418 was used, but 
other process are the same to TrkC Cells’ one.  The cell’s viability was assessed through 
an MTT conversion assay.254  Briefly, 20 mL of MTT (5mg/mL, in Hank’s balanced salt 
solution, HBSS) were added and the cells were incubated for an additional 2 – 3 h.  
Thereafter, the cells were lysed and the dark blue crystals solubilized with 100 mL of an 
aqueous solution containing 35 % (v/v) DMF, 15 % (v/v) glacial acetic acid, 15 % (w/v) 
SDS with an adjusted pH of 3.8.  The optical density (OD) of each well (at 570 mm) was 
measured with a BioTek Synergy 4 Microplate Reader.  The viability of each cell line in 
response to the treatment with tested compounds was calculated as: % dead cells = 100 – 
(OD treated/OD control) ×100. 
 
Calcein AM Cell Viability Assays with IY-IY-Ros, and YI-YI-Ros 
4T1 cells were maintained in monolayer cultures in DMEM supplemented with 10% 
FBS.  Cells (10,000-12,000 cells/well for NIH3T3-TrkC and WT; 5,000-7,000 cells/well 
for 4T1, 50 µL, in Ham’s medium) were plated on 96-well plates and allowed to adhere 
at 37 °C in 5% CO2 and 95 % air for 12 h.  The cells were then treated with 50 µL of 
each test compounds in PHFM-II (protein free medium) at 0 to 30 µM concentrations.  
The cells were incubated for 30 h at 37 °C, then, 100 µL of a 2 µM calcein AM solution 
(life technologies) were added to each well and incubated for 45 min at 37 °C.  Finally, 
fluorescence was measured in constant intervals (5-10 min) at an excitation wavelength 
of 485 nm and an emission wavelength of 530 nm using a BioTek Synergy 4 Microplate 
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Reader.  The viability of each cell line in response to the treatment with tested 
compounds was calculated as: % dead cells = 100 - (F treated/F control) x 100. 
 
Table D-S4.  Summary of Cytotoxicities in Different Cells. 
 
compounds IC50 (µM) TrkCa WTb 
   
IY-IY-Ros 15.80 ± 0.18 27.58 ± 1.38 
YI-YI-Ros 25.80 ± 2.24 25.79 ± 1.79 
 4T1c 
  
IY-IY-Ros 19.88 ± 2.53 
aTrkC: TrkC-overexpressed NIH3T3 cells. bWT: wild-type NIH3T3 cells. c4T1: murine 
beast cancer cell line 
 
Competition Assay  
 
 
Figure D-S1. Competition assay.  Dose-dependent reduction of YI-YI-Ros cytotoxicity (red) in 
competition with the TrkC ligand IY-IY-TEG (green) does not occur for TrkC cells.  
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IY-IY-Ros with MitoTracker 
Fluorescence Microscopy 
Subcellular protein localization was measured on living NIH-TrkC and 4T1 cells using a 
Zeiss 510 META NLO Multiphoton Microscope System consisting of an Axiovert 200 
MOT microscope.  Throughout, digital images were captured with a 40x / 1.3 oil 
objective with the following filter sets:  
• for LysoTracker® Green DND-26 (abbreviated to “LysoTracker Green” above): 
excitation 488 nm; emission BP 500-530 
• for rosamine conjugates: excitation 543 nm; emission BP 565-615  
Sequential optical sections (Z-stacks) from the basal-to-apical surfaces of the cell were 
acquired.  Digital image acquisition was initiated approximately 1 µm below the basal 
surface of the cells and optical slices were collected at 0.5 µm steps through their apical 
surface.  These wide-field images were subjected to deconvolution using Intelligent 
Imaging Innovations (3I) software. 
 
Lysosomal Colocalization 
Cells were incubated with IY-IY-Ros for 30 min at 37 oC.  After the cells were washed 
with PBS, LysoTracker Green was added and the cells were incubated for 30 min at 37 
oC.  The cells were washed again with PBS before imaging. 
 
Mitochondrial Colocalization 
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Cells were incubated with 2mor-Ros for 30 min at 37 oC.  After the cells were washed 
with PBS, MitoTracker Green was added and the cells were incubated for 20 min at 37 
oC.  The cells were washed again with PBS before imaging. 
 
 
Figure D-S2.  IY-IY-Ros and MitoTracker do not colocalize in TrkC cells.   
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APPENDIX E 
SUPPORTING INFORMATION FOR CHAPTER III 
 
General Procedures  
All reactions were carried out under an atmosphere of dry nitrogen.  Glassware 
was oven-dried prior to use.  Unless otherwise indicted, common reagents or materials 
were obtained from commercial source and used without further purification.  All α-
amino acids used were of the L-configuration. Dry DMF, (<50 ppm water) was 
purchased from Acros.  Triethylamine (Et3N) was distilled from CaH2.  Tetrahydrofuran 
(THF), Acetonitrile (MeCN), dichloromethane (CH2Cl2), and methanol (MeOH) were 
dried by Mbraun solvent drying system. Other solvents and reagents were used as 
received. 
NMR spectra were recorded on a Bruker-400 MHz and Inova-500 MHz 
spectrometers (1H at 400 MHz or 500 MHz, and 13C at 100 or 125 MHz) at room 
temperature unless other mentioned.  Chemical shifts of 1H NMR spectra were recorded 
and chemical shifts are reported in ppm from the solvent resonance (CDCl3 7.26 ppm, 
CD3OD 3.30 ppm, DMSO-d6 2.50 ppm).  Data are reported as follows: chemical shift, 
multiplicity (s = singlet, br = broad, d = doublet, t = triplet, q = quartet, m = multiplet), 
coupling constants, and number of protons.  Proton decoupled 13C NMR spectra were 
also recorded in ppm from tetramethylsilane (TMS) resonance (CDCl3 77.0, CD3OD 
49.1, DMSO-d6 39.5 ppm).  Analytical thin layer chromatography (TLC) was performed 
on EM Reagents 0.25 mm silica-gel 60-F plates, and visualized with UV light.  Flash 
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chromatography was performed using silica gel 60 (230–400 mesh).  MS were measured 
under ESI or MALDI conditions.  
Analytical HPLC analyses were carried out on 150 x 4.6 mm C-18 column using 
gradient conditions (10 – 90% B, flow rate = 0.75 mL/min).  Preparative HPLC was 
carried out on 100 x 21.2 mm C-18 column using gradient conditions (10 – 70% B, flow 
rate = 10.0 mL/min).  The eluents used were: solvent A (H2O with 0.1% TFA) and 
solvent B (CH3CN with 0.1% TFA).   
The purity of all biologically evaluated compounds is > 95% confirmed by 
analytical HPLC. 
 
Syntheses Of DiiodoBODIPY Derivatives 
 
 
 
10-(3-Chloropropyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinine (3).  2,4-Dimethylpyrrole (2.0 mL, 19 mmol) was added 
to a solution of 4-chlorobutanoyl chloride (0.99 mL, 8.8 mmol) in CH2Cl2 (20 mL) over 
N
H
Cl Cl
O
(i) CH2Cl2
25 oC, 30 min
(ii) TEA, BF3.OEt2
25 oC, 14 h
N BF2
N
Cl
NaN3, DMF
40 oC, 36 h N BF2
N
N3
3 4
I2, HIO3
EtOH
60 oC, 30 min
N BF2
N
N3
I
I
B
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10 min at 0 ºC.  The reaction was stirred at 0 ºC for 30 min, then warmed up to 25 ºC 
and stirred for an additional 30 min.  Triethylamine (3.7 mL, 26 mmol) was then added 
in small portions at 0 ºC and the mixture was stirred at 25 ºC for 10 min.  BF3•OEt2 (5.5 
mL, 44 mmol) was then added in portions and the mixture was stirred at 25 ºC for 14 h.  
The reaction was quenched with careful addition of H2O (20 mL) and the system was 
stirred vigorously for 15 min.  The aqueous layer was extracted with CH2Cl2 (3 × 10 
mL). The organic layers were combined and washed with H2O (2 × 10 mL) and brine 
(10 mL).  The organic layer was dried over MgSO4, filtered, and the solvent was 
removed under reduced pressure.  The brown powder was dissolved in small amount of 
CH2Cl2 and filtered through a short plug of silica.  The solvent was removed under 
reduced pressure and the remaining powder was recrystallized from ethyl acetate to yield 
0.90 g (32 %) of 4 as a red needles.  1H NMR (300 MHz, CDCl3) δ 6.06 (s, 2H), 3.70 (t, 
J = 6.0 Hz, 2H), 3.13 (t, J = 8.4 Hz, 2H), 2.52 (s, 6H), 2.43 (s, 6H), 2.08-2.16 (m, 2H).  
13C (100 MHz, CDCl3) δ 154.4, 144.4, 140.3, 131.4, 121.8, 44.7, 34.0, 25.9, 16.5, 14.4.  
HRMS (ESI) calcd for C16H19BClF2N2 {M-H}- 323.1298, found 323.1287.  
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1H-NMR of compound 3 
 
13C-NMR of compound 3 
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10-(3-Azidopropyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-
c:2',1'-f][1,3,2]diazaborinine (4).  Sodium azide (240 mg, 3.6 mmol) was added to a 
solution of 4 (600 mg, 1.9 mmol) in DMF (36 mL).  The mixture was stirred at 40 ºC for 
36 h.  Water (20 mL) was then added and the suspension was extracted with ethyl 
acetate (3 × 20 mL).  The combined organic layers were washed with H2O (2 × 20 mL) 
and brine (20 mL).  The organic layer was dried over MgSO4, filtered and the solvent 
was removed under reduced pressure to afford 600 mg (99 %) of 5 as an orange powder.  
1H NMR (500 MHz, CDCl3) δ 6.06 (s, 2H), 3.49 (t, J = 6.0 Hz, 2H), 3.03 (t, J = 8.4 Hz, 
2H), 2.51 (s, 6H), 2.46 (s, 6H), 1.86-1.93 (m, 2H).  13C (100 MHz, CDCl3) δ 154.3, 
144.6, 140.3, 131.4, 121.9, 51.5, 31.4, 25.6, 16.5, 14.4.  HRMS (ESI) calcd for 
C16H19BF2N5 {M-H}- 330.1702, found 330.1712.  FT-IR (NaCl): N3 band at 2098 cm-1. 
 
1H-NMR of compound 4 
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13C-NMR of compound 4 
10-(3-Azidopropyl)-5,5-difluoro-2,8-diiodo-1,3,7,9-tetramethyl-5H-4λ4,5λ4-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine (B).  Iodine (585 mg, 2.31 mmol) and 
iodic acid (342 mg, 1.94 mmol) were added to a suspension of 5 (351 mg, 0.92 mmol) in 
ethanol (20 mL).  The mixture was stirred at 60 ºC for 30 min.  The mixture was cooled 
to 25 ºC and water (30 mL) was added.  The product was extracted with CH2Cl2 (3 × 20 
mL).  The combined organic layers were dried over MgSO4, filtered, and the solvent was 
removed under reduced pressure.  The residue was purified by flash silica 
chromatography eluting with hexanes:CH2Cl2 (3:1 to 2:1) to yield 351 mg (65 %) of B as 
a red powder.  1H NMR (400 MHz, CDCl3) δ 3.53 (t, J = 6.5 Hz, 2H), 3.13 (t, J = 8.5 
Hz, 2H), 2.61 (s, 6H), 2.48 (s, 6H), 1.85-1.92 (m, 2H).  13C (100 MHz, CDCl3) δ 155.8, 
144.3, 142.2, 131.3, 86.8, 51.4, 31.0, 26.5, 19.1, 16.2. HRMS (ESI) calcd for 
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C16H17BF2I2N5 {M-H}- 581.9635, found 581.9609.  FT-IR (NaCl): N3 band at 2106 cm-1. 
 
1H-NMR of compound B 
 
 
13C-NMR of compound B 
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Experimental Procedures And Characterization Of IY-IY-PDT And YI-YI-PDT 
 
 
 
 
 
IY-IY-TEG, and YI-YI-TEG (structure A) were prepared via the previously published 
methodology from our group.77,190  To a solution of B (1.5 equiv) and IY-IY-TEG or 
YI-YI-TEG (1.0 equiv) in DMSO:H2O:CH2Cl2 (2:1:2, 0.01 M) were added CuSO4 (0.1 
equiv, from 0.05 M aqueous solution) and fresh Na ascorbate (0.4 equiv, from 0.05 M 
aqueous solution) at 25 °C.  The mixture was stirred at 25 °C for 24 h.  The reactions 
were monitored by analytical HPLC.  The crude compounds were lyophilized to remove 
DMSO, and then purified by RP-preparative HPLC to obtain the bivalent mimics IY-IY-
PDT or YI-YI-PDT.  The final products were lyophilized three times in 1.0 % acetic 
acid to remove TFA. 
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IY-IY-PDT 
After purification and lyophilization, the product was obtained as a red powder (27-35 % 
yield).  The purity was found to be ca. >99% by HPLC analysis, retention time 16.083. 
1H NMR (400 MHz, DMSO-d6) δ 8.38 (br, 4H), 8.29 (s, 2H), 8.23 (s, 1H), 7.00 (d, 4H, J 
= 8.5 Hz), 6.78 (br, 2H), 6.61 (d, 4H, J = 8.4 Hz), 6.17 (t, 2H, J = 7.3 Hz), 4.63-4.54 (m, 
2H), 4.38 (t, 2H, J = 5.6 Hz), 3.64-3.42 (m, 30H), 3.34-3.19 (m, 4H), 3.06-2.98 (m, 2H), 
2.53 (s, 6H), 2.25 (s, 6H), 2.14-2.07 (m, 2H), 1.98-1.87 (m, 2H), 1.40-1.30 (m, 2H), 
1.08-0.94 (m, 2H), 0.93-0.86 (m, 6H), 0.79-0.70 (m, 6H) 
13C NMR (100 MHz, DMSO-d6) δ 166.4, 158.6, 158.3, 156.8, 155.2, 145.7, 144.6, 
143.3, 142.0, 131.3, 130.7, 125.9, 125.0, 115.5, 115.5, 88.1, 70.3, 70.3, 70.2, 70.1, 70.0, 
69.5, 69.4, 63.9, 51.2, 49.6, 45.4, 42.7, 42.2, 37.7, 31.8, 25.6, 19.0, 16.3, 15.2, 14.1, 11.3 
Hi-Res MALDI-MS: m/z calcd for C68H93BF2I2N21O7+ {M+H}+ 1618.5723 found 
1618.5836. 
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1H-NMR of compound 1 or IY-IY-PDT 
 
COSY-NMR of compound 1 or IY-IY-PDT 
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13C-NMR of compound 1 or IY-IY-PDT 
 
YI-YI-PDT 
After purification and lyophilization, the product was obtained as a red powder (34-42 % 
yield).  The purity was found to be ca. >99% by HPLC analysis, retention time 16.283. 
1H NMR (400 MHz, DMSO-d6) δ 8.46 (br, 4H), 8.23 (s, 2H), 8.16 (s, 1H), 7.01 (br, 1H), 
6.88 (d, 4H, J = 8.4 Hz), 6.83 (br, 2H), 6.61 (d, 4H, J = 8.4 Hz), 5.70 (d, 2H, J = 9.7 Hz), 
4.70-4.63 (m, 2H), 4.60 (t, 2H, J = 5.4 Hz), 3.79-3.43 (m, 30H), 3.46-3.38 (m, 4H), 3.23-
3.07 (m, 2H), 3.06-2.98 (m, 2H), 2.50 (s, 6H), 2.25 (s, 6H), 2.15-2.04 (m, 2H), 0.98-0.90 
(m, 6H), 0.89-0.84 (m, 2H), 0.84-0.78 (m, 6H), 0.77-0.72 (m, 2H).  13C NMR (100 MHz, 
DMSO-d6) δ 166.4, 158.9, 158.4, 156.7, 155.2, 145.7, 144.6, 143.9, 143.3, 131.3, 130.7, 
126.0, 125.0, 123.6, 115.5, 115.5, 88.0, 70.3, 70.3, 70.2, 70.1, 70.0, 69.4, 69.4, 63.9, 
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49.6, 48.8, 45.6, 43.6, 42.1, 38.0, 31.8, 26.5, 24.2, 18.7, 16.3, 15.4, 11.0.  Hi-Res 
MALDI-MS: m/z calcd for C68H93BF2I2N21O7+ {M+H}+ 1618.5723 found 1618.5946. 
 
 
1H-NMR of compound 2 or YI-YI-PDT 
 
COSY-NMR of compound 2 or YI-YI-PDT 
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13C-NMR of compound 2 or YI-YI-PDT 
 
Photophysical Properties For IY-IY-PDT And YI-YI-PDT 
 
 
Figure E-S1.  a UV-Vis and b fluorescence spectra (excited at 480 nm) of 1 and 2 (both at 5.5 
mM) in DMSO. 
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Table E-S1.  Absorption and Fluorescence Data for compound 1 and 2 in DMSO 
Compound λabs (nm) ε (M-1 cm-1) λemiss (nm)a 
ΦF
b  (in 
DMEM) 
1 or IY-IY-PDT 532 61430 550 0.02 (0.01) 
2 or YI-YI-PDT 532 50221 550 0.03 (0.01) 
aExcited at 480 nm. bRelative to Rhodamine G6 in EtOH (ΦF = 0.94). 
 
Cellular Studies For IY-IY-PDT And YI-YI-PDT 
 
Table E-S2.  Summary Of Photocytotoxicities In Different Cells. 
 
 
aTrkC: TrkC-overexpressed NIH3T3 cells. bWT: wild-type NIH3T3 cells. cSY5Y: 
human neuroblastoma cells. 
 
 
 
 
compounds IC50 (µM) NIH3T3-TrkCa       NIH3T3-WTb SY5Yc 
  
IY-IY-PDT   0.35 ± 0.06            > 2 
 
       0.15 ± 0.02 
 
IY-IY-PDT > 2            > 2        0.54 ± 0.04 
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Figure E-S2.  a Confocal imaging of: first row, the featured targeting ligand on TrkC+ cells 
showing the compound is internalized; second row, the negative control YI-YI-PDT is not 
localized under the same conditions; third row, the featured agent is not observed in TrkC- cells 
under the same conditions.  b Quantitative indications of the fluorescence intensity in each of the 
three experiments described above (error bars from 100 cells). 
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Figure E-S3.  Photoinduced cytotoxicity assays.  YI-YI-PDT (a negative control) show similar 
cytotoxicity for the TrkC expressing cells, NIH3T3-TrkC (red) and non-TrkC cells, NIH3T3-WT 
(blue).  In the experiments the cells were illuminated with a broad spectrum source, filtered to 
only deliver photons of >480 nm wavelength, at a flux of approximately 12.2 mW/cm2 for 10 
mins.  Error bars were based on 3 runs.  
 
 
Figure E-S4.  YI-YI-PDT partially colocalizes with LysoTracker Red in TrkC+ cells.   
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APPENDIX F 
SUPPORTING INFORMATION FOR CHAPTER IV 
 
 
 
Figure F-S1.  Structure of IY-IY-TEG. 
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Figure F-S2.  Compounds induced non-selective photocytotoxicity in TrkC+ and TrkC- cells 
when treated for prolonged periods. 4T1 and 67NR cells were cultured in 96-well plates. After 
24 h, 1-PDT, 2-PDT and I2-BODIPY with indicated concentrations were added to cells and 
incubated for 2 h, 4 h and 6 h. Media was removed and the cells were washed with PBS before 
new media was added. Cells were then irradiated with 7.3 J/cm2 of light at a fluence rate of 12.2 
mW/cm2. MTT was carried out 24 h after irradiation. Data represent mean ± SEM of three 
independent experiments. * p < 0.05, ** p < 0.005 vs 2 hours treatment, Student’s t-test. 
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Figure F-S3.  Uptake of compounds in TrkC+ cells.  4T1 cells were cultured in 2-well 
chambers. After 48 h, 1-PDT and 2-PDT were added to cells (final concentration is 0.5 µM) and 
incubated for 2 h. Media was removed and the cells were washed with PBS before new media 
was added.  Images were captured using confocal microscope (20X). 
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Figure F-S4. Biodistribution of 1-PDT in 4T1 tumor bearing mice. Biodistribution of 1-PDT 
was monitored in 4T1 tumor bearing mice (n=3) up to 72 h. Significant fluorescent signals were 
detected the liver (20 folds more than that of the tumor), kidney and lung within the first 3 h post 
administration.  Although the amount of 1-PDT in tumor was significantly lower (p<0.05 for all 
monitoring time points, One way ANOVA-Tukey post-hoc test) than that of the liver, the tumor 
accumulation level of 1-PDT was found to resemble to that of the heavily vascularized kidney 
and lung in the first 3 hours post 1-PDT administration, and persistently higher than that of these 
organs in the following 69 hours of monitoring period. Taking into consideration of the 
relatively lower vascularization in tumor compare to the kidney and lung, and the consistency of 
the 1-PDT level within the tumor throughout the monitoring period, it would be fair to suggest 
that the accumulation of 1-PDT in tumor is somehow not random but associated to the targeting 
of 1-PDT by the associated IY ligands to the tumor tissue.  
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Figure F-S5.  1-PDT in the dark did not promote 4T1 tumor growth. 4T1 tumor cells were 
inoculated subcutaneously to female balb/c mice. Both 1-PDT and 2-PDT were intravenously 
injected via tail vein when the tumor size reached 70-100 mm3. Tumor size was monitored for 30 
days. Graph represents mean ± SEM of seven 4T1 tumor bearing mice. 
 
 
 
In the graph of % of initial tumor volume, 1-PDT has slower tumor growth compared to 
2-PDT in dark. We hypothesize that 1-PDT might indirectly regulates certain cytokines 
profile and immune response; we are currently working on exploring this idea.   
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APPENDIX G 
SUPPORTING INFORMATION FOR CHAPTER V 
 
 
 
Scheme S1.  Synthesis of 3a. 
 
Synthesis of 5-3. 
Tyrosine azide (41 mg, 0.2 mmol) was dissolved in DMF (0.4 mL), then cooled to 0 oC.  
EDCI (41 mg, 0.22 mmol) and HOAt (20 mg, 0.21 mmol) were added to the solution. 
After stirring at 0 oC for 30 min, 5-2 (35 mg, 0.04 mmol) was added to the above 
suspension followed by DIPEA (70 µL, 0.4 mmol).  Then, the resulting solution was 
warmed to 25 oC and stirred for 24 h.  Solvent was removed under reduced pressure.  
After that, the residue was purified by reverse phase MPLC using H2O:CH3CN 
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(gradient) to afford 5-3 as a green powder (30 mg, 60 %).  1H-NMR (400 MHz, DMSO-
d6) δ 10.28 (s, 2H), 9.23 (s, 2H), 8.61 (d, J = 8.9 Hz, 2H), 8.61-8.60 (m, 6H), 8.17 (d, J = 
8.8 Hz, 2H), 7.94 (d, J = 7.6 Hz, 2H), 7.68 (t, J = 8.0 Hz, 2H), 7.51 (s, 2H), 7.16-7.09 
(m, 6H), 6.69 (d, J = 8.8 Hz, 2H), 4.66-4.61 (m, 2H), 4.09-4.05 (m, 2H), 3.59 (s, 6H), 
3.13-3.11 (m, 2H), 3.04-2.99 (m, 6H).  13C (100 MHz, DMSO-d6) δ 169.4, 162.5, 157.9, 
156.6, 143.1, 140.0, 132.5, 132.3, 130.5, 129.6, 128.9, 127.5, 123.7, 120.0, 63.8, 56.1, 
54.0, 52.4, 49.0, 42.3.  
 
Synthesis of 3a. 
5-3 (50 mg, 0.04 mmol) and Boc-Isoleucine alkyne (20 mg, 0.09 mmol) were dissolved 
in DMSO (1 mL).  Then, aqueous solution of CuSO4 (0.1 M, 78 µL, 0.008 mmol) and 
sodium ascorbate (0.2 M, 156 µL, 0.032 mmol) were added to the mixture at 25 °C.  The 
reaction was stirred at 25 °C for 24 h (monitored by C18-TLC).  Solvent was removed 
under reduced pressure.  After that, the residue was purified by reverse phase MPLC 
using H2O:CH3CN (gradient) to afford Boc-3a as a green powder (39 mg, 58 %).  
Subsequently, Boc-3a  (39 mg, 0.023 mmol) was dissolved in 1,4-dioxane (0.5 mL).  
Then HCl in 1,4-dioxane (2 M, 0.5 mL) was added into the solution.  Reaction mixture 
was stirred at 25 °C for 1h, then solvent was removed under reduced pressure to give 
desired product 3a as green solid quantitatively. 
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Figure G-S1.  Structure of control compound (isomer of 3a). 
 
 
 
 
 
Figure G-S2.  Histochemistry on human breast tissue array.  Fluorescently labeled TrkC mAb 
also stained the normal tissue (a); but much brighter staining was observed on malignant breast 
cancer tissue (b) (example from 3 cases). 
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APPENDIX H 
ATTEMPTED REACTIONS 
 
 
 
Conditions: 
TFA removed BF2 and Boc 
HCl removed Boc and Iodine 
BF3 remove Boc and Iodine 
 
Successful Condition: 
10 eq. iPr2EtN, 15 eq. BF3•OEt2 in CH2Cl2 at 25 oC 
 
 
Iodine fell off by using this condition. 
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or 
 
Iodine was reduced when using Cu catalyst reaction. 
 
 
problem with epimerization 
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Product contained free IY ligand, difficult to separate. 
 
 
This reaction gave low yield (10 %). 
 
 
No new spot was obsereved on TLC after 24 h. 
 
 
BF2 fell off under this condition. 
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Trace amount of product was obtained. 
 
 
This reaction gave low yield (10 %). 
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Reaction was extremely slow, could not identify product peak in HPLC. 
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